<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id>
<journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Frontiers in Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-0640</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31551825</article-id>
<article-id pub-id-type="pmc">6738329</article-id>
<article-id pub-id-type="doi">10.3389/fpsyt.2019.00605</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Psychiatry</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sethi</surname>
<given-names>Rickinder</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/613906" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gómez-Coronado</surname>
<given-names>Nieves</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/674204" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Walker</surname>
<given-names>Adam J.</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/124132" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Robertson</surname>
<given-names>Oliver D’Arcy</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/615441" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Agustini</surname>
<given-names>Bruno</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/440653/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Berk</surname>
<given-names>Michael</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dodd</surname>
<given-names>Seetal</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/504290" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup><institution>Department of Psychiatry, Western University</institution>, <addr-line>London, ON</addr-line>, <country>Canada</country></aff>
<aff id="aff2">
<sup>2</sup><institution>Unidad de Gestión Clinica Salud Mental, Hospital Universitario Virgen del Rocio</institution>, <addr-line>Sevilla</addr-line>, <country>Spain</country></aff>
<aff id="aff3">
<sup>3</sup><institution>IMPACT Strategic Research Centre, Deakin University</institution>, <addr-line>Geelong, VIC</addr-line>, <country>Australia</country></aff>
<aff id="aff4">
<sup>4</sup><institution>University Hospital Geelong, Barwon Health</institution>, <addr-line>Geelong, VIC</addr-line>, <country>Australia</country></aff>
<aff id="aff5">
<sup>5</sup><institution>Department of Psychiatry, The University of Melbourne</institution>, <addr-line>Parkville, VIC</addr-line>, <country>Australia</country></aff>
<aff id="aff6">
<sup>6</sup><institution>Orygen, The National Centre of Excellence in Youth Mental Health</institution>, <addr-line>Parkville, VIC</addr-line>, <country>Australia</country></aff>
<aff id="aff7">
<sup>7</sup><institution>Department of Psychiatry, Florey Institute of Neuroscience and Mental Health</institution>, <addr-line>Parkville, VIC</addr-line>, <country>Australia</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Richard G. Boles, Center for Neurological and Neurodevelopmental Health (CNNH), United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Marisa Moller, North-West University, South Africa; Akira Monji, Saga University, Japan</p>
</fn>
<corresp id="fn001">*Correspondence: Michael Berk <email xlink:href="mailto:michael.berk@barwonhealth.org.au" xlink:type="simple">michael.berk@barwonhealth.org.au</email>
</corresp>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Molecular Psychiatry, a section of the journal Frontiers in Psychiatry</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>9</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>10</volume>
<elocation-id>605</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>9</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>7</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Sethi, Gómez-Coronado, Walker, Robertson, Agustini, Berk and Dodd</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Sethi, Gómez-Coronado, Walker, Robertson, Agustini, Berk and Dodd</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Neuropsychiatric disorders, such as depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, and neurodevelopmental disorders such as autism spectrum disorder, are associated with significant illness burden. Accumulating evidence supports an association between these disorders and inflammation. Consequently, anti-inflammatory agents, such as the cyclooxygenase-2 inhibitors, represent a novel avenue to prevent and treat neuropsychiatric illness. In this paper, we first review the role of inflammation in psychiatric pathophysiology including inflammatory cytokines’ influence on neurotransmitters, the hypothalamic–pituitary–adrenal axis, and microglial mechanisms. We then discuss how cyclooxygenase-2-inhibitors influence these pathways with potential therapeutic benefit, with a focus on celecoxib, due to its superior safety profile. A search was conducted in PubMed, Embase, and PsychINFO databases, in addition to Clinicaltrials.gov and the Stanley Medical Research Institute trial registries. The results were presented as a narrative review. Currently available outcomes for randomized controlled trials up to November 2017 are also discussed. The evidence reviewed here suggests cyclooxygenase-2 inhibitors, and in particular celecoxib, may indeed assist in treating the symptoms of neuropsychiatric disorders; however, further studies are required to assess appropriate illness stage-related indication.</p>
</abstract>
<kwd-group>
<kwd>depression</kwd>
<kwd>bipolar disorder</kwd>
<kwd>schizophrenia</kwd>
<kwd>obsessive compulsive disorder</kwd>
<kwd>autism spectrum disorder</kwd>
<kwd>psychiatry</kwd>
<kwd>inflammation</kwd>
<kwd>cyclooxygenase-2 inhibitors</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="363"></ref-count>
<page-count count="21"></page-count>
<word-count count="8684"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>The immune system involves a complex array of cells, tissues, and organs working in concert to protect the body from foreign molecules at both the intracellular and extracellular level (<xref ref-type="bibr" rid="B1">1</xref>). Pro-inflammatory and anti-inflammatory cytokines, along with other mechanisms, balance the inflammatory response (<xref ref-type="bibr" rid="B1">1</xref>). External causes of inflammation include microbial or viral infections, cigarette smoking, poor dietary composition, air pollution, and trauma (both physical and psychological), among others (<xref ref-type="bibr" rid="B2">2</xref>). Internal causes may include ischemic events or malignancy (<xref ref-type="bibr" rid="B1">1</xref>). In instances where inflammatory mediators are unable to inhibit the pro-inflammatory immune reaction, a chronic inflammatory state may ensue. Chronic activation of this system can lower the allostatic load threshold, contributing to the development of neuropsychiatric disorders (<xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>While monoaminergic dysregulation remains a prevailing hypothesis regarding neuropsychiatric disorders, refractory illnesses remain a significant challenge in addition to a relative paucity of novel treatment options (<xref ref-type="bibr" rid="B3">3</xref>). In recent years, the inflammatory model has been revisited due to the fragmented efficacy of the current management approaches. As a result, more attention is being paid to pharmacotherapies that lay outside the traditional vault of psychotropic agents such as antidepressants and antipsychotics. Cyclooxygenase-2 inhibitors, best known for their role in acute pain management, are a potent example of this pharmacological appropriation. Celecoxib and rofecoxib—selective cyclooxygenase-2 inhibitors—have been investigated for their efficacy as both stand-alone therapies and augmentation agents in psychiatry.</p>
<p>The purpose of this paper is twofold: first, to review the relationship between inflammation and neuropsychiatric illnesses, and second, to provide a review of randomized control trials (RCTs) that investigate the use of cyclooxygenase-2 inhibitors for the treatment of select neuropsychiatric illnesses.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<p>A Boolean search was conducted for literature published up to November 19, 2017. We searched PubMed, Embase, and PsychINFO databases, and the Clinicaltrials.gov and The Stanley Medical Research Institute trial registries. Search terms included are attached in Appendix A. Articles were selected for human, randomized clinical trials and treatment efficacy. The search was augmented by manually searching the references of key papers and related literature. We adhered to PRISMA guidelines and flowsheet attached in Appendix A. <xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref> contains a summary chart of the results. The results were presented as a narrative review format.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Clinical trials investigating celecoxib in neuropsychiatric disorders.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1" valign="top">Study</th>
<th colspan="1" rowspan="1" valign="top">Sample</th>
<th colspan="1" rowspan="1" valign="top">Study Design</th>
<th colspan="1" rowspan="1" valign="top">Intervention and Dosage</th>
<th colspan="1" rowspan="1" valign="top">Outcome Measures</th>
<th colspan="1" rowspan="1" valign="top">Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1" valign="top">Muller et al. (<xref ref-type="bibr" rid="B4">4</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Depression,<break></break><italic>n</italic> = 40</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>6 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg + Reboxetine<break></break>VS Placebo + Reboxetine</td>
<td colspan="1" rowspan="1" valign="top">HAM-D</td>
<td colspan="1" rowspan="1" valign="top">Favor of adjuvant celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Akhondzadeh et al. (<xref ref-type="bibr" rid="B5">5</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Depression,<break></break><italic>n</italic> = 40</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>6 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg + fluoxetine<break></break>VS Placebo + fluoxetine</td>
<td colspan="1" rowspan="1" valign="top">HRDS</td>
<td colspan="1" rowspan="1" valign="top">Favor of adjuvant celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Fields et al. (<xref ref-type="bibr" rid="B6">6</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Depression,<break></break><italic>n</italic> = 2,528<break></break>Elderly cohort</td>
<td colspan="1" rowspan="1" valign="top">Double-blind,<break></break>Multicenter, randomized, placebo-controlled add-on trial<break></break>6 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg VS Naproxen 440 mg VS<break></break>Placebo</td>
<td colspan="1" rowspan="1" valign="top">GDS,<break></break>Modified Mini-Mental State Exam (3MS-E)</td>
<td colspan="1" rowspan="1" valign="top">Not in favor of celecoxib monotherapy</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Abbasi et al. (<xref ref-type="bibr" rid="B7">7</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Depression,<break></break><italic>n</italic> = 40</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>6 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg + sertraline<break></break>VS Placebo + sertraline</td>
<td colspan="1" rowspan="1" valign="top">HAM-D</td>
<td colspan="1" rowspan="1" valign="top">Favor of adjuvant celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Majd et al. (<xref ref-type="bibr" rid="B8">8</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Depression,<break></break><italic>n</italic> = 30</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>8 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 200 mg + sertraline<break></break>VS Placebo + sertraline</td>
<td colspan="1" rowspan="1" valign="top">HAM-D, HAM-A</td>
<td colspan="1" rowspan="1" valign="top">Not in favor of celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Jafari et al. (<xref ref-type="bibr" rid="B9">9</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Depression,<break></break><italic>n</italic> = 40<break></break>Comorbid brucellosis</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>8 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 200 mg + antibiotics<break></break>VS Placebo + antibiotics</td>
<td colspan="1" rowspan="1" valign="top">HDRS</td>
<td colspan="1" rowspan="1" valign="top">Favor of adjuvant celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Mohammad et al. (<xref ref-type="bibr" rid="B10">10</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Depression,<break></break><italic>n</italic> = 52<break></break>Comorbid breast cancer</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>6 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg VS diclofenac 100 mg</td>
<td colspan="1" rowspan="1" valign="top">HDRS</td>
<td colspan="1" rowspan="1" valign="top">Favor of celecoxib monotherapy</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Alamdarsaravi et al. (<xref ref-type="bibr" rid="B11">11</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Depression,<break></break><italic>n</italic> = 40<break></break>Comorbid colorectal cancer</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>6 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg<break></break>VS Placebo</td>
<td colspan="1" rowspan="1" valign="top">HDRS</td>
<td colspan="1" rowspan="1" valign="top">Favor of celecoxib monotherapy</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Nery et al. (<xref ref-type="bibr" rid="B12">12</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Bipolar disorder–depression or mixed episode,<break></break><italic>n</italic> = 28</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial,<break></break>6 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg + TAU<break></break>VS Placebo + TAU</td>
<td colspan="1" rowspan="1" valign="top">HDRS</td>
<td colspan="1" rowspan="1" valign="top">Favor of adjuvant celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Kargar et al. (<xref ref-type="bibr" rid="B13">13</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Bipolar disorder–mania,<break></break><italic>n</italic> = 35</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial,</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg + ECT<break></break>VS Placebo + ECT</td>
<td colspan="1" rowspan="1" valign="top">YMRS, BDNF serum levels</td>
<td colspan="1" rowspan="1" valign="top">Not in favor of celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Arabzadeh et al. (<xref ref-type="bibr" rid="B14">14</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Bipolar disorder – mania,<break></break><italic>n</italic> = 46</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial,<break></break>6 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg + Sodium Valproate<break></break>VS Placebo + Sodium Valproate</td>
<td colspan="1" rowspan="1" valign="top">YMRS, HDRS</td>
<td colspan="1" rowspan="1" valign="top">Favor of adjuvant celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Shalbafan et al. (<xref ref-type="bibr" rid="B15">15</xref>)</td>
<td colspan="1" rowspan="1" valign="top">OCD,<break></break><italic>n</italic> = 54</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>10 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg + Fluvoxamine 200 mg VS Placebo + Fluvoxamine 200 mg</td>
<td colspan="1" rowspan="1" valign="top">Y-BOCS</td>
<td colspan="1" rowspan="1" valign="top">Favor of adjuvant celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Sayyah et al. (<xref ref-type="bibr" rid="B16">16</xref>)</td>
<td colspan="1" rowspan="1" valign="top">OCD, <italic>n</italic> = 56</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>8 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg + Fluoxetine VS Placebo + Fluoxetine</td>
<td colspan="1" rowspan="1" valign="top">Y-BOCS</td>
<td colspan="1" rowspan="1" valign="top">Favor of adjuvant celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Muller et al. (<xref ref-type="bibr" rid="B17">17</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Schizophrenia,<break></break><italic>n</italic> = 50</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>5 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg + Risperidone VS Placebo + Risperidone</td>
<td colspan="1" rowspan="1" valign="top">PANSS,<break></break>Simpson-Angus Rating Scale of EPS (SAS)</td>
<td colspan="1" rowspan="1" valign="top">Favor of adjuvant celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Rapaport et al. (<xref ref-type="bibr" rid="B18">18</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Schizophrenia,<break></break><italic>n</italic> = 38</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>9 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg + TAU<break></break>VS Placebo + TAU</td>
<td colspan="1" rowspan="1" valign="top">PANSS, Scale for the Assessment of Negative Symptoms (SANS),<break></break>CGI-S,<break></break>Clinical Global Impression: Improvement (CGI-I), HAM-A</td>
<td colspan="1" rowspan="1" valign="top">Not in favor of celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Akhondzadeh et al. (<xref ref-type="bibr" rid="B19">19</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Schizophrenia,<break></break><italic>n</italic> = 60</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>8 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg + Risperidone<break></break>VS Placebo + Risperidone</td>
<td colspan="1" rowspan="1" valign="top">PANSS,<break></break>ESRS</td>
<td colspan="1" rowspan="1" valign="top">Favor of adjuvant celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Muller et al. (<xref ref-type="bibr" rid="B20">20</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Schizophrenia, <italic>n</italic> = 49</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>6 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg+ Amisulpride 200–1,000 mg<break></break>VS Placebo + Amisulpride 200–1,000 mg</td>
<td colspan="1" rowspan="1" valign="top">PANSS, CGI</td>
<td colspan="1" rowspan="1" valign="top">Favor of adjuvant celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Muller<break></break>Trial ID: 01T-418<break></break>(yet to publish)</td>
<td colspan="1" rowspan="1" valign="top">Schizophrenia,<break></break><italic>n</italic> = 40</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>8 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg + Risperidone VS Placebo + Risperidone</td>
<td colspan="1" rowspan="1" valign="top">PANSS, SANS, CBI, ESRS, Barnes Akathisia<break></break>QOL</td>
<td colspan="1" rowspan="1" valign="top">Not in favor of celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Zhang<break></break>Trial ID: 03T-459<break></break>(yet to publish)</td>
<td colspan="1" rowspan="1" valign="top">Schizophrenia,<break></break><italic>n</italic> = 250</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial<break></break>12 weeks</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 400 mg + Risperidone<break></break>VS Placebo + Risperidone</td>
<td colspan="1" rowspan="1" valign="top">PANSS, BPRS, SANS, ICG, WCST, N-back Test, WMS-R, CPT, WAIS-R, FSIQ, SAS, AIMS, MANOVAs</td>
<td colspan="1" rowspan="1" valign="top">Favor of adjuvant celecoxib</td>
</tr>
<tr>
<td colspan="1" rowspan="1" valign="top">Asadabadi et al. (<xref ref-type="bibr" rid="B21">21</xref>)</td>
<td colspan="1" rowspan="1" valign="top">Autism,<break></break><italic>n</italic> = 40</td>
<td colspan="1" rowspan="1" valign="top">Double-blind, randomized, placebo-controlled add-on trial</td>
<td colspan="1" rowspan="1" valign="top">Celecoxib 300 mg BID + Risperidone VS Placebo + Risperidone</td>
<td colspan="1" rowspan="1" valign="top">Autism Behaviour Checklist Community Edition (ABC-C)Rating Scale<break></break>(Irritability subsection)</td>
<td colspan="1" rowspan="1" valign="top">Favor of adjuvant celecoxib</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="s2_1">
<title>The Link Between Inflammatory System, the Brain, and Mental Illness</title>
<p>In 1927, Julius Wagner-Jauregg became the first and the only psychiatrist thus far to win a Nobel Prize in Medicine. His impactful discovery involved the association with inflammation <italic>via</italic> malaria inoculation to cure neuropsychiatric symptoms of syphilis (<xref ref-type="bibr" rid="B22">22</xref>). Unfortunately, this inflammatory etiological theory was set aside during the advent of the psychotropic revolution (<xref ref-type="bibr" rid="B23">23</xref>). While support for the monoamine hypothesis in neuropsychiatric disorders continued to gain traction in subsequent decades, a residual group of patients exhibited persistent treatment-refractory illnesses and chronic debilitating symptoms suggestive of alternate hypotheses for neuropsychiatric conditions (<xref ref-type="bibr" rid="B3">3</xref>).</p>
<sec id="s2_1_1">
<title>Innate and Adaptive Immunity</title>
<p>Immune system responses are typically classified as either innate or adaptive. The innate immune system features elements that are both genetically heritable and evolutionarily ancient, found in all multicellular organisms (<xref ref-type="bibr" rid="B24">24</xref>,). The innate system’s principal phagocytes include neutrophils, monocytes, and macrophages, which work in synergy to establish the first-line barrier of immunity (<xref ref-type="bibr" rid="B26">26</xref>). This line of defense is supplemented by the adaptive immune system, which includes specialized cells, B-lymphocytes and T-lymphocytes. Both response sectors produce a composite operation of moderating immunotransmitters, defined by cytokines. These immunomodulatory cytokines are typically categorized as pro-inflammatory or anti-inflammatory on the basis of their general effects. Pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFα), interferon gamma (IFNγ), and interleukin (IL)-1 and IL-6 are primarily secreted by monocytes and macrophages, promoting additional complex inflammatory response systems, discussed in detail elsewhere [e.g., Ref. (<xref ref-type="bibr" rid="B27">27</xref>)]. Anti-inflammatory cytokines include IL-4, IL-10, IL-11, and IL-13 (<xref ref-type="bibr" rid="B26">26</xref>,). In simplistic terms, imbalanced pro-inflammatory over anti-inflammatory cytokine load will preferentially increase the throughput of pathological cellular pathways.</p>
</sec>
<sec id="s2_1_2">
<title>Central Nervous System Immunity</title>
<p>The blood–brain barrier is the brain’s primary defense against chemical insult. During peripheral inflammatory activation, there is increased permeability of the blood–brain barrier (<xref ref-type="bibr" rid="B29">29</xref>,). Such increases in blood–brain permeability may exacerbate or possibly even initiate neuropsychiatric and neurological disorders [see Ref. (<xref ref-type="bibr" rid="B31">31</xref>) for a review]. Furthermore, recent identification of lymphatic vessels within the central nervous system (CNS) reveals an alternate route of communication with the immune system to the brain (<xref ref-type="bibr" rid="B32">32</xref>). Once activated, a host of cellular and chemical pathways within the brain can result in significant structural change.</p>
<p>Microglia are specialized macrophages localized to the CNS that also play an important regulatory role in inflammatory response. They secrete neurotrophic factors important for cellular repair and signal recruitment for immune cells (<xref ref-type="bibr" rid="B26">26</xref>,,). The role microglia play in inflammation-driven neuronal damage and degeneration is also well established (<xref ref-type="bibr" rid="B35">35</xref>). Microglia have been shown to express different phenotypes or polarizations, classified as M1 and M2. M1 polarization is influenced by the pro-inflammatory state and acts in neuronal apoptosis, while the M2 polarization, in contrast, promotes neurogenesis (<xref ref-type="bibr" rid="B32">32</xref>,–<xref ref-type="bibr" rid="B39">39</xref>). Interferon alpha (IFNα) has been shown to induce a pro-inflammatory shift in microglial phenotype, from M2 to M1, resulting in depressive symptoms in mice (<xref ref-type="bibr" rid="B40">40</xref>,).</p>
</sec>
<sec id="s2_1_3">
<title>Inflammation and Neuropsychiatric Symptoms</title>
<p>When anti-inflammatory regulators are unable to balance pro-inflammatory reactions, inflammation can persist, in conjunction with sub-threshold neuropsychiatric symptoms (<xref ref-type="bibr" rid="B42">42</xref>). The following mechanisms describe the cytokine communication with neuropsychiatric symptoms and thus support the inflammatory hypothesis.</p>
<p>Pro-inflammatory markers have been associated with the development of neuropsychiatric symptoms (<xref ref-type="bibr" rid="B43">43</xref>). IL-6 activates the type 2 immune response, prompting the B-cell maturation pathway, consequently producing antibodies directed against extracellular pathogens. In addition, IL-6 activates the release of C-reactive protein (CRP) from the liver. Elevated levels of CRP and IL-6 in childhood were associated with an increased risk of developing depressive and psychotic symptoms in the future (<xref ref-type="bibr" rid="B44">44</xref>). Consistent with this, a significant association has been reported between CRP and several neuropsychiatric disorders, including depression, anxiety, and schizophrenia (<xref ref-type="bibr" rid="B45">45</xref>,). CRP is a well-established biomarker for an active inflammatory process and is a significant independent predictor of coronary heart disease risk (<xref ref-type="bibr" rid="B47">47</xref>–<xref ref-type="bibr" rid="B53">53</xref>). Furthermore, elevated CRP and IL-6 levels have also been associated with cognitive dysfunction (<xref ref-type="bibr" rid="B54">54</xref>). Studies have shown that biomarkers such as CRP and IL-6 may shed light on subtyping depression (<xref ref-type="bibr" rid="B55">55</xref>,). Several meta-analyses have demonstrated significant evidence of elevated pro-inflammatory cytokines in patients with depressive symptoms (<xref ref-type="bibr" rid="B43">43</xref>,,), bipolar disorder (<xref ref-type="bibr" rid="B58">58</xref>–<xref ref-type="bibr" rid="B60">60</xref>), schizophrenia (<xref ref-type="bibr" rid="B58">58</xref>,), obsessive compulsive disorder (OCD) (<xref ref-type="bibr" rid="B62">62</xref>), and autism spectrum disorders (ASDs) (<xref ref-type="bibr" rid="B63">63</xref>). These pro-inflammatory markers include CRP, IL-6, TNFα, and the IL-1 receptor antagonist (IL-1Ra) (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B57">57</xref>–<xref ref-type="bibr" rid="B63">63</xref>). In addition, pro-inflammatory cytokines have been shown to trend toward normalization with symptom improvement indicating treatment response (<xref ref-type="bibr" rid="B64">64</xref>). Participation from microglia and peripheral macrophages are identified in activated inflammatory networks (<xref ref-type="bibr" rid="B65">65</xref>). An exaggerated immune response can be responsible for neuronal damage and decreased brain derived neurotrophic factor (BDNF), a protein integral to neuronal growth, plasticity, and survival (<xref ref-type="bibr" rid="B66">66</xref>–<xref ref-type="bibr" rid="B70">70</xref>). Excessive activation of the immune system may exacerbate mental illness in a subgroup of vulnerable individuals (<xref ref-type="bibr" rid="B71">71</xref>, <xref ref-type="bibr" rid="B72">72</xref>). The inflammatory hypothesis suggests that hyperactivation of the immune system may produce nitro-oxidative stress and alterations of the kynurenine pathway, subsequently dysregulating monoamine levels and activating the glutamatergic system (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B73">73</xref>).</p>
<p>The evidence for cytokine-induced neuropsychiatric symptoms in healthy participants favors the inflammatory model. For example, healthy participants received an infusion of endotoxin to induce an inflammatory response, with resultant mood symptoms (<xref ref-type="bibr" rid="B74">74</xref>). Similarly, healthy individuals who received exogenous cytokines (IL-2, IFNα, and TNFα) also developed neuropsychiatric symptoms, including depression, mania, emotional dysregulation, cognitive impairment, and/or avolition (<xref ref-type="bibr" rid="B75">75</xref>). Elevated serum pro-inflammatory markers, TNFα, IL-6, and cortisol levels were observed by <italic>Salmonella abortus equi</italic> endotoxin injections (<xref ref-type="bibr" rid="B76">76</xref>). Subsequently, the subjects also exhibited neuropsychiatric symptoms of appetite changes, mood and anxiety symptoms, and cognitive decline without physical sickness symptoms (<xref ref-type="bibr" rid="B77">77</xref>). These findings were replicated with other vaccinations of healthy individuals (<xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B78">78</xref>). Preclinical research has yielded similar findings, wherein lipopolysaccharide (LPS) and IL-1 injections in mice were found to result in sickness behavior, an analog to depressive symptoms (<xref ref-type="bibr" rid="B79">79</xref>).</p>
<p>Notably, pro-inflammatory agents such as recombinant IFNα and IL-2 have been used in the treatment of hepatitis C and carcinomas, respectively (<xref ref-type="bibr" rid="B80">80</xref>, <xref ref-type="bibr" rid="B81">81</xref>). Interestingly, while effective for treating the targeted indication, IFNα was found to induce significant neuropsychiatric side effects with up to 80% of patients endorsing mild to moderate depressive symptoms (<xref ref-type="bibr" rid="B82">82</xref>–<xref ref-type="bibr" rid="B84">84</xref>). Grigoleit et al. (<xref ref-type="bibr" rid="B85">85</xref>) identified a positive dose-dependent association in IL-6, IL-10, TNFα, cortisol, and norepinephrine with neuropsychiatric symptoms. While some studies have reported that serum IL-6 and TNFα also appeared elevated in OCD patients compared to healthy controls [e.g., Ref. (<xref ref-type="bibr" rid="B86">86</xref>)], it should be noted that an earlier meta-analysis of OCD patients revealed no significant difference in TNFα or IL-6 (<xref ref-type="bibr" rid="B62">62</xref>). However, these authors did note a reduced level of pro-inflammatory IL-1β in OCD patients (<xref ref-type="bibr" rid="B62">62</xref>).</p>
</sec>
<sec id="s2_1_4">
<title>Autoimmune Conditions and Neuropsychiatric Disorders</title>
<p>Autoimmune and infectious conditions such as rheumatoid arthritis (<xref ref-type="bibr" rid="B87">87</xref>), type 1 diabetes (<xref ref-type="bibr" rid="B88">88</xref>), systemic lupus erythematosus (<xref ref-type="bibr" rid="B89">89</xref>), hepatitis, and sepsis (<xref ref-type="bibr" rid="B90">90</xref>) increase the risk of neuropsychiatric symptoms. An extensive Danish-based study found a 62% increased risk of mood disorders after infection-related hospitalizations (<xref ref-type="bibr" rid="B90">90</xref>). In patients who suffer from both Crohn’s disease and depression, exacerbations of both physical and mental illnesses tend to occur at the same time (<xref ref-type="bibr" rid="B91">91</xref>). Patients experiencing psoriasis and anxiety symptoms were shown to benefit from treatment with cytokine inhibitors (<xref ref-type="bibr" rid="B92">92</xref>–<xref ref-type="bibr" rid="B94">94</xref>). In addition, a greater prevalence of autoimmune conditions such as pemphigus in bipolar disorder is observed (<xref ref-type="bibr" rid="B95">95</xref>). In a large epidemiological study, multiple infections and autoimmune disorders were associated with the increased lifetime prevalence of schizophrenia spectrum disorders (<xref ref-type="bibr" rid="B96">96</xref>).</p>
<p>In summary, multiple studies have indicated a positive association between inflammation and neuropsychiatric symptoms. Elevated pro-inflammatory markers are consistently associated with neuropsychiatric symptoms and reveal a bidirectional relationship.</p>
</sec>
</sec>
<sec id="s2_2">
<title>Cyclooxygenase-2 (COX-2) Inhibitors</title>
<p>The COX pathway involves the precursor substrate of arachidonic acid (AA) to produce thromboxane, prostacyclin, and prostaglandins (PG) D2, E2, F2, and I2. AA is extracted from cell membranes by phospholipases, predominately cytoplasmic phospholipase A2 (cPLA2), and metabolized by the COX enzymes. The two rate-limiting enzymes within the COX pathways are COX-1 and COX-2. COX-1 is constitutionally expressed, and thus responsible for baseline prostaglandin levels, whereas COX-2 is inducible and expressed exclusively in the CNS, kidney, thymus, GI tract, and possibly in the female reproductive system (<xref ref-type="bibr" rid="B97">97</xref>–<xref ref-type="bibr" rid="B100">100</xref>). However, during inflammatory processes, COX-2 expression is promoted by and regulated by inflammatory stimuli, including lipopolysaccharide (LPS), IL-1, IL-6, TNF, IFNγ, and AA (<xref ref-type="bibr" rid="B101">101</xref>–<xref ref-type="bibr" rid="B108">108</xref>). The variability of isotype expressions COX-1 and COX-2 might be explained by the target tissue and type of insult (<xref ref-type="bibr" rid="B109">109</xref>, <xref ref-type="bibr" rid="B110">110</xref>). The COX-2 enzyme produces prostaglandins, thromboxanes, prostacyclins, and leukotrienes downstream, which are suspected to be culprits for inflammation and neoplastic growth, in particular PGE<sub>2</sub> (<xref ref-type="bibr" rid="B111">111</xref>). Furthermore, COX-2 expression is supported by microglia (<xref ref-type="bibr" rid="B112">112</xref>) and is auto-regulated <italic>via</italic> its by-products, PGE<sub>2</sub> and PGF<sub>2</sub>α, perpetuating the inflammation process (<xref ref-type="bibr" rid="B113">113</xref>, <xref ref-type="bibr" rid="B114">114</xref>). Additionally, PGE<sub>2</sub> promotes IL-6 production (<xref ref-type="bibr" rid="B115">115</xref>), subsequently reinforcing this positive inflammatory feedback loop (<xref ref-type="fig" rid="f1">
<bold>Figure 1</bold>
</xref>). Notably, in COX-2 gene knockout mice, a decrease in PGE<sub>2</sub> and nuclear factor (NF)-κB activity was observed (<xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B116">116</xref>, <xref ref-type="bibr" rid="B117">117</xref>).</p>
<fig id="f1" position="float">
<label>Figure 1</label>
<caption>
<p>COX-2 contributes to inflammation through PGE<sub>2</sub> and IL-6 and is selectively inhibited by celecoxib and rofecoxib. Activated by inflammatory cytokines including PGE<sub>2</sub> and IL-6, AA (the precursor substrate of the COX-2 pathway) is extracted from phospholipid membranes by phospholipases such as cPLA2. COX-2 then drives production of prostaglandins including prostaglandin H<sub>2</sub> (PGH<sub>2</sub>), which in turn is converted to PGE<sub>2</sub>
<italic>via</italic> PGE synthase. An accumulation of PGE<sub>2</sub> leads to increased IL-6 (along with other cytokines) contributing to the inflammatory milieu, further potentiation of the pathway and neurotoxicity contributing to psychopathology. Celecoxib and rofecoxib exert selective inhibition of COX-2 reducing this pathway’s contribution to inflammation mediated neurotoxicity (→ = activates/increases, ⊥ = inhibits).</p>
</caption>
<graphic xlink:href="fpsyt-10-00605-g001"></graphic>
</fig>
<p>In 1995, the first generation of selective COX-2 inhibitors, celecoxib and rofecoxib, entered clinical trials (<xref ref-type="bibr" rid="B118">118</xref>). Over the next 4 years, numerous trials demonstrated selective COX-2 inhibitors could reduce pain and inflammation (<xref ref-type="bibr" rid="B119">119</xref>). From 2000 to 2004, larger trials such as CLASS, VIGOR, and TARGET identified the reduced gastrointestinal risks associated with COX-2 inhibitors, however, highlighted the increased cardiovascular risks leading to rofecoxib being pulled from the market (<xref ref-type="bibr" rid="B120">120</xref>–<xref ref-type="bibr" rid="B123">123</xref>). In 2005, valdecoxib was also withdrawn from the market for similar concerns by the Food and Drug Administration (FDA). In 2011, celecoxib was withdrawn from the market for the indication of cancer prevention while still being indicated for rheumatoid arthritis, osteoarthritis, and acute pain. Subsequently, this led to cautious prescribing due to concerns of cardiovascular side effects (<xref ref-type="bibr" rid="B124">124</xref>).</p>
<p>Preclinical trials have shown that rofecoxib can increase serotonin levels in the frontal and temporoparietal cortex (<xref ref-type="bibr" rid="B125">125</xref>). In addition, celecoxib was shown to potentiate the effects of reboxetine and fluoxetine on cortical noradrenaline and serotonin output (<xref ref-type="bibr" rid="B126">126</xref>).</p>
<p>Although ubiquitously expressed, COX-1 is typically described as gastro-protective and neuroprotective (<xref ref-type="bibr" rid="B127">127</xref>, <xref ref-type="bibr" rid="B128">128</xref>), and pre-clinical data reveal some contradictory evidence regarding the inflammatory classifications of the COX isoforms. COX-2 may have anti-inflammatory and neuroprotective properties, aiding in neurotransmitter release, long-term potentiation, blood flow regulation, and memory consolidation (<xref ref-type="bibr" rid="B129">129</xref>). It was reported that COX-2 gene knockout mice were susceptible to inflammation compared to healthy mice (<xref ref-type="bibr" rid="B130">130</xref>, <xref ref-type="bibr" rid="B131">131</xref>). Deletion of the COX-2 gene causes increased permeability of the blood–brain barrier and leukocyte infiltration (<xref ref-type="bibr" rid="B132">132</xref>). Another study showed that maximal COX-2 expression coincided with inflammatory resolution and was associated with minimal PGE<sub>2</sub> synthesis (<xref ref-type="bibr" rid="B133">133</xref>).</p>
<p>Nevertheless, COX-2 inhibitors have proven to be beneficial in glutamate-mediated death prevention and suppression of pro-inflammatory cytokines (<xref ref-type="bibr" rid="B134">134</xref>, <xref ref-type="bibr" rid="B135">135</xref>). Kainic acid (KA), a potent neurotoxin, elicits excitatory effects on <italic>N</italic>-methyl-D-aspartate (NMDA) receptors resulting in status epilepticus, neurodegeneration, and memory loss (<xref ref-type="bibr" rid="B134">134</xref>–<xref ref-type="bibr" rid="B138">138</xref>). KA has also been shown to increase COX-2 expression in the CNS (<xref ref-type="bibr" rid="B139">139</xref>); therefore, COX-2 inhibitors have been shown to prevent KA-induced neuronal death (<xref ref-type="bibr" rid="B140">140</xref>). There appears to be mounting evidence of therapeutic effect of COX-2 inhibitors in mediating glutamatergic processes (<xref ref-type="bibr" rid="B141">141</xref>–<xref ref-type="bibr" rid="B143">143</xref>). As well, there seems to be appropriate evidence for COX pathway in neuropsychiatric disorders.</p>
</sec>
<sec id="s2_3">
<title>Pathophysiology of Neuropsychiatric Disorders and the Efficacy of Cyclooxygenase-2 Inhibitors</title>
<p>We have now established there is substantive evidence for inflammation being a driver of neuropsychiatric symptoms by negatively impacting on neuronal proliferation, survival, and differentiation (<xref ref-type="bibr" rid="B144">144</xref>, <xref ref-type="bibr" rid="B145">145</xref>). Furthermore, the COX pathway potentiates the inflammatory process and may exacerbate inflammation mediated neurodegeneration. COX-2 inhibition reduces this inflammatory load and thus the impact of these pathways on the brain.</p>
<p>In this section, we address the proposed mechanisms by which inflammatory states influence central monoamine effects, the hypothalamic–pituitary–adrenal (HPA) axis, and microglial activation, pathways at the center of neuropsychiatric pathogenesis. Discussion will focus on specific conditions including depression, bipolar disorder, schizophrenia, ASD, and OCD. Herein, a number of clinical trials investigating the efficacy of the cyclooxygenase-2 inhibitors for neuropsychiatric disorders are discussed, summarized in <xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>. Particular attention is being paid to the operative inflammatory pathways inherent to these conditions and the potential role for COX-2 inhibitors in their management.</p>
<sec id="s2_3_1">
<title>Neurotransmitter Dysregulation Hypothesis</title>
<p>The dysregulation of the neurotransmitters such as serotonin, norepinephrine, dopamine, acetylcholine, and glutamate has been the foci of the biochemical etiology of neuropsychiatric illnesses. While treatment with antidepressants and neuroleptics aims to modulate monoamine signaling, there is a wealth of evidence supporting secondary mechanisms of action including effects on inflammatory pathways (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B146">146</xref>). During inflammation, the pro-inflammatory cytokines IL-2 and IFNα have been shown to directly increase enzyme activity of the indoleamine-pyrrole 2,3-dioxygenase (IDO) enzyme of the kynurenine pathway, which promotes conversion of tryptophan to kynurenine, consequently depleting the antecedent supply to serotonin (<xref ref-type="bibr" rid="B147">147</xref>), in addition to direct catabolism of serotonin by IL-6 and IFNα (<xref ref-type="bibr" rid="B148">148</xref>, <xref ref-type="bibr" rid="B149">149</xref>). This evidence supports the monoamine hypothesis regarding the hypoactive serotonin state featured in mood disorders (<xref ref-type="bibr" rid="B150">150</xref>–<xref ref-type="bibr" rid="B152">152</xref>). IFNα administration led to inflammation by increasing the concentration of kynurenine pathway metabolites in the CSF, namely kynurenine, kynurenic acid, and quinolinic acid (QUIN) (<xref ref-type="bibr" rid="B153">153</xref>). These metabolites have been presented as inducers of depressive and anxiety symptoms (<xref ref-type="bibr" rid="B154">154</xref>). Notably, QUIN can selectively activate NMDA receptors (<xref ref-type="bibr" rid="B155">155</xref>, <xref ref-type="bibr" rid="B156">156</xref>) and has been associated with numerous neurological diseases, including: Alzheimer’s disease, anxiety, depression, epilepsy, human immunodeficiency virus-associated neurocognitive disorders, and Huntington’s disease (<xref ref-type="bibr" rid="B155">155</xref>, <xref ref-type="bibr" rid="B157">157</xref>–<xref ref-type="bibr" rid="B161">161</xref>). QUIN has also been shown to cause neurodegeneration <italic>via</italic> multiple models (<xref ref-type="bibr" rid="B159">159</xref>).</p>
</sec>
<sec id="s2_3_2">
<title>HPA Axis Dysregulation</title>
<p>During a stress response, the HPA axis is activated (<xref ref-type="bibr" rid="B162">162</xref>). The hypothalamus secretes two hormones, corticotrophin releasing hormone (CRH) and arginine vasopressin, which act on the pituitary gland to increase adrenocorticotropic hormone (ACTH) release, subsequently accelerating the production of cortisol to aid in the homeostasis feedback loop (<xref ref-type="bibr" rid="B163">163</xref>). Studies have demonstrated an elevated inflammation state perpetuating cytokines such as IL-1, IL-6, TNFα, and IFNα; these in turn activate the HPA axis elevating levels of CRH, ACTH, and cortisol (<xref ref-type="bibr" rid="B162">162</xref>, <xref ref-type="bibr" rid="B164">164</xref>–<xref ref-type="bibr" rid="B167">167</xref>). This relationship furthermore supports the feedback loop maintaining a hyperactive HPA system (<xref ref-type="bibr" rid="B163">163</xref>). Chronic elevation of endogenous glucocorticoids results in mood symptoms (<xref ref-type="bibr" rid="B163">163</xref>, <xref ref-type="bibr" rid="B167">167</xref>). Additionally, it is proposed that cortisol increases the catabolizing enzyme tryptophan 2,3-dioxygenase (TDO) to deplete the precursor to serotonin implicating an association with the serotonin dysregulation (<xref ref-type="bibr" rid="B168">168</xref>, <xref ref-type="bibr" rid="B169">169</xref>).</p>
<p>Contrary to advantageous effects of steroids in managing infections, there is evidence that glucocorticoid treatment duration for acute infections versus chronic infections results in changes of glucocorticoid receptor function and concentrations (<xref ref-type="bibr" rid="B170">170</xref>, <xref ref-type="bibr" rid="B171">171</xref>). This subsequently influences HPA axis hyperactivity, which elevates cortisol and results in decreased function and quantity of glucocorticoid receptors resulting in impaired feedback and glucocorticoid resistance (<xref ref-type="bibr" rid="B170">170</xref>). Glucocorticoid resistance that is seen in depressed patients may also be a result of changes in expressed glucocorticoid receptors ratio <italic>via</italic> cellular phosphorylation (<xref ref-type="bibr" rid="B172">172</xref>–<xref ref-type="bibr" rid="B174">174</xref>). Patients with neuropsychiatric illnesses also exhibited heightened plasma, urine, and cerebrospinal fluid (CSF) levels of cortisol and anatomical changes in the pituitary and adrenal glands (<xref ref-type="bibr" rid="B175">175</xref>–<xref ref-type="bibr" rid="B178">178</xref>). Pavon et al. (<xref ref-type="bibr" rid="B179">179</xref>) reported elevated cortisol levels in depressed patients associated with elevated TNFα, in addition to decreased levels of IL-1β, suggesting that increased cortisol may influence inflammatory cytokines. However, it is important to bear in mind that while some subtypes of depression (namely melancholic or endogenous) are associated with hyperactive HPA axis, glucocorticoid resistance, and increased circulating cortisol levels, atypical and seasonal depression has been consistently reported to have normal or hypoactive HPA axis function (<xref ref-type="bibr" rid="B180">180</xref>, <xref ref-type="bibr" rid="B181">181</xref>). Therefore, the hypothesis is supported regarding the impairment of the HPA axis through cellular mechanisms and dysfunctional feedback leading to HPA axis dysfunction, one of the most consistent findings in biological psychiatry, which is exhibited by patients with depression, bipolar disorder, and schizophrenia (<xref ref-type="bibr" rid="B169">169</xref>, <xref ref-type="bibr" rid="B182">182</xref>).</p>
</sec>
<sec id="s2_3_3">
<title>Microglial Hyperactivation Hypothesis</title>
<p>Microglia function as macrophages of the CNS by clearing foreign particles and promoting healing after traumatic brain injury (<xref ref-type="bibr" rid="B183">183</xref>). They are also involved in the pruning process of neurons by tagging unutilized synapses for degradation to rebuild more active neurons during the maturation process (<xref ref-type="bibr" rid="B184">184</xref>). Pathological synaptic pruning may also contribute to prodromal, remittent and relapsing, and chronic stages of neuropsychiatric disorders (<xref ref-type="bibr" rid="B185">185</xref>–<xref ref-type="bibr" rid="B187">187</xref>). Prolonged microglial activation induces synaptic pruning subsequent to the accumulation of two pro-inflammatory cytokines, specifically TNFα and IL-1β, leading to neuronal apoptosis (<xref ref-type="bibr" rid="B188">188</xref>, <xref ref-type="bibr" rid="B189">189</xref>). The subsequent dysfunctional neuronal pathways may be compensated by adaptive systems, which may resultantly produce and preserve maladaptive behaviors (<xref ref-type="bibr" rid="B190">190</xref>, <xref ref-type="bibr" rid="B191">191</xref>). Individuals at an ultra-high risk for developing schizophrenia also appear to have significantly elevated activity of microglia (<xref ref-type="bibr" rid="B192">192</xref>). Histological changes in activated microglia have been observed in patients with schizophrenia who had committed suicide during an acute episode of psychosis (<xref ref-type="bibr" rid="B193">193</xref>). In contrast, conflicting data derived from post-mortem studies have reported reductions in microglial density and activation (<xref ref-type="bibr" rid="B194">194</xref>). These findings may indicate a difference of microglial activation depending on the stage of illness among other factors (<xref ref-type="bibr" rid="B194">194</xref>). Aberrant microglial activation is seen in other neuropsychiatric disorders including Alzheimer’s dementia, Parkinson’s disease, multiple sclerosis, herpes encephalitis, traumatic brain injury, and stroke (<xref ref-type="bibr" rid="B195">195</xref>, <xref ref-type="bibr" rid="B196">196</xref>). Alterations in brain morphology have been described across the spectrum on neuropsychiatric conditions (<xref ref-type="bibr" rid="B197">197</xref>–<xref ref-type="bibr" rid="B201">201</xref>). Duration of mental illnesses also has evidence of significant brain morphologic changes (<xref ref-type="bibr" rid="B201">201</xref>). Mechanisms that may encourage these anatomical reductions include oxidative and nitrosative stress through activation of microglia (<xref ref-type="bibr" rid="B202">202</xref>).</p>
</sec>
</sec>
<sec id="s2_4">
<title>Depression</title>
<p>Major depressive disorder (MDD) is highly prevalent throughout the world, and the prevalence has increased over time (<xref ref-type="bibr" rid="B73">73</xref>). The estimated lifetime prevalence of major depression and persistent depressive disorder in adults is 12% (<xref ref-type="bibr" rid="B203">203</xref>). In unipolar depression, inflammation and depressive symptoms share a bidirectional relationship. Immunological markers such as CRP, and cytokines IL-1, IL-6, and TNFα, are elevated in patients with depression (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B204">204</xref>, <xref ref-type="bibr" rid="B205">205</xref>). A recent meta-analysis comprised of 3,212 participants noted elevations in the concentrations of IL-6, TNFα, IL-10, the soluble IL-2 receptor, C-C chemokine ligand 2, IL-13, IL-18, IL-12, IL-1 receptor antagonist, and the soluble TNF receptor 2 in depression patients (<xref ref-type="bibr" rid="B1">1</xref>). Several groups of authors have reported that IL-6 may be a useful biomarker for predicting treatment response (<xref ref-type="bibr" rid="B115">115</xref>, <xref ref-type="bibr" rid="B204">204</xref>–<xref ref-type="bibr" rid="B207">207</xref>). A prospective study revealed a correlation with elevated serum IL-6, as those with higher levels were more likely to be depressed by 18 years of age than individuals on the lower end levels (<xref ref-type="bibr" rid="B208">208</xref>). Pro-inflammatory cytokines have been shown to trend toward normalization with symptom improvement indicating treatment response (<xref ref-type="bibr" rid="B64">64</xref>).</p>
<p>Studies have shown biomarkers such as CRP and IL-6 may shed light on depression subtypes (<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B56">56</xref>). An interesting larger scale study, The Netherlands Study of Depression and Anxiety (NESDA), extrapolated gender variance while evaluating CRP and IL-6 (<xref ref-type="bibr" rid="B181">181</xref>). The authors described an increased level of CRP and IL-6 with normal levels of TNFα in male patients with depressive symptoms; however, there were no associations with the cytokines in women with depressive symptoms (<xref ref-type="bibr" rid="B209">209</xref>). Additionally, they noted a differential role of the HPA function, inflammatory markers, and metabolic variables between melancholic and atypical depression subtypes (<xref ref-type="bibr" rid="B181">181</xref>).</p>
<p>Elevated levels of kynurenine pathway toxic metabolites such as QUIN are also observed in patients with depression (<xref ref-type="bibr" rid="B210">210</xref>). Interestingly, in a 6-week RCT, Krause et al. (<xref ref-type="bibr" rid="B211">211</xref>) noted a correlation with kynurenine/tryptophan ratios that was predictive of celecoxib response to significant improvements in the Hamilton Depression Scale (HAMD-17) scores. Subsequently, the kynurenine/tryptophan ratio shows some promise as a potential biomarker for predicting response to COX-2 inhibitors.</p>
<p>Gałecki et al. (<xref ref-type="bibr" rid="B212">212</xref>) reported an increase of non-coding micro ribonucleic acid (mRNA) expression of the COX-2 enzyme in recurrent depression. COX-2 inhibitors decrease IDO activity, subsequently decreasing glutamatergic-active by-products such as QUIN, which may add in neuro-stabilizing effects (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B213">213</xref>, <xref ref-type="bibr" rid="B214">214</xref>). Higher concentrations of QUIN and 3-hydroxykynurenine have been reported in depression (<xref ref-type="bibr" rid="B210">210</xref>). Preclinical studies have shown that celecoxib administration in rats was associated with reductions in PGE<sub>2</sub> levels and a reversal of stress-induced depressive-like behaviors (<xref ref-type="bibr" rid="B215">215</xref>, <xref ref-type="bibr" rid="B216">216</xref>). PGE<sub>2</sub> had been shown to contribute to monoamine imbalance with decreased norepinephrine central neuronal release and dysregulation of the HPA axis (<xref ref-type="bibr" rid="B217">217</xref>). Consequently, this alters cortisol synthesis and subsequently suppresses serotonin (<xref ref-type="bibr" rid="B215">215</xref>, <xref ref-type="bibr" rid="B218">218</xref>–<xref ref-type="bibr" rid="B220">220</xref>). Consistent with this assertion, an animal-based model of depression in rats demonstrated that celecoxib independently enhances the release of serotonin in the brain (<xref ref-type="bibr" rid="B126">126</xref>).</p>
<p>Celecoxib has also been shown to attenuate pro-inflammatory cytokines IL-1β and TNFα and significantly increase IL-10 levels in animal models (<xref ref-type="bibr" rid="B109">109</xref>, <xref ref-type="bibr" rid="B221">221</xref>). IL-1β has been identified as a modulator of BDNF (<xref ref-type="bibr" rid="B144">144</xref>). Some evidence exists indicating that elevated levels of IL-6 results in a reduction in BDNF, implicating in imbalanced neurogenesis, resulting in neural circuitry dysfunction in depressive symptomology (<xref ref-type="bibr" rid="B144">144</xref>). In a preclinical study with rats with a depression-like phenotype, augmentation with acetylsalicylic acid, a non-selective COX inhibitor, enhanced the efficacy of fluoxetine (<xref ref-type="bibr" rid="B222">222</xref>).</p>
<p>To date, several reviews have suggested that celecoxib may be efficacious for the management of depressive symptoms (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B223">223</xref>, <xref ref-type="bibr" rid="B224">224</xref>); however, some have suggested it is clinically inadequate (<xref ref-type="bibr" rid="B225">225</xref>). Abbasi et al. assigned adjuvant celecoxib to MDD patients on sertraline and measured IL-6 levels in samples of their serum. They reported a correlation between decreasing IL-6 concentrations and improvement in the Hamilton Depression Rating Scale (HDRS) scores as outlined in <xref ref-type="table" rid="T1">
<bold>Table 1</bold>
</xref>, along with the key findings of all clinical trials assessing celecoxib in neuropsychiatric disorders appearing in this review. In another RCT (<xref ref-type="bibr" rid="B8">8</xref>) assessing celecoxib augmentation with sertraline in the treatment of drug-naïve women with depression, the authors reported an improvement in HDRS and Hamilton Anxiety Rating Scale (HAM-A) scores compared to the placebo group after 4 weeks of treatment. However, there were no significant differences between both groups at the end of the 8-week trial. Interestingly, the remission rates in the celecoxib group were statistically higher in comparison to the placebo group. Subsequently, Akhondzadeh et al. assessed the HDRS in 40 individuals in a 6-week RCT receiving fluoxetine plus celecoxib versus fluoxetine alone. They demonstrated significant improvements in depressive symptoms, and response and remission rates in the celecoxib group (<xref ref-type="bibr" rid="B5">5</xref>). Another RCT found more significant improvements in depressive symptoms in the adjuvant celecoxib group with reboxetine compared to reboxetine alone (<xref ref-type="bibr" rid="B4">4</xref>). However, Fields commented that there were no significant changes in late-life depressive symptoms in patients prescribed either placebo, celecoxib, or naproxen (<xref ref-type="bibr" rid="B6">6</xref>). These discrepancies in the efficacy of COX-2 inhibitors for this indication might be explained by methodological heterogeneity and variance in target sample characteristics. For example, the Geriatric Depression Scale (GDS) was used for the geriatric patients with a yearly frequency, which may not be a specific tool for detecting variations in depression diagnosis (<xref ref-type="bibr" rid="B226">226</xref>). However, the study did have strength in having a large sample size and median follow-up of 2 years with patients.</p>
<p>Inflammation may be the primary mechanism of pathogenesis in brucellosis (<xref ref-type="bibr" rid="B227">227</xref>, <xref ref-type="bibr" rid="B228">228</xref>). Therefore, Jafari et al. assessed 40 individuals with celecoxib for treatment of mild to moderate depression due to acute brucellosis. They reported an improvement of the HDRS in the 8-week trial with the celecoxib with antibiotics group than placebo with antibiotics (<xref ref-type="bibr" rid="B9">9</xref>).</p>
<p>In patients with comorbid osteoarthritis, pooled data from five post-approval trials, each at 6 weeks in length, participants were randomized in placebo, ibuprofen or naproxen, or celecoxib groups while assessing the Patient Health Questionnaire-9 (PHQ-9). The authors report a trend toward a reduction in PHQ-9 depression scores. However, this lack of robust data is possibly due to the lack of efficacious dosing of celecoxib of 200 mg (<xref ref-type="bibr" rid="B229">229</xref>).</p>
<p>Interestingly, celecoxib may exhibit benefits in patients with colorectal cancer. Investigations have illustrated that celecoxib initiation in the head, neck, and gastrointestinal cancer population is associated with improvements in biological symptoms of depression, including an increase in appetite, body mass index, and quality of life (<xref ref-type="bibr" rid="B230">230</xref>, <xref ref-type="bibr" rid="B231">231</xref>). A 6-week RCT included 40 colon cancer participants randomly assigned to either celecoxib monotherapy or a placebo group, which resulted in significant improvements in the HDRS among the former group, starting as early as week 2 and was sustained until the end of the trial (<xref ref-type="bibr" rid="B11">11</xref>).</p>
<p>Another cancer trial consisted of 52 outpatients with breast cancer undergoing 6 weeks of treatment with either celecoxib or diclofenac for mild to moderate depression. The outcome measures were scored using the HDRS to compare the COX-2 inhibitor with an indiscriminate COX-inhibitor. They reported significant improvements in depressive symptoms in both groups by week 3 and significantly more considerable improvements with the celecoxib group compared to diclofenac by week 6. None of the participants experienced remission HDRS less than or equal to 7 (<xref ref-type="bibr" rid="B10">10</xref>). A meta-analysis demonstrated with 150 participants showed that the adjunctive celecoxib cohort had better response rates and remissions compared to placebo (<xref ref-type="bibr" rid="B224">224</xref>). In summary, interactions between the immune system and neurotransmitters, the tryptophan/kynurenine system, and the glutamatergic system provide links between the immune system and depression; furthermore, data are suggestive of a role for celecoxib in treatment of depressive symptoms (<xref ref-type="bibr" rid="B115">115</xref>).</p>
</sec>
<sec id="s2_5">
<title>Bipolar Disorder</title>
<p>The estimated lifetime prevalence of bipolar disorder among adults worldwide is 1% to 3% (<xref ref-type="bibr" rid="B232">232</xref>). For many, bipolar disorder is a chronic and debilitating illness, with patients often experiencing poor inter-episodic remission (<xref ref-type="bibr" rid="B233">233</xref>, <xref ref-type="bibr" rid="B234">234</xref>). Pro-inflammatory markers, such as IL-4, TNFα, IL-1β, and CCL2 cytokine, which have an established role of inflammation in neuronal damage and degeneration, have been observed to be elevated in patients with bipolar disorder (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B233">233</xref>–<xref ref-type="bibr" rid="B236">236</xref>). Elevated CRP levels were also identified in a meta-analysis of 730 patients with bipolar disorder (<xref ref-type="bibr" rid="B237">237</xref>).</p>
<p>Interestingly, during the euthymic phase of bipolar disorder, IL-4 has been shown to return to baseline levels; this apparent relationship between inflammatory and mood states provides an avenue for prospective biomarker investigations (<xref ref-type="bibr" rid="B65">65</xref>, <xref ref-type="bibr" rid="B238">238</xref>). Furthermore, accumulating evidence is suggestive of chronic low-grade inflammation in bipolar patients (<xref ref-type="bibr" rid="B239">239</xref>, <xref ref-type="bibr" rid="B240">240</xref>). Scans employing positron emission tomography (PET) have supported neuroanatomical changes and hyperactive microglial state in bipolar disorder (<xref ref-type="bibr" rid="B241">241</xref>–<xref ref-type="bibr" rid="B244">244</xref>). Gray matter reduction was observed in the anterior limbic region (<xref ref-type="bibr" rid="B197">197</xref>, <xref ref-type="bibr" rid="B198">198</xref>) including ventricular enlargement (<xref ref-type="bibr" rid="B245">245</xref>). Lithium, a well-established mood stabilizer, has been shown to reduce IL-2, IL-6, IL-10, and IFNα levels after long-term use, possibly inferring its nebulous mechanism of action through anti-inflammatory processes (<xref ref-type="bibr" rid="B246">246</xref>). In addition, lithium has some potential in neurogenesis, which may be linked with particular anti-inflammatory mechanisms (<xref ref-type="bibr" rid="B202">202</xref>). Preclinical data also suggest that these mood stabilizing effects may downregulate the AA cascade, therefore decreasing COX-2 and prostaglandin levels (<xref ref-type="bibr" rid="B247">247</xref>–<xref ref-type="bibr" rid="B253">253</xref>).</p>
<p>A clinical trial investigated the efficacy of celecoxib in bipolar depression or mixed episode and found lower HAM-D scores initially after 1 week; however, no statistically significant difference was found at the end of the 6-week trial (<xref ref-type="bibr" rid="B12">12</xref>). In another study, celecoxib augmentation was trialed in individuals with acute mania without psychotic features alongside treatment-as-usual. This 6-week RCT demonstrated that adjuvant celecoxib with valproate was significantly effective for treatment in acute mania compared to valproate and placebo (<xref ref-type="bibr" rid="B14">14</xref>). The difference in trial outcomes may suggest greater inflammatory impact and therefore COX-2 inhibitor efficacy during the manic phase of illness, as opposed to the depressive phase; this is also supported by the relative increase in inflammatory markers in the former illness phase (<xref ref-type="bibr" rid="B66">66</xref>).</p>
<p>Electroconvulsive therapy (ECT) is an effective treatment modality for various phases of illness in bipolar disorder (<xref ref-type="bibr" rid="B254">254</xref>). ECT is reported to affect monoamines, hormones, in addition to the immune system, cytokines, ACTH, and cortisol (<xref ref-type="bibr" rid="B255">255</xref>–<xref ref-type="bibr" rid="B257">257</xref>). Immunomodulatory effects have also been reported, for example, effects on the kynurenine pathway <italic>via</italic> the decrease of QUIN concentrations in unipolar and bipolar depression (<xref ref-type="bibr" rid="B258">258</xref>, <xref ref-type="bibr" rid="B259">259</xref>).</p>
<p>Kargar et al. (<xref ref-type="bibr" rid="B260">260</xref>) assessed cytokine and CRP changes in patients receiving both ECT and celecoxib, reporting a reduction in TNFα, but no significant changes in other inflammatory markers, such as IL-1β, IL-6, and CRP. However, they noted greater clinical improvement of depressive symptoms in the first week of celecoxib intervention but no persisting differences thereafter (<xref ref-type="bibr" rid="B260">260</xref>). Notably, the authors hypothesized that immunomodulatory effects associated with ECT might explain the baseline return of TNFα concentrations; however, no significant cytokine changes were observed. This may also be due to the post-ECT acute induction of cytokines hindering statistical significance (<xref ref-type="bibr" rid="B255">255</xref>, <xref ref-type="bibr" rid="B261">261</xref>). Another RCT with 35 ECT participants with focus on BDNF levels in patients with mania concluded no statistical difference in BDNF levels or treatment efficacy with adjuvant celecoxib (<xref ref-type="bibr" rid="B13">13</xref>). The authors of this study suggested these effects were nearing statistical significance, and that their BDNF sampling protocol may have been a confounding factor (<xref ref-type="bibr" rid="B13">13</xref>). A longer multicenter trial has been proposed to assess augmentation with celecoxib and/or minocycline alongside treatment as usual (TAU) in bipolar I or bipolar II patients in depressive state; however, these results are yet to be published (<xref ref-type="bibr" rid="B262">262</xref>). Bipolar disorder has significant associations with inflammatory modulation resulting in aberrant brain changes that warrant further investigation of the roles of anti-inflammatory agents. In particular, celecoxib shows some promise requiring further investigation, particularly during a set phase of the bipolar illness.</p>
</sec>
<sec id="s2_6">
<title>Schizophrenia</title>
<p>Schizophrenia is a severe, chronic, and among the most disabling and economically catastrophic medical disorders. The World Health Organization ranks schizophrenia as one of the top 10 illnesses contributing to the global burden of disease (<xref ref-type="bibr" rid="B263">263</xref>). The dysregulation of dopamine and glutamatergic pathways in various brain regions are implicated in the positive, negative, and cognitive symptom domains of schizophrenia (<xref ref-type="bibr" rid="B264">264</xref>). Pro-inflammatory cytokines such as IL-1β and IL-6 can influence neuronal development, specifically on the dopaminergic and serotonergic systems (<xref ref-type="bibr" rid="B265">265</xref>–<xref ref-type="bibr" rid="B268">268</xref>). IL-1β administration after birth can influence the dopamine system in adulthood, which has been associated in dopaminergic and serotonergic neuronal moderation in rat models (<xref ref-type="bibr" rid="B266">266</xref>). In schizophrenia, elevated serum and CSF concentrations of kynurenine were reported (<xref ref-type="bibr" rid="B269">269</xref>). Developing findings are suggesting that infectious exposure during the prenatal period may contribute to the pathogenesis of schizophrenia (<xref ref-type="bibr" rid="B270">270</xref>). Raised maternal levels of IL-8 during pregnancy are associated with an increased risk for schizophrenia in offspring, in addition to decreased brain volumes, independent of the inflammatory etiology (<xref ref-type="bibr" rid="B271">271</xref>). Maternal immune activation in animal models generated oxidative stress in the fetus (<xref ref-type="bibr" rid="B264">264</xref>). Observed infectious agents including <italic>Toxoplasma gondii</italic>, Chlamydia, bornavirus cytomegalovirus, and influenza seem to increase the risk of schizophrenia. This may, however, occur as a result of the immune response rather than an infectious etiology (<xref ref-type="bibr" rid="B270">270</xref>). Several epidemiological studies have observed an elevated prevalence of schizophrenia in cohorts born during influenza epidemics (<xref ref-type="bibr" rid="B272">272</xref>) and significant association with immunological disorders (<xref ref-type="bibr" rid="B273">273</xref>). There is a higher prevalence of schizophrenia in individuals with celiac disease, bullous pemphigoid, interstitial cystitis, thyrotoxicosis, and acquired hemolytic anemia (<xref ref-type="bibr" rid="B273">273</xref>, <xref ref-type="bibr" rid="B274">274</xref>). Surprisingly, rheumatoid arthritis reveals lower rates of co-morbid schizophrenia compared to the general population (<xref ref-type="bibr" rid="B275">275</xref>).</p>
<p>Post-mortem brain studies from schizophrenia patients have revealed significant inflammatory processes (<xref ref-type="bibr" rid="B276">276</xref>). In addition, PET imaging has signified microglial activation resulting in brain morphological changes in first-episode and chronic psychosis (<xref ref-type="bibr" rid="B277">277</xref>–<xref ref-type="bibr" rid="B280">280</xref>). These morphological changes have been expressed during prodromal phases of first-episode psychosis (<xref ref-type="bibr" rid="B281">281</xref>–<xref ref-type="bibr" rid="B283">283</xref>), suggestive of neurotoxic processes resulting in poor prognosis (<xref ref-type="bibr" rid="B281">281</xref>, <xref ref-type="bibr" rid="B284">284</xref>). Moreover, some authors have shown a relationship between brain volume, IL-1, and IL-6 (<xref ref-type="bibr" rid="B285">285</xref>–<xref ref-type="bibr" rid="B287">287</xref>). Collectin inflammatory markers have also been implicated in patients with schizophrenia, C4A in particular, whose role is to influence microglial hyperactivity, neurodegeneration, and subsequent brain cortical volume reductions (<xref ref-type="bibr" rid="B288">288</xref>, <xref ref-type="bibr" rid="B289">289</xref>). These microglial changes may derive from established elevations in serum pro-inflammatory factors, such as PGE<sub>2</sub>, CRP, IL-1β, IL- 6, IL-8, and TNFα (<xref ref-type="bibr" rid="B290">290</xref>–<xref ref-type="bibr" rid="B292">292</xref>). In addition, cytokines have shown some correlation with negative symptoms, cognitive deficits, and psychomotor retardation (<xref ref-type="bibr" rid="B293">293</xref>–<xref ref-type="bibr" rid="B295">295</xref>).</p>
<p>Positive correlations with cognitive severity and inflammatory markers have also been highlighted (<xref ref-type="bibr" rid="B296">296</xref>–<xref ref-type="bibr" rid="B298">298</xref>). In the first-episode and acutely relapsed patients with psychosis, an elevated level of pro-inflammatory cytokines, IL-6, TNFα, TGF-β, and IFNγ, was observed (<xref ref-type="bibr" rid="B61">61</xref>). In addition, IL-10 concentrations were decreased in acutely relapsed patients compared to controls (<xref ref-type="bibr" rid="B61">61</xref>). Cytokine concentrations at different stages of the disease and variable treatment agents may alter neuroprogression (<xref ref-type="bibr" rid="B115">115</xref>, <xref ref-type="bibr" rid="B299">299</xref>).</p>
<p>Further support is provided from studies suggesting antipsychotics may exhibit immune-modulatory properties (<xref ref-type="bibr" rid="B264">264</xref>); however, there remains evidence that is contrary to this notion (<xref ref-type="bibr" rid="B300">300</xref>, <xref ref-type="bibr" rid="B301">301</xref>). Patients undergoing long-term treatment with antipsychotics exhibit reduced pro-inflammatory cytokine levels (IL-1β, IL-6, sIL-6R, and TNFα) (<xref ref-type="bibr" rid="B302">302</xref>–<xref ref-type="bibr" rid="B304">304</xref>) and elevated anti-inflammatory markers (sIL-1RA, sIL-2R, and IL-10) (<xref ref-type="bibr" rid="B305">305</xref>–<xref ref-type="bibr" rid="B307">307</xref>). Second-generation antipsychotics may elicit more potent anti-inflammatory effects than to first-generation agents (<xref ref-type="bibr" rid="B303">303</xref>, <xref ref-type="bibr" rid="B308">308</xref>).</p>
<p>Dysregulation of the tryptophan metabolism has been implicated with notable elevations of kynurenic acid in patients with schizophrenia (<xref ref-type="bibr" rid="B309">309</xref>). Furthermore, long-term antipsychotic treatments have an impact on kynurenic acid concentrations in rodent models (<xref ref-type="bibr" rid="B310">310</xref>). Preclinical studies suggest that COX-2 inhibitors protect against glutamate-mediated neurotoxicity, which may highlight an application to mediate neurodegeneration in kynurenine system (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B135">135</xref>, <xref ref-type="bibr" rid="B311">311</xref>).</p>
<p>One of the first RCTs evaluating the use of COX inhibitors for schizophrenia indication consisted of 50 patients with acute exacerbation of psychosis who were admitted and treated with risperidone with one group augmented with celecoxib versus placebo for 5 weeks (<xref ref-type="bibr" rid="B17">17</xref>). The celecoxib group revealed significant positive effects on the Positive and Negative Syndrome Scale (PANSS) (<xref ref-type="bibr" rid="B17">17</xref>). <italic>Post hoc</italic> analyses indicated an improvement in cognition parameters with augmentation of celecoxib in schizophrenia in this trial (<xref ref-type="bibr" rid="B312">312</xref>).</p>
<p>In contrast, Rapaport and colleagues assessed outpatients with schizophrenia on stable psychotropic regimens of olanzapine or risperidone, finding no significant changes with celecoxib augmentation in several of the psychometric parameters (<xref ref-type="bibr" rid="B18">18</xref>). This finding could be explained by differences in the study cohorts, given the participants in Müller’s study were acutely psychotic, whereas Rapaport’s sample consisted of patients in more stabilized psychotic states.</p>
<p>During an 8-week RCT, the treatment of 60 acutely psychotic patients was augmented with celecoxib (<xref ref-type="bibr" rid="B19">19</xref>). The risperidone and celecoxib combination was superior in the improvement of PANSS total scores over risperidone alone (<xref ref-type="bibr" rid="B19">19</xref>). Also, the Extrapyramidal Symptoms Rating Scale (ESRS) scores for the placebo group were higher than in the celecoxib group over the trial but not statistically significant (<xref ref-type="bibr" rid="B18">18</xref>). Müller et al. (<xref ref-type="bibr" rid="B20">20</xref>) completed a 6-week, RCT of 49 patients during their first-episode of schizophrenia. They were treated with amisulpride with random assignment of celecoxib or placebo (<xref ref-type="bibr" rid="B20">20</xref>). There was an improvement in the PANSS in the adjunct celecoxib group compared to the placebo group (<xref ref-type="bibr" rid="B20">20</xref>). The adjunct celecoxib group in this study also showed a significant improvement on the clinical global impression (CGI) scale (<xref ref-type="bibr" rid="B20">20</xref>). Overall, a superior therapeutic effect with augmentation with celecoxib was found, in particular a trend for improvement in negative symptoms.</p>
<p>A recent meta-analysis, including the above RCTs in addition to two inaccessible RCTs, revealed that adjunctive celecoxib did not prove efficacy over placebo in overall samples (<xref ref-type="bibr" rid="B313">313</xref>). However, with the sub-analysis, they discovered superior efficacy with celecoxib to placebo in first-episode patients (<xref ref-type="bibr" rid="B313">313</xref>). This may be explained by data from preclinical studies suggesting celecoxib’s effects on cytokines and behavioral symptoms are dependent on the stage of illness and time of intervention (<xref ref-type="bibr" rid="B217">217</xref>).</p>
<p>It is important to note the comorbid conditions that may contribute to inflammation and confound interpretation of outcomes, including trauma, stress, smoking, metabolic syndrome, diet, exercise, and poor dental hygiene (<xref ref-type="bibr" rid="B2">2</xref>). Nonetheless, there is an apparent association between inflammation and schizophrenia, with celecoxib demonstrating promise possibly during early disease onset.</p>
</sec>
<sec id="s2_7">
<title>Autism Spectrum Disorder</title>
<p>ASD is a neurodevelopmental disorder defined by impairments in two domains: 1) shortages in social communication and social interaction and 2) restricted repetitive patterns of behavior, interests, and activities (<xref ref-type="bibr" rid="B314">314</xref>). The prevalence of ASD in Western countries appears to have increased, possibly as a result of definition changes and heightened awareness. The pathogenesis of ASD remains idiopathic, although the consensus points to altered brain development leading to impairment in social and communication maturation, therefore resulting in restricted interests and repetitive behaviors (<xref ref-type="bibr" rid="B315">315</xref>). These brain morphologic aberrations appear to be a result of neural pruning processes and neuroinflammation (<xref ref-type="bibr" rid="B316">316</xref>–<xref ref-type="bibr" rid="B319">319</xref>).</p>
<p>An association with ASD and inflammatory response through the measles, mumps, and rubella (MMR) vaccine and enterocolitis were reported first in 1998 (<xref ref-type="bibr" rid="B320">320</xref>) and subsequently retracted. However, controversy still exists among these allegations in select groups, despite it being established that there is no causal association between MMR vaccine and ASD (<xref ref-type="bibr" rid="B320">320</xref>–<xref ref-type="bibr" rid="B324">324</xref>).</p>
<p>Similar to discussions in Schizophrenia section with respect to schizophrenia, prenatal infections during early development may also be associated with the development of ASD (<xref ref-type="bibr" rid="B325">325</xref>–<xref ref-type="bibr" rid="B327">327</xref>). Moreover, there seem to be shared immune-related genetic abnormalities between the two disorders (<xref ref-type="bibr" rid="B325">325</xref>, <xref ref-type="bibr" rid="B328">328</xref>). Aberrant activity of the glutamatergic system might play a role in neurotoxicity of both disorders. Kynurenine pathway abnormalities may also be linked to 16p11.2 mutations in ASD resulting in glutamatergic activity (<xref ref-type="bibr" rid="B329">329</xref>).</p>
<p>Associations with changes in the immunomodulatory system of ASD patients have been identified. Disruption in immunomodulatory proponents such as T-cells and monocytes have been noted (<xref ref-type="bibr" rid="B316">316</xref>, <xref ref-type="bibr" rid="B330">330</xref>), in addition to changes in the concentration of immunoglobulins (<xref ref-type="bibr" rid="B331">331</xref>) and autoantibodies production (<xref ref-type="bibr" rid="B332">332</xref>). Furthermore, polymorphisms identified in macrophage migration inhibitory factor (MIF), seen in ASD-related abnormalities, seem to also activate the COX-2 system in microglia (<xref ref-type="bibr" rid="B333">333</xref>, <xref ref-type="bibr" rid="B334">334</xref>).</p>
<p>Post-mortem studies revealed greater microglial densities in the visual cortex, cerebellum, anterior cingulate gyri, and dorsolateral prefrontal cortex (DLPFC) of ASD patients (<xref ref-type="bibr" rid="B335">335</xref>–<xref ref-type="bibr" rid="B338">338</xref>). Some studies have also shown elevated TNFα, IFNγ, IL-1, IL-6, IL-8, IL-12, CCL2, CCL5, and CCL11 in plasma and CSF of autistic subjects (<xref ref-type="bibr" rid="B317">317</xref>, <xref ref-type="bibr" rid="B318">318</xref>, <xref ref-type="bibr" rid="B338">338</xref>–<xref ref-type="bibr" rid="B340">340</xref>).</p>
<p>A study showed that repurposed anti-inflammatory agents such as pioglitazone resulted in moderation of irritability, lethargy, stereotypy, and hyperactivity symptoms in ASD (<xref ref-type="bibr" rid="B341">341</xref>). The pioglitazone class of drugs has been shown to inhibit COX-2 in LPS-stimulated microglia and neurons (<xref ref-type="bibr" rid="B342">342</xref>, <xref ref-type="bibr" rid="B343">343</xref>). Celecoxib in the rat model has shown to also inhibit LPS-induced neuronal toxicity (<xref ref-type="bibr" rid="B344">344</xref>).</p>
<p>Our search yielded only one randomized, double-blind placebo-controlled trial of celecoxib combination with risperidone. Asadabadi et al. (<xref ref-type="bibr" rid="B21">21</xref>) assessed 40 patients diagnosed with ASD in a 10-week trial with the aberrant behavior checklist-community edition (ABC-C), which showed superior efficacy of adjuvant celecoxib with risperidone in the domains of irritability, social withdrawal, and stereotypy in children with ASD.</p>
<p>Paucity of evidence is opportune for further investigations with COX-2 inhibitors in neurodevelopmental disorders such as ASD as seen by preclinical and limited clinical data.</p>
</sec>
<sec id="s2_8">
<title>Obsessive-Compulsive Disorder</title>
<p>Obsessive-compulsive disorder (OCD) is a relatively common neuropsychiatric disorder with a reported lifetime prevalence of 1–3% in the general population (<xref ref-type="bibr" rid="B345">345</xref>, <xref ref-type="bibr" rid="B346">346</xref>). At least one-third of individuals with OCD fail to adequately respond to current pharmacological treatment (<xref ref-type="bibr" rid="B347">347</xref>, <xref ref-type="bibr" rid="B348">348</xref>). The cortico-striatal-thalamo-cortical (CSTC) circuit dysfunction is implicated in the pathophysiology of OCD (<xref ref-type="bibr" rid="B349">349</xref>).</p>
<p>There is evidence of early childhood infections, pediatric acute-onset neuropsychiatric syndrome (PANS), which encompasses pediatric autoimmune neuropsychiatric disorders associated with streptococcal (PANDAS), evoking OCD-like neuropsychiatric symptoms (<xref ref-type="bibr" rid="B15">15</xref>). This is suggestive of an inflammatory etiology to a subsect of this illness. Furthermore, immunomodulation treatment resulted in improvement of OCD-like neuropsychiatric symptoms (<xref ref-type="bibr" rid="B350">350</xref>).</p>
<p>Although the minority of cases of OCD results from PANS, it is speculated that the active inflammatory model may be relevant for the progression of OCD. As well, brain morphological changes have also been noted in OCD indicating progression in the neurodegenerative process (<xref ref-type="bibr" rid="B351">351</xref>). Rodent models exposed to LPS-induced inflammation exhibited increased anxiety with reduced exploration in the open field test (<xref ref-type="bibr" rid="B352">352</xref>, <xref ref-type="bibr" rid="B353">353</xref>). The inducible chemokine, CXCL12, resulted in anxiety-like features in rat models (<xref ref-type="bibr" rid="B353">353</xref>), further supporting the role of inflammation in neuropsychiatric symptoms in anxiety disorders.</p>
<p>Animal models are suggestive of alternative microglial phenotypes, resulting in OCD-like behavior (<xref ref-type="bibr" rid="B354">354</xref>). Translocator protein distribution volume, a marker of increased microglial activation and thus neuroinflammation (<xref ref-type="bibr" rid="B355">355</xref>–<xref ref-type="bibr" rid="B358">358</xref>), was investigated after a prior study found increased expression in PANDAS patients (<xref ref-type="bibr" rid="B359">359</xref>). Kumar et al. discovered an increased translocator protein density in the CSTC circuit compared to healthy controls. Interestingly, this circuit involves multiple neuropsychiatric disorders aforementioned such as Huntington disease, cerebral vascular disease, Tourette disorders, and Sydenham chorea (<xref ref-type="bibr" rid="B360">360</xref>, <xref ref-type="bibr" rid="B361">361</xref>). Repurposed microglial modulators such as minocycline have shown a reduction in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) scores in a recent RCT in combination with fluvoxamine (<xref ref-type="bibr" rid="B362">362</xref>).</p>
<p>Most recently, Konuk et al. (<xref ref-type="bibr" rid="B86">86</xref>) reported significantly elevated levels of both IL-6 and TNFα in OCD patients compared to healthy controls. Furthermore, a correlation between elevated TNFα and onset with minimal association between IL-6 levels and duration of illness (<xref ref-type="bibr" rid="B86">86</xref>). A meta-analysis revealed no significant findings in TNFα and IL-6 plasma levels in OCD patients relative to controls; however, the authors did note reduced IL-1β in OCD patients (<xref ref-type="bibr" rid="B62">62</xref>). As celecoxib is shown to reduce levels of both IL-6 and TNFα, support for improving clinical symptoms of OCD is plausible (<xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>Sayyah et al. (<xref ref-type="bibr" rid="B16">16</xref>) noted an improvement in the Y-BOCS for OCD patients with the augmentation of celecoxib with fluoxetine compared to fluoxetine alone. In addition, another recent RCT utilizing fluvoxamine with celecoxib augmentation compared to fluvoxamine alone noted an improvement in the celecoxib group (<xref ref-type="bibr" rid="B15">15</xref>). It is proposed that the notable efficacy in OCD, in addition to the microglial mechanisms, results from increased monoamines such as norepinephrine and serotonin <italic>via</italic> inhibition of prostaglandin synthesis by celecoxib (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B306">306</xref>). However, further studies with larger sample sizes, longer duration, and measurements of pro-inflammatory markers may provide more robust evidence.</p>
</sec>
</sec>
<sec id="s3" sec-type="conclusions">
<title>Conclusion</title>
<p>Evidence for the inflammatory hypothesis and the role of anti-inflammatory agents continues to accumulate suggesting etiological impact on the development of neuropsychiatric conditions, such as depression, bipolar disorder, schizophrenia, ASD, and OCD. A promising body of evidence suggests a role for COX-2 inhibition, in particular celecoxib, for phase-related interventions in bipolar disorder, schizophrenia, and possibly depression, ASD, and OCD. Despite the paucity of data for COX-2 inhibitors and investigated agents, including aspirin, minocycline, and statins, with purported pleiotropic anti-inflammatory mechanisms, further research is necessary to clarify the role of immunomodulation therapies and their comparative efficacies for integration of the psychiatric professions’ current paradigm of treatment modalities (<xref ref-type="bibr" rid="B146">146</xref>, <xref ref-type="bibr" rid="B363">363</xref>).</p>
</sec>
<sec id="s4">
<title>Author Contributions</title>
<p>RS was the primary author of this manuscript, conducted initial literature search, review and synthesis of first draft and subsequent revisions. NG-C contributed to literature search and revisions. AW contributed to synthesis initial draft and revisions. OR contributed to manuscript draft, revisions and created figure. BA contributed to drafting and revision process. MB and SD were lead investigators providing initial concept and ongoing guidance throughout.</p>
</sec>
<sec id="s5" sec-type="funding-information">
<title>Funding</title>
<p>Berk A is supported by Stanley Medical Research Foundation NIH, MBF, NHMRC, NHMRC Senior Principal Research Fellowship (APP1059660 and APP1156072), Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, MBF, Rotary Health, Meat and Livestock Board Woolworths, BeyondBlue, Geelong Medical Research Foundation Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier. Berk is the speaker in Astra Zeneca, Bristol Myers Squibb Eli Lilly, Glaxo SmithKline Lundbeck, Pfizer, Sanofi Synthelabo Servier, Solvay, Wyeth; and consultant in AstraZeneca, Bristol Myers Squibb Eli Lilly, Bioadvantex, Merck, Glaxo SmithKline Lundbeck, Janssen Cilag Servier. Berk is a co-inventor of two provisional patents regarding the use of NAC and related compounds for psychiatric indications, which, while assigned to the Mental Health Research Institute, could lead to personal remuneration upon a commercialisation event.Walker A is supported by the Trisno Family Fellowship.</p>
</sec>
<sec id="s6">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s7">
<title>Abbreviations</title>
<p>3MS-E, Modified Mini-Mental State Exam; AA, arachidonic acid; ABC-C, autism behavior checklist community edition; ACTH, adrenocorticotropic hormone; ASD, autism spectrum disorder; BDNF, brain derived neurotrophic factor; CCL2, C-C motif chemokine ligand 2; CGI-I, Clinical Global Impression: Improvement; CGI-S, Clinical Global Impression: Severity; CNS, central nervous system; COX, cyclooxygenase; CSF, cerebrospinal fluid; cPLA2, cytoplasmic phospholipase A2; CRH, corticotrophin releasing hormone; CRP, C-reactive protein; ECT, electroconvulsive therapy; ESRS, Extrapyramidal Symptoms Rating Scale; GDS, Geriatric Depression Scale; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; HDRS, Hamilton Depression Rating Scale; IDO, indolamine 2,3 dioxygenase; IL, interleukin; IL-1ra, interleukin-1 receptor antagonist; IFNα, interferon alpha; IFN-γ, interferon gamma; KA, kainic acid; LPS, lipopolysaccharide; MDD, major depressive disorder; mRNA, microribonucleic acid; NMDA, <italic>N</italic>-methyl-D-aspartate; NF, nuclear factor; OCD, obsessive compulsive disorder; PANS, pediatric acute-onset neuropsychiatric syndrome; PANDAS, pediatric autoimmune neuropsychiatric disorders associated with streptococcal; PANSS, Positive and Negative Syndrome Scale; PHQ-9, Patient Health Questionnaire-9; PGE2, prostaglandin E2; QUIN, quinolinic acid; RCT, randomized control trial; SANS, Scale for the Assessment of Negative Symptoms; SAS, Simpson–Angus Rating Scale of EPS; TAU, treatment as usual; TDO, tryptophan 2,3-dioxygenase; TNFα, tumor necrosis factor alpha</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The team would like to thank the IMPACT Strategic Research Centre for their support in providing work spaces and accommodation for our international team during the initial stages of this manuscript. Without their support this work would not have been achievable and their generosity should not go without thanks.</p>
</ack>
<sec id="s8" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fpsyt.2019.00605/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fpsyt.2019.00605/full#supplementary-material</ext-link></p>
<supplementary-material content-type="local-data" id="SM1">
<media xlink:href="DataSheet_1.docx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kohler</surname><given-names>CA</given-names></name><name><surname>Freitas</surname><given-names>TH</given-names></name><name><surname>Maes</surname><given-names>M</given-names></name><name><surname>de Andrade</surname><given-names>NQ</given-names></name><name><surname>Liu</surname><given-names>CS</given-names></name><name><surname>Fernandes</surname><given-names>BS</given-names></name><etal></etal></person-group>
<article-title>Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies</article-title>. <source/>Acta Psychiatr Scand (<year>2017</year>) <volume>135</volume>(<issue>5</issue>):<page-range>373–87</page-range>. <pub-id pub-id-type="doi">10.1111/acps.12698</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>LJ</given-names></name><name><surname>Jacka</surname><given-names>FN</given-names></name><name><surname>O’Neil</surname><given-names>A</given-names></name><name><surname>Pasco</surname><given-names>JA</given-names></name><name><surname>Moylan</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>So depression is an inflammatory disease, but where does the inflammation come from</article-title>? <source/>BMC Med (<year>2013</year>) <volume>11</volume>(<issue>1</issue>):<fpage>200</fpage>. <pub-id pub-id-type="doi">10.1186/1741-7015-11-200</pub-id>
<pub-id pub-id-type="pmid">24228900</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huynh</surname><given-names>NN</given-names></name><name><surname>McIntyre</surname><given-names>RS</given-names></name></person-group>
<article-title>What are the implications of the STAR*D trial for primary care? A review and synthesis</article-title>. <source/>Prim Care Companion J Clin Psychiatry (<year>2008</year>) <volume>10</volume>(<issue>2</issue>):<page-range>91–6</page-range>. <pub-id pub-id-type="doi">10.4088/PCC.v10n0201</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muller</surname><given-names>N</given-names></name><name><surname>Schwarz</surname><given-names>MJ</given-names></name><name><surname>Dehning</surname><given-names>S</given-names></name><name><surname>Douhe</surname><given-names>A</given-names></name><name><surname>Cerovecki</surname><given-names>A</given-names></name><name><surname>Goldstein-Muller</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine</article-title>. <source/>Mol Psychiatry (<year>2006</year>) <volume>11</volume>(<issue>7</issue>):<page-range>680–4</page-range>. <pub-id pub-id-type="doi">10.1038/sj.mp.4001805</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akhondzadeh</surname><given-names>S</given-names></name><name><surname>Jafari</surname><given-names>S</given-names></name><name><surname>Raisi</surname><given-names>F</given-names></name><name><surname>Nasehi</surname><given-names>AA</given-names></name><name><surname>Ghoreishi</surname><given-names>A</given-names></name><name><surname>Salehi</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial</article-title>. <source/>Depress Anxiety (<year>2009</year>) <volume>26</volume>(<issue>7</issue>):<page-range>607–11</page-range>. <pub-id pub-id-type="doi">10.1002/da.20589</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fields</surname><given-names>C</given-names></name><name><surname>Drye</surname><given-names>L</given-names></name><name><surname>Vaidya</surname><given-names>V</given-names></name><name><surname>Lyketsos</surname><given-names>C</given-names></name></person-group>
<article-title>Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial</article-title>. <source/>Am J Geriatr Psychiatry (<year>2012</year>) <volume>20</volume>(<issue>6</issue>):<page-range>505–13</page-range>. <pub-id pub-id-type="doi">10.1097/JGP.0b013e318227f4da</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abbasi</surname><given-names>SH</given-names></name><name><surname>Hosseini</surname><given-names>F</given-names></name><name><surname>Modabbernia</surname><given-names>A</given-names></name><name><surname>Ashrafi</surname><given-names>M</given-names></name><name><surname>Akhondzadeh</surname><given-names>S</given-names></name></person-group>
<article-title>Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study</article-title>. <source/>J Affect Disord (<year>2012</year>) <volume>141</volume>(<issue>2–3</issue>):<page-range>308–14</page-range>. <pub-id pub-id-type="doi">10.1016/j.jad.2012.03.033</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Majd</surname><given-names>M</given-names></name><name><surname>Hashemian</surname><given-names>F</given-names></name><name><surname>Hosseini</surname><given-names>SM</given-names></name><name><surname>Vahdat Shariatpanahi</surname><given-names>M</given-names></name><name><surname>Sharifi</surname><given-names>A</given-names></name></person-group>
<article-title>A randomized, double-blind, placebo-controlled trial of celecoxib uugmentation of sertraline in treatment of drug-naive depressed women: a pilot study</article-title>. <source/>IJPR (<year>2015</year>) <volume>14</volume>(<issue>3</issue>):<page-range>891–9</page-range>.</mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jafari</surname><given-names>S</given-names></name><name><surname>Ashrafizadeh</surname><given-names>SG</given-names></name><name><surname>Zeinoddini</surname><given-names>A</given-names></name><name><surname>Rasoulinejad</surname><given-names>M</given-names></name><name><surname>Entezari</surname><given-names>P</given-names></name><name><surname>Seddighi</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial</article-title>. <source/>J Clin Pharm Ther (<year>2015</year>) <volume>40</volume>(<issue>4</issue>):<page-range>441–6</page-range>. <pub-id pub-id-type="doi">10.1111/jcpt.12287</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohammadinejad</surname><given-names>P</given-names></name><name><surname>Arya</surname><given-names>P</given-names></name><name><surname>Esfandbod</surname><given-names>M</given-names></name><name><surname>Kaviani</surname><given-names>A</given-names></name><name><surname>Najafi</surname><given-names>M</given-names></name><name><surname>Kashani</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double-blind, placebo-controlled, randomized trial</article-title>. <source/>Ann Pharmacother (<year>2015</year>) <volume>49</volume>(<issue>9</issue>):<page-range>953–61</page-range>. <pub-id pub-id-type="doi">10.1177/1060028015592215</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alamdarsaravi</surname><given-names>M</given-names></name><name><surname>Ghajar</surname><given-names>A</given-names></name><name><surname>Noorbala</surname><given-names>A-A</given-names></name><name><surname>Arbabi</surname><given-names>M</given-names></name><name><surname>Emami</surname><given-names>A</given-names></name><name><surname>Shahei</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: a randomized double-blind, placebo controlled trial</article-title>. <source/>Psychiatry Res (<year>2017</year>) <volume>255</volume>:<fpage>59</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.psychres.2017.05.029</pub-id>
<pub-id pub-id-type="pmid">28528242</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nery</surname><given-names>FG</given-names></name><name><surname>Monkul</surname><given-names>ES</given-names></name><name><surname>Hatch</surname><given-names>JP</given-names></name><name><surname>Fonseca</surname><given-names>M</given-names></name><name><surname>Zunta-Soares</surname><given-names>GB</given-names></name><name><surname>Frey</surname><given-names>BN</given-names></name><etal></etal></person-group>
<article-title>Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study</article-title>. <source/>Hum Psychopharmacol (<year>2008</year>) <volume>23</volume>(<issue>2</issue>):<fpage>87</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1002/hup.912</pub-id>
<pub-id pub-id-type="pmid">18172906</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kargar</surname><given-names>M</given-names></name><name><surname>Yoosefi</surname><given-names>A</given-names></name><name><surname>Akhondzadeh</surname><given-names>S</given-names></name><name><surname>Artonian</surname><given-names>V</given-names></name><name><surname>Ashouri</surname><given-names>A</given-names></name><name><surname>Ghaeli</surname><given-names>P</given-names></name></person-group>
<article-title>Effect of adjunctive celecoxib on BDNF in manic patients undergoing electroconvulsive therapy: a randomized double blind controlled trial</article-title>. <source/>Pharmacopsychiatry (<year>2015</year>) <volume>48</volume>(<issue>7</issue>):<page-range>268–73</page-range>. <pub-id pub-id-type="doi">10.1055/s-0035-1559667</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arabzadeh</surname><given-names>S</given-names></name><name><surname>Ameli</surname><given-names>N</given-names></name><name><surname>Zeinoddini</surname><given-names>A</given-names></name><name><surname>Rezaei</surname><given-names>F</given-names></name><name><surname>Farokhnia</surname><given-names>M</given-names></name><name><surname>Mohammadinejad</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial</article-title>. <source/>Bipolar Disord (<year>2015</year>) <volume>17</volume>(<issue>6</issue>):<page-range>606–14</page-range>. <pub-id pub-id-type="doi">10.1111/bdi.12324</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shalbafan</surname><given-names>M</given-names></name><name><surname>Mohammadinejad</surname><given-names>P</given-names></name><name><surname>Shariat</surname><given-names>SV</given-names></name><name><surname>Alavi</surname><given-names>K</given-names></name><name><surname>Zeinoddini</surname><given-names>A</given-names></name><name><surname>Salehi</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: a double-blind, placebo-controlled, randomized trial</article-title>. <source/>Pharmacopsychiatry (<year>2015</year>) <volume>48</volume>(<issue>4–5</issue>):<page-range>136–40</page-range>. <pub-id pub-id-type="doi">10.1055/s-0035-1549929</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sayyah</surname><given-names>M</given-names></name><name><surname>Boostani</surname><given-names>H</given-names></name><name><surname>Pakseresht</surname><given-names>S</given-names></name><name><surname>Malayeri</surname><given-names>A</given-names></name></person-group>
<article-title>A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder</article-title>. <source/>Psychiatry Res (<year>2011</year>) <volume>189</volume>(<issue>3</issue>):<page-range>403–6</page-range>. <pub-id pub-id-type="doi">10.1016/j.psychres.2011.01.019</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muller</surname><given-names>N</given-names></name><name><surname>Riedel</surname><given-names>M</given-names></name><name><surname>Scheppach</surname><given-names>C</given-names></name><name><surname>Brandstatter</surname><given-names>B</given-names></name><name><surname>Sokullu</surname><given-names>S</given-names></name><name><surname>Krampe</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia</article-title>. <source/>Am J Psychiatry (<year>2002</year>) <volume>159</volume>(<issue>6</issue>):<page-range>1029–34</page-range>. <pub-id pub-id-type="doi">10.1176/appi.ajp.159.6.1029</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rapaport</surname><given-names>MH</given-names></name><name><surname>Delrahim</surname><given-names>KK</given-names></name><name><surname>Bresee</surname><given-names>CJ</given-names></name><name><surname>Maddux</surname><given-names>RE</given-names></name><name><surname>Ahmadpour</surname><given-names>O</given-names></name><name><surname>Dolnak</surname><given-names>D</given-names></name></person-group>
<article-title>Celecoxib augmentation of continuously ill patients with schizophrenia</article-title>. <source/>Biol Psychiatry (<year>2005</year>) <volume>57</volume>(<issue>12</issue>):<page-range>1594–6</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2005.02.024</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akhondzadeh</surname><given-names>S</given-names></name><name><surname>Tabatabaee</surname><given-names>M</given-names></name><name><surname>Amini</surname><given-names>H</given-names></name><name><surname>Ahmadi Abhari</surname><given-names>SA</given-names></name><name><surname>Abbasi</surname><given-names>SH</given-names></name><name><surname>Behnam</surname><given-names>B</given-names></name></person-group>
<article-title>Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial</article-title>. <source/>Schizophr Res (<year>2007</year>) <volume>90</volume>(<issue>1–3</issue>):<page-range>179–85</page-range>. <pub-id pub-id-type="doi">10.1016/j.schres.2006.11.016</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Müller</surname><given-names>N</given-names></name><name><surname>Krause</surname><given-names>D</given-names></name><name><surname>Dehning</surname><given-names>S</given-names></name><name><surname>Musil</surname><given-names>R</given-names></name><name><surname>Schennach-Wolff</surname><given-names>R</given-names></name><name><surname>Obermeier</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment</article-title>. <source/>Schizophr Res (<year>2010</year>) <volume>121</volume>(<issue>1–3</issue>):<page-range>118–24</page-range>. <pub-id pub-id-type="doi">10.1016/j.schres.2010.04.015</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Asadabadi</surname><given-names>M</given-names></name><name><surname>Mohammadi</surname><given-names>MR</given-names></name><name><surname>Ghanizadeh</surname><given-names>A</given-names></name><name><surname>Modabbernia</surname><given-names>A</given-names></name><name><surname>Ashrafi</surname><given-names>M</given-names></name><name><surname>Hassanzadeh</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial</article-title>. <source/>Psychopharmacology (<year>2013</year>) <volume>225</volume>(<issue>1</issue>):<page-range>51–9</page-range>. <pub-id pub-id-type="doi">10.1007/s00213-012-2796-8</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raju</surname><given-names>TN</given-names></name></person-group>
<article-title>Hot brains: manipulating body heat to save the brain</article-title>. <source/>Pediatrics (<year>2006</year>) <volume>117</volume>(<issue>2</issue>):e<page-range>320–1</page-range>. <pub-id pub-id-type="doi">10.1542/peds.2005-1934</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lopez-Munoz</surname><given-names>F</given-names></name><name><surname>Alamo</surname><given-names>C</given-names></name></person-group>
<article-title>Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today</article-title>. <source/>Curr Pharm Des (<year>2009</year>) <volume>15</volume>(<issue>14</issue>):<page-range>1563–86</page-range>. <pub-id pub-id-type="doi">10.2174/138161209788168001</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chaplin</surname><given-names>DD</given-names></name></person-group>
<article-title>Overview of the immune response</article-title>. <source/>J Allergy Clin Immunol (<year>2010</year>) <volume>125</volume>(2 <issue>Suppl 2</issue>):<page-range>S3–23</page-range>. <pub-id pub-id-type="doi">10.1016/j.jaci.2009.12.980</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Simon</surname><given-names>AK</given-names></name><name><surname>Hollander</surname><given-names>GA</given-names></name><name><surname>McMichael</surname><given-names>A</given-names></name></person-group>
<article-title>Evolution of the immune system in humans from infancy to old age</article-title>. <source/>Proc R Soc B: Biol Sci (<year>2015</year>) <volume>282</volume>(<issue>1821</issue>):<fpage>20143085</fpage>. <pub-id pub-id-type="doi">10.1098/rspb.2014.3085</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>JX</given-names></name><name><surname>Zhang</surname><given-names>GX</given-names></name></person-group>
<article-title>Macrophages: a double-edged sword in experimental autoimmune encephalomyelitis</article-title>. <source/>Immunol Lett (<year>2014</year>) <volume>160</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2014.03.006</pub-id>
<pub-id pub-id-type="pmid">24698730</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McNamara</surname><given-names>RK</given-names></name><name><surname>Lotrich</surname><given-names>FE</given-names></name></person-group>
<article-title>Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target</article-title>? <source/>Expert Rev Neurother (<year>2012</year>) <volume>12</volume>(<issue>9</issue>):<page-range>1143–61</page-range>. <pub-id pub-id-type="doi">10.1586/ern.12.98</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kronfol</surname><given-names>Z</given-names></name><name><surname>Remick</surname><given-names>DG</given-names></name></person-group>
<article-title>Cytokines and the brain: implications for clinical psychiatry</article-title>. <source/>Am J Psychiatry (<year>2000</year>) <volume>157</volume>(<issue>5</issue>):<page-range>683–94</page-range>. <pub-id pub-id-type="doi">10.1176/appi.ajp.157.5.683</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Banks</surname><given-names>WA</given-names></name><name><surname>Kastin</surname><given-names>AJ</given-names></name><name><surname>Broadwell</surname><given-names>RD</given-names></name></person-group>
<article-title>Passage of cytokines across the blood-brain barrier</article-title>. <source/>Neuroimmunomodulation (<year>1995</year>) <volume>2</volume>(<issue>4</issue>):<page-range>241–8</page-range>. <pub-id pub-id-type="doi">10.1159/000097202</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Quan</surname><given-names>N</given-names></name><name><surname>Whiteside</surname><given-names>M</given-names></name><name><surname>Herkenham</surname><given-names>M</given-names></name></person-group>
<article-title>Time course and localization patterns of interleukin-1beta messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide</article-title>. <source/>Neuroscience (<year>1998</year>) <volume>83</volume>(<issue>1</issue>):<page-range>281–93</page-range>. <pub-id pub-id-type="doi">10.1016/S0306-4522(97)00350-3</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morris</surname><given-names>G</given-names></name><name><surname>Fernandes</surname><given-names>BS</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name></person-group>
<article-title>Leaky brain in neurological and psychiatric disorders: drivers and consequences</article-title>. <source/>Aust N Z J Psychiatry (<year>2018</year>) <volume>52</volume>(<issue>10</issue>):<fpage>92448</fpage>. <pub-id pub-id-type="doi">10.1177/0004867418796955</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haroon</surname><given-names>E</given-names></name><name><surname>Raison</surname><given-names>CL</given-names></name><name><surname>Miller</surname><given-names>AH</given-names></name></person-group>
<article-title>Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior</article-title>. <source/>Neuropsychopharmacology (<year>2012</year>) <volume>37</volume>(<issue>1</issue>):<page-range>137–62</page-range>. <pub-id pub-id-type="doi">10.1038/npp.2011.205</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bentivoglio</surname><given-names>M</given-names></name><name><surname>Mariotti</surname><given-names>R</given-names></name><name><surname>Bertini</surname><given-names>G</given-names></name></person-group>
<article-title>Neuroinflammation and brain infections: historical context and current perspectives</article-title>. <source/>Brain Res Rev (<year>2011</year>) <volume>66</volume>(<issue>1-2</issue>):<page-range>152–73</page-range>. <pub-id pub-id-type="doi">10.1016/j.brainresrev.2010.09.008</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Block</surname><given-names>ML</given-names></name><name><surname>Zecca</surname><given-names>L</given-names></name><name><surname>Hong</surname><given-names>JS</given-names></name></person-group>
<article-title>Microglia-mediated neurotoxicity: uncovering the molecular mechanisms</article-title>. <source/>Nat Rev Neurosci (<year>2007</year>) <volume>8</volume>(<issue>1</issue>):<fpage>57</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2038</pub-id>
<pub-id pub-id-type="pmid">17180163</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>BI</given-names></name><name><surname>Kemp</surname><given-names>DE</given-names></name><name><surname>Soczynska</surname><given-names>JK</given-names></name><name><surname>McIntyre</surname><given-names>RS</given-names></name></person-group>
<article-title>Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature</article-title>. <source/>J Clin Psychiatry (<year>2009</year>) <volume>70</volume>(<issue>8</issue>):<page-range>1078–90</page-range>. <pub-id pub-id-type="doi">10.4088/JCP.08r04505</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Najjar</surname><given-names>S</given-names></name><name><surname>Pearlman</surname><given-names>DM</given-names></name><name><surname>Alper</surname><given-names>K</given-names></name><name><surname>Najjar</surname><given-names>A</given-names></name><name><surname>Devinsky</surname><given-names>O</given-names></name></person-group>
<article-title>Neuroinflammation and psychiatric illness</article-title>. <source/>J Neuroinflammation (<year>2013</year>) <volume>10</volume>:<fpage>43</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-10-43</pub-id>
<pub-id pub-id-type="pmid">23547920</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Orihuela</surname><given-names>R</given-names></name><name><surname>McPherson</surname><given-names>CA</given-names></name><name><surname>Harry</surname><given-names>GJ</given-names></name></person-group>
<article-title>Microglial M1/M2 polarization and metabolic states</article-title>. <source/>Br J Pharmacol (<year>2016</year>) <volume>173</volume>(<issue>4</issue>):<page-range>649–65</page-range>. <pub-id pub-id-type="doi">10.1111/bph.13139</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Butovsky</surname><given-names>O</given-names></name><name><surname>Bruck</surname><given-names>W</given-names></name><name><surname>Hanisch</surname><given-names>UK</given-names></name></person-group>
<article-title>Microglial phenotype: is the commitment reversible</article-title>? <source/>Trends Neurosci (<year>2006</year>) <volume>29</volume>(<issue>2</issue>):<fpage>68</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2005.12.005</pub-id>
<pub-id pub-id-type="pmid">16406093</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Kesteren</surname><given-names>CF</given-names></name><name><surname>Gremmels</surname><given-names>H</given-names></name><name><surname>de Witte</surname><given-names>LD</given-names></name><name><surname>Hol</surname><given-names>EM</given-names></name><name><surname>Van Gool</surname><given-names>AR</given-names></name><name><surname>Falkai</surname><given-names>PG</given-names></name><etal></etal></person-group>
<article-title>Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies</article-title>. <source/>Transl Psychiatry (<year>2017</year>) <volume>7</volume>(<issue>3</issue>):<fpage>e1075</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2017.4</pub-id>
<pub-id pub-id-type="pmid">28350400</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="editor"><name><surname>Cherry</surname><given-names>JD</given-names></name><name><surname>Olschowka</surname><given-names>JA</given-names></name><name><surname>O’Banion</surname><given-names>MK</given-names></name></person-group>
<article-title>Neuroinflammation and M2 microglia: the good, the bad, and the inflamed</article-title>. <source/>J Neuroinflammation (<year>2014</year>) <volume>11</volume>(<issue>1</issue>):<fpage>98</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-11-98</pub-id>
<pub-id pub-id-type="pmid">24889886</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wachholz</surname><given-names>S</given-names></name><name><surname>Esslinger</surname><given-names>M</given-names></name><name><surname>Plumper</surname><given-names>J</given-names></name><name><surname>Manitz</surname><given-names>MP</given-names></name><name><surname>Juckel</surname><given-names>G</given-names></name><name><surname>Friebe</surname><given-names>A</given-names></name></person-group>
<article-title>Microglia activation is associated with IFN-alpha induced depressive-like behavior</article-title>. <source/>Brain Behav Immun (<year>2016</year>) <volume>55</volume>:<page-range>105–13</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2015.09.016</pub-id>
</mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sokol</surname><given-names>CL</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name></person-group>
<article-title>The chemokine system in innate immunity</article-title>. <source/>Cold Spring Harb Perspect Biol (<year>2015</year>) <volume>7</volume>(<issue>5</issue>):<elocation-id>a016303</elocation-id>. <pub-id pub-id-type="doi">10.1101/cshperspect.a016303</pub-id>
<pub-id pub-id-type="pmid">25635046</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kohler</surname><given-names>O</given-names></name><name><surname>Krogh</surname><given-names>J</given-names></name><name><surname>Mors</surname><given-names>O</given-names></name><name><surname>Benros</surname><given-names>ME</given-names></name></person-group>
<article-title>Inflammation in depression and the potential for anti-inflammatory treatment</article-title>. <source/>Curr Neuropharmacol (<year>2016</year>) <volume>14</volume>(<issue>7</issue>):<page-range>732–42</page-range>. <pub-id pub-id-type="doi">10.2174/1570159X14666151208113700</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kohler-Forsberg</surname><given-names>O</given-names></name><name><surname>Buttenschon</surname><given-names>HN</given-names></name><name><surname>Tansey</surname><given-names>KE</given-names></name><name><surname>Maier</surname><given-names>W</given-names></name><name><surname>Hauser</surname><given-names>J</given-names></name><name><surname>Dernovsek</surname><given-names>MZ</given-names></name><etal></etal></person-group>
<article-title>Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression</article-title>. <source/>Brain Behav Immun (<year>2017</year>) <volume>62</volume>:<page-range>344–50</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2017.02.020</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Inoshita</surname><given-names>M</given-names></name><name><surname>Numata</surname><given-names>S</given-names></name><name><surname>Tajima</surname><given-names>A</given-names></name><name><surname>Kinoshita</surname><given-names>M</given-names></name><name><surname>Umehara</surname><given-names>H</given-names></name><name><surname>Nakataki</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>A significant causal association between C-reactive protein levels and schizophrenia</article-title>. <source/>Sci Rep (<year>2016</year>) <volume>6</volume>:<fpage>26105</fpage>. <pub-id pub-id-type="doi">10.1038/srep26105</pub-id>
<pub-id pub-id-type="pmid">27193331</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wium-Andersen</surname><given-names>MK</given-names></name><name><surname>Orsted</surname><given-names>DD</given-names></name><name><surname>Nielsen</surname><given-names>SF</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name></person-group>
<article-title>Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals</article-title>. <source/>JAMA Psychiatry (<year>2013</year>) <volume>70</volume>(<issue>2</issue>):<page-range>176–84</page-range>. <pub-id pub-id-type="doi">10.1001/2013.jamapsychiatry.102</pub-id>
</mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Wheeler</surname><given-names>JG</given-names></name><name><surname>Hirschfield</surname><given-names>GM</given-names></name><name><surname>Eda</surname><given-names>S</given-names></name><name><surname>Eiriksdottir</surname><given-names>G</given-names></name><name><surname>Rumley</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease</article-title>. <source/>N Engl J Med (<year>2004</year>) <volume>350</volume>(<issue>14</issue>):<page-range>1387–97</page-range>. <pub-id pub-id-type="doi">10.1056/NEJMoa032804</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koenig</surname><given-names>W</given-names></name><name><surname>Sund</surname><given-names>M</given-names></name><name><surname>Frohlich</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>HG</given-names></name><name><surname>Lowel</surname><given-names>H</given-names></name><name><surname>Doring</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992</article-title>. <source/>Circulation (<year>1999</year>) <volume>99</volume>(<issue>2</issue>):<page-range>237–42</page-range>. <pub-id pub-id-type="doi">10.1161/01.CIR.99.2.237</pub-id>
</mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lindahl</surname><given-names>B</given-names></name><name><surname>Toss</surname><given-names>H</given-names></name><name><surname>Siegbahn</surname><given-names>A</given-names></name><name><surname>Venge</surname><given-names>P</given-names></name><name><surname>Wallentin</surname><given-names>L</given-names></name></person-group>
<article-title>Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease</article-title>. <source/>N Engl J Med (<year>2000</year>) <volume>343</volume>(<issue>16</issue>):<page-range>1139–47</page-range>. <pub-id pub-id-type="doi">10.1056/NEJM200010193431602</pub-id>
</mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name><name><surname>Ginsberg</surname><given-names>HN</given-names></name><name><surname>Masana</surname><given-names>L</given-names></name><name><surname>Descamps</surname><given-names>OS</given-names></name><etal></etal></person-group>
<article-title>Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society</article-title>. <source/>Eur Heart J (<year>2013</year>) <volume>34</volume>(<issue>45</issue>):<page-range>3478–90</page-range>. <pub-id pub-id-type="doi">10.1093/eurheartj/eht273</pub-id>
</mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pepys</surname><given-names>MB</given-names></name><name><surname>Hirschfield</surname><given-names>GM</given-names></name></person-group>
<article-title>C-reactive protein: a critical update</article-title>. <source/>J Clin Invest (<year>2003</year>) <volume>111</volume>(<issue>12</issue>):<page-range>1805–12</page-range>. <pub-id pub-id-type="doi">10.1172/JCI200318921</pub-id>
</mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name></person-group>
<article-title>C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women</article-title>. <source/>N Engl J Med (<year>2000</year>) <volume>342</volume>(<issue>12</issue>):<page-range>836–43</page-range>. <pub-id pub-id-type="doi">10.1056/NEJM200003233421202</pub-id>
</mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Lemaitre</surname><given-names>RN</given-names></name><name><surname>Psaty</surname><given-names>BM</given-names></name><name><surname>Ives</surname><given-names>DG</given-names></name><name><surname>Evans</surname><given-names>RW</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project</article-title>. <source/>Arterioscler Thromb Vasc Biol (<year>1997</year>) <volume>17</volume>(<issue>6</issue>):<page-range>1121–7</page-range>. <pub-id pub-id-type="doi">10.1161/01.ATV.17.6.1121</pub-id>
</mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krogh</surname><given-names>J</given-names></name><name><surname>Benros</surname><given-names>ME</given-names></name><name><surname>Jorgensen</surname><given-names>MB</given-names></name><name><surname>Vesterager</surname><given-names>L</given-names></name><name><surname>Elfving</surname><given-names>B</given-names></name><name><surname>Nordentoft</surname><given-names>M</given-names></name></person-group>
<article-title>The association between depressive symptoms, cognitive function, and inflammation in major depression</article-title>. <source/>Brain Behav Immun (<year>2014</year>) <volume>35</volume>:<page-range>70–6</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2013.08.014</pub-id>
</mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Furtado</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>MA</given-names></name></person-group>
<article-title>Examining the role of neuroinflammation in major depression</article-title>. <source/>Psychiatry Res (<year>2015</year>) <volume>229</volume>(<issue>1–2</issue>):<fpage>27</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.psychres.2015.06.009</pub-id>
<pub-id pub-id-type="pmid">26187338</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karlovic</surname><given-names>D</given-names></name><name><surname>Serretti</surname><given-names>A</given-names></name><name><surname>Vrkic</surname><given-names>N</given-names></name><name><surname>Martinac</surname><given-names>M</given-names></name><name><surname>Marcinko</surname><given-names>D</given-names></name></person-group>
<article-title>Serum concentrations of CRP, IL-6, TNF-alpha and cortisol in major depressive disorder with melancholic or atypical features</article-title>. <source/>Psychiatry Res (<year>2012</year>) <volume>198</volume>(<issue>1</issue>):<fpage>74</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.psychres.2011.12.007</pub-id>
<pub-id pub-id-type="pmid">22386567</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Felger</surname><given-names>JC</given-names></name><name><surname>Lotrich</surname><given-names>FE</given-names></name></person-group>
<article-title>Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications</article-title>. <source/>Neuroscience (<year>2013</year>) <volume>246</volume>:<fpage>199</fpage>–<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.04.060</pub-id>
<pub-id pub-id-type="pmid">23644052</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goldsmith</surname><given-names>DR</given-names></name><name><surname>Rapaport</surname><given-names>MH</given-names></name><name><surname>Miller</surname><given-names>BJ</given-names></name></person-group>
<article-title>A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression</article-title>. <source/>Mol Psychiatry (<year>2016</year>) <volume>21</volume>(<issue>12</issue>):<page-range>1696–709</page-range>. <pub-id pub-id-type="doi">10.1038/mp.2016.3</pub-id>
</mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Modabbernia</surname><given-names>A</given-names></name><name><surname>Taslimi</surname><given-names>S</given-names></name><name><surname>Brietzke</surname><given-names>E</given-names></name><name><surname>Ashrafi</surname><given-names>M</given-names></name></person-group>
<article-title>Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies</article-title>. <source/>Biol Psychiatry (<year>2013</year>) <volume>74</volume>(<issue>1</issue>):<fpage>15</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2013.01.007</pub-id>
<pub-id pub-id-type="pmid">23419545</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Munkholm</surname><given-names>K</given-names></name><name><surname>Vinberg</surname><given-names>M</given-names></name><name><surname>Vedel Kessing</surname><given-names>L</given-names></name></person-group>
<article-title>Cytokines in bipolar disorder: a systematic review and meta-analysis</article-title>. <source/>J Affect Disord (<year>2013</year>b) <volume>144</volume>(<issue>1–2</issue>):<fpage>16</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2012.06.010</pub-id>
<pub-id pub-id-type="pmid">22749156</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>BJ</given-names></name><name><surname>Buckley</surname><given-names>P</given-names></name><name><surname>Seabolt</surname><given-names>W</given-names></name><name><surname>Mellor</surname><given-names>A</given-names></name><name><surname>Kirkpatrick</surname><given-names>B</given-names></name></person-group>
<article-title>Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects</article-title>. <source/>Biol Psychiatry (<year>2011</year>b) <volume>70</volume>(<issue>7</issue>):<page-range>663–71</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2011.04.013</pub-id>
</mixed-citation>
</ref>
<ref id="B62">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gray</surname><given-names>SM</given-names></name><name><surname>Bloch</surname><given-names>MH</given-names></name></person-group>
<article-title>Systematic review of proinflammatory cytokines in obsessive-compulsive disorder</article-title>. <source/>Curr Psychiatry Rep (<year>2012</year>) <volume>14</volume>(<issue>3</issue>):<page-range>220–8</page-range>. <pub-id pub-id-type="doi">10.1007/s11920-012-0272-0</pub-id>
</mixed-citation>
</ref>
<ref id="B63">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Masi</surname><given-names>A</given-names></name><name><surname>Quintana</surname><given-names>DS</given-names></name><name><surname>Glozier</surname><given-names>N</given-names></name><name><surname>Lloyd</surname><given-names>AR</given-names></name><name><surname>Hickie</surname><given-names>IB</given-names></name><name><surname>Guastella</surname><given-names>AJ</given-names></name></person-group>
<article-title>Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis</article-title>. <source/>Mol Psychiatry (<year>2015</year>) <volume>20</volume>(<issue>4</issue>):<page-range>440–6</page-range>. <pub-id pub-id-type="doi">10.1038/mp.2014.59</pub-id>
</mixed-citation>
</ref>
<ref id="B64">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hannestad</surname><given-names>J</given-names></name><name><surname>DellaGioia</surname><given-names>N</given-names></name><name><surname>Bloch</surname><given-names>M</given-names></name></person-group>
<article-title>The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis</article-title>. <source/>Neuropsychopharmacology (<year>2011</year>) <volume>36</volume>(<issue>12</issue>):<page-range>2452–9</page-range>. <pub-id pub-id-type="doi">10.1038/npp.2011.132</pub-id>
</mixed-citation>
</ref>
<ref id="B65">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Licinio</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>ML</given-names></name></person-group>
<article-title>Pathways and mechanisms for cytokine signaling of the central nervous system</article-title>. <source/>J Clin Invest (<year>1997</year>) <volume>100</volume>(<issue>12</issue>):<page-range>2941–7</page-range>. <pub-id pub-id-type="doi">10.1172/JCI119846</pub-id>
</mixed-citation>
</ref>
<ref id="B66">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brietzke</surname><given-names>E</given-names></name><name><surname>Stertz</surname><given-names>L</given-names></name><name><surname>Fernandes</surname><given-names>BS</given-names></name><name><surname>Kauer-Sant’anna</surname><given-names>M</given-names></name><name><surname>Mascarenhas</surname><given-names>M</given-names></name><name><surname>Escosteguy Vargas</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder</article-title>. <source/>J Affect Disord (<year>2009</year>) <volume>116</volume>(<issue>3</issue>):<page-range>214–7</page-range>. <pub-id pub-id-type="doi">10.1016/j.jad.2008.12.001</pub-id>
</mixed-citation>
</ref>
<ref id="B67">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>GS</given-names></name><name><surname>Cereser</surname><given-names>KM</given-names></name><name><surname>Fernandes</surname><given-names>BS</given-names></name><name><surname>Kauer-Sant’Anna</surname><given-names>M</given-names></name><name><surname>Fries</surname><given-names>GR</given-names></name><name><surname>Stertz</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients</article-title>. <source/>J Psychiatr Res (<year>2009</year>) <volume>43</volume>(<issue>14</issue>):<page-range>1171–4</page-range>. <pub-id pub-id-type="doi">10.1016/j.jpsychires.2009.04.002</pub-id>
</mixed-citation>
</ref>
<ref id="B68">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>BS</given-names></name><name><surname>Molendijk</surname><given-names>ML</given-names></name><name><surname>Kohler</surname><given-names>CA</given-names></name><name><surname>Soares</surname><given-names>JC</given-names></name><name><surname>Leite</surname><given-names>CM</given-names></name><name><surname>Machado-Vieira</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies</article-title>. <source/>BMC Med (<year>2015</year>a) <volume>13</volume>:<fpage>289</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-015-0529-7</pub-id>
<pub-id pub-id-type="pmid">26621529</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>BS</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Turck</surname><given-names>CW</given-names></name><name><surname>Steiner</surname><given-names>J</given-names></name><name><surname>Goncalves</surname><given-names>CA</given-names></name></person-group>
<article-title>Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis</article-title>. <source/>Mol Psychiatry (<year>2014</year>) <volume>19</volume>(<issue>7</issue>):<page-range>750–1</page-range>. <pub-id pub-id-type="doi">10.1038/mp.2013.172</pub-id>
</mixed-citation>
</ref>
<ref id="B70">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>BS</given-names></name><name><surname>Steiner</surname><given-names>J</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Molendijk</surname><given-names>ML</given-names></name><name><surname>Gonzalez-Pinto</surname><given-names>A</given-names></name><name><surname>Turck</surname><given-names>CW</given-names></name><etal></etal></person-group>
<article-title>Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications</article-title>. <source/>Mol Psychiatry (<year>2015</year>b) <volume>20</volume>(<issue>9</issue>):<page-range>1108–19</page-range>. <pub-id pub-id-type="doi">10.1038/mp.2014.117</pub-id>
</mixed-citation>
</ref>
<ref id="B71">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dantzer</surname><given-names>R</given-names></name><name><surname>O’Connor</surname><given-names>JC</given-names></name><name><surname>Freund</surname><given-names>GG</given-names></name><name><surname>Johnson</surname><given-names>RW</given-names></name><name><surname>Kelley</surname><given-names>KW</given-names></name></person-group>
<article-title>From inflammation to sickness and depression: when the immune system subjugates the brain</article-title>. <source/>Nat Rev Neurosci (<year>2008</year>) <volume>9</volume>(<issue>1</issue>):<fpage>46</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2297</pub-id>
<pub-id pub-id-type="pmid">18073775</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leonard</surname><given-names>BE</given-names></name></person-group>
<article-title>The concept of depression as a dysfunction of the immune system</article-title>. <source/>Curr Immunol Rev (<year>2010</year>) <volume>6</volume>(<issue>3</issue>):<page-range>205–12</page-range>. <pub-id pub-id-type="doi">10.2174/157339510791823835</pub-id>
</mixed-citation>
</ref>
<ref id="B73">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andrade</surname><given-names>L</given-names></name><name><surname>Caraveo-Anduaga</surname><given-names>JJ</given-names></name><name><surname>Berglund</surname><given-names>P</given-names></name><name><surname>Bijl</surname><given-names>RV</given-names></name><name><surname>De Graaf</surname><given-names>R</given-names></name><name><surname>Vollebergh</surname><given-names>W</given-names></name><etal></etal></person-group>
<article-title>The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys</article-title>. <source/>Int J Methods Psychiatr Res (<year>2003</year>) <volume>12</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1002/mpr.138</pub-id>
<pub-id pub-id-type="pmid">12830306</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wright</surname><given-names>CE</given-names></name><name><surname>Strike</surname><given-names>PC</given-names></name><name><surname>Brydon</surname><given-names>L</given-names></name><name><surname>Steptoe</surname><given-names>A</given-names></name></person-group>
<article-title>Acute inflammation and negative mood: mediation by cytokine activation</article-title>. <source/>Brain Behav Immun (<year>2005</year>) <volume>19</volume>(<issue>4</issue>):<page-range>345–50</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2004.10.003</pub-id>
</mixed-citation>
</ref>
<ref id="B75">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O’Connor</surname><given-names>J</given-names></name><name><surname>Lawson</surname><given-names>M</given-names></name><name><surname>André</surname><given-names>C</given-names></name><name><surname>Moreau</surname><given-names>M</given-names></name><name><surname>Lestage</surname><given-names>J</given-names></name><name><surname>Castanon</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>‘Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice</article-title>. <source/>Mol Psychiatry (<year>2009</year>) <volume>14</volume>(<issue>5</issue>):<page-range>511–22</page-range>. <pub-id pub-id-type="doi">10.1038/sj.mp.4002148</pub-id>
</mixed-citation>
</ref>
<ref id="B76">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reichenberg</surname><given-names>A</given-names></name><name><surname>Yirmiya</surname><given-names>R</given-names></name><name><surname>Schuld</surname><given-names>A</given-names></name><name><surname>Kraus</surname><given-names>T</given-names></name><name><surname>Haack</surname><given-names>M</given-names></name><name><surname>Morag</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Cytokine-associated emotional and cognitive disturbances in humans</article-title>. <source/>Arch Gen Psychiatry (<year>2001</year>) <volume>58</volume>(<issue>5</issue>):<page-range>445–52</page-range>. <pub-id pub-id-type="doi">10.1001/archpsyc.58.5.445</pub-id>
</mixed-citation>
</ref>
<ref id="B77">
<label>77</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Euteneuer</surname><given-names>F</given-names></name><name><surname>Schwarz</surname><given-names>MJ</given-names></name><name><surname>Hennings</surname><given-names>A</given-names></name><name><surname>Riemer</surname><given-names>S</given-names></name><name><surname>Stapf</surname><given-names>T</given-names></name><name><surname>Selberdinger</surname><given-names>V</given-names></name><etal></etal></person-group>
<article-title>Depression, cytokines and experimental pain: evidence for sex-related association patterns</article-title>. <source/>J Affect Disord (<year>2010</year>) <volume>131</volume>(<issue>1</issue>):<page-range>143–9</page-range>. <pub-id pub-id-type="doi">10.1016/j.jad.2010.11.017</pub-id>
</mixed-citation>
</ref>
<ref id="B78">
<label>78</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brydon</surname><given-names>L</given-names></name><name><surname>Walker</surname><given-names>C</given-names></name><name><surname>Wawrzyniak</surname><given-names>A</given-names></name><name><surname>Whitehead</surname><given-names>D</given-names></name><name><surname>Okamura</surname><given-names>H</given-names></name><name><surname>Yajima</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans</article-title>. <source/>Brain Behav Immun (<year>2009</year>) <volume>23</volume>(<issue>2</issue>):<page-range>217–24</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2008.09.007</pub-id>
</mixed-citation>
</ref>
<ref id="B79">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dunn</surname><given-names>AJ</given-names></name><name><surname>Swiergiel</surname><given-names>AH</given-names></name></person-group>
<article-title>Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice</article-title>. <source/>Pharmacol Biochem Behav (<year>2005</year>) <volume>81</volume>(<issue>3</issue>):<page-range>688–93</page-range>. <pub-id pub-id-type="doi">10.1016/j.pbb.2005.04.019</pub-id>
</mixed-citation>
</ref>
<ref id="B80">
<label>80</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>Suciu</surname><given-names>S</given-names></name><name><surname>Santinami</surname><given-names>M</given-names></name><name><surname>Testori</surname><given-names>A</given-names></name><name><surname>Kruit</surname><given-names>WH</given-names></name><name><surname>Marsden</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial</article-title>. <source/>Lancet (<year>2008</year>) <volume>372</volume>(<issue>9633</issue>):<page-range>117–26</page-range>. <pub-id pub-id-type="doi">10.1016/S0140-6736(08)61033-8</pub-id>
</mixed-citation>
</ref>
<ref id="B81">
<label>81</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liang</surname><given-names>TJ</given-names></name><name><surname>Ghany</surname><given-names>MG</given-names></name></person-group>
<article-title>Current and future therapies for hepatitis C virus infection</article-title>. <source/>N Engl J Med (<year>2013</year>) <volume>368</volume>(<issue>20</issue>):<page-range>1907–17</page-range>. <pub-id pub-id-type="doi">10.1056/NEJMra1213651</pub-id>
</mixed-citation>
</ref>
<ref id="B82">
<label>82</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Friebe</surname><given-names>A</given-names></name><name><surname>Horn</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>F</given-names></name><name><surname>Janssen</surname><given-names>G</given-names></name><name><surname>Schmid-Wendtner</surname><given-names>MH</given-names></name><name><surname>Volkenandt</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma</article-title>. <source/>Psychosomatics (<year>2010</year>) <volume>51</volume>(<issue>6</issue>):<page-range>466–73</page-range>. <pub-id pub-id-type="doi">10.1176/appi.psy.51.6.466</pub-id>
</mixed-citation>
</ref>
<ref id="B83">
<label>83</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reichenberg</surname><given-names>A</given-names></name><name><surname>Gorman</surname><given-names>JM</given-names></name><name><surname>Dieterich</surname><given-names>DT</given-names></name></person-group>
<article-title>Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study</article-title>. <source/>Aids (<year>2005</year>) <volume>19</volume>
<issue>Suppl 3</issue>:<page-range>S174–8</page-range>. <pub-id pub-id-type="doi">10.1097/01.aids.0000192087.64432.ae</pub-id>
</mixed-citation>
</ref>
<ref id="B84">
<label>84</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Udina</surname><given-names>M</given-names></name><name><surname>Castellvi</surname><given-names>P</given-names></name><name><surname>Moreno-Espana</surname><given-names>J</given-names></name><name><surname>Navines</surname><given-names>R</given-names></name><name><surname>Valdes</surname><given-names>M</given-names></name><name><surname>Forns</surname><given-names>X</given-names></name><etal></etal></person-group>
<article-title>Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis</article-title>. <source/>J Clin Psychiatry (<year>2012</year>) <volume>73</volume>(<issue>8</issue>):<page-range>1128–38</page-range>. <pub-id pub-id-type="doi">10.4088/JCP.12r07694</pub-id>
</mixed-citation>
</ref>
<ref id="B85">
<label>85</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grigoleit</surname><given-names>J-S</given-names></name><name><surname>Kullmann</surname><given-names>JS</given-names></name><name><surname>Wolf</surname><given-names>OT</given-names></name><name><surname>Hammes</surname><given-names>F</given-names></name><name><surname>Wegner</surname><given-names>A</given-names></name><name><surname>Jablonowski</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Dose-dependent effects of endotoxin on neurobehavioral functions in humans</article-title>. <source/>PLoS One (<year>2011</year>) <volume>6</volume>(<issue>12</issue>):<elocation-id>e28330</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0028330</pub-id>
<pub-id pub-id-type="pmid">22164271</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konuk</surname><given-names>N</given-names></name><name><surname>Tekın</surname><given-names>IO</given-names></name><name><surname>Ozturk</surname><given-names>U</given-names></name><name><surname>Atik</surname><given-names>L</given-names></name><name><surname>Atasoy</surname><given-names>N</given-names></name><name><surname>Bektas</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Plasma levels of tumor necrosis factor-alpha and interleukin-6 in obsessive compulsive disorder</article-title>. <source/>Mediators Inflamm (<year>2007</year>) <volume>2007</volume>:<fpage>65704</fpage>. <pub-id pub-id-type="doi">10.1155/2007/65704</pub-id>
<pub-id pub-id-type="pmid">17497035</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dickens</surname><given-names>C</given-names></name><name><surname>McGowan</surname><given-names>L</given-names></name><name><surname>Clark-Carter</surname><given-names>D</given-names></name><name><surname>Creed</surname><given-names>F</given-names></name></person-group>
<article-title>Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis</article-title>. <source/>Psychosom Med (<year>2002</year>) <volume>64</volume>(<issue>1</issue>):<fpage>52</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1097/00006842-200201000-00008</pub-id>
<pub-id pub-id-type="pmid">11818586</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Korczak</surname><given-names>DJ</given-names></name><name><surname>Pereira</surname><given-names>S</given-names></name><name><surname>Koulajian</surname><given-names>K</given-names></name><name><surname>Matejcek</surname><given-names>A</given-names></name><name><surname>Giacca</surname><given-names>A</given-names></name></person-group>
<article-title>Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link</article-title>. <source/>Diabetologia (<year>2011</year>) <volume>54</volume>(<issue>10</issue>):<page-range>2483–93</page-range>. <pub-id pub-id-type="doi">10.1007/s00125-011-2240-3</pub-id>
</mixed-citation>
</ref>
<ref id="B89">
<label>89</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>T</given-names></name><name><surname>Yin</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name></person-group>
<article-title>Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis</article-title>. <source/>BMC Psychiatry (<year>2017</year>) <volume>17</volume>(<issue>1</issue>):<fpage>70</fpage>. <pub-id pub-id-type="doi">10.1186/s12888-017-1234-1</pub-id>
<pub-id pub-id-type="pmid">28196529</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benros</surname><given-names>ME</given-names></name><name><surname>Waltoft</surname><given-names>BL</given-names></name><name><surname>Nordentoft</surname><given-names>M</given-names></name><name><surname>Ostergaard</surname><given-names>SD</given-names></name><name><surname>Eaton</surname><given-names>WW</given-names></name><name><surname>Krogh</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study</article-title>. <source/>JAMA Psychiatry (<year>2013</year>) <volume>70</volume>(<issue>8</issue>):<page-range>812–20</page-range>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.1111</pub-id>
</mixed-citation>
</ref>
<ref id="B91">
<label>91</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mardini</surname><given-names>HE</given-names></name><name><surname>Kip</surname><given-names>KE</given-names></name><name><surname>Wilson</surname><given-names>JW</given-names></name></person-group>
<article-title>Crohn’s disease: a two-year prospective study of the association between psychological distress and disease activity</article-title>. <source/>Dig Dis Sci (<year>2004</year>) <volume>49</volume>(<issue>3</issue>):<page-range>492–7</page-range>. <pub-id pub-id-type="doi">10.1023/B:DDAS.0000020509.23162.cc</pub-id>
</mixed-citation>
</ref>
<ref id="B92">
<label>92</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Langley</surname><given-names>RG</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Schenkel</surname><given-names>B</given-names></name><name><surname>Szapary</surname><given-names>P</given-names></name><name><surname>Hsu</surname><given-names>MC</given-names></name><etal></etal></person-group>
<article-title>Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial</article-title>. <source/>J Am Acad Dermatol (<year>2010</year>) <volume>63</volume>(<issue>3</issue>):<page-range>457–65</page-range>. <pub-id pub-id-type="doi">10.1016/j.jaad.2009.09.014</pub-id>
</mixed-citation>
</ref>
<ref id="B93">
<label>93</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Augustin</surname><given-names>M</given-names></name><name><surname>Signorovitch</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>AP</given-names></name><name><surname>Wu</surname><given-names>EQ</given-names></name><name><surname>Gupta</surname><given-names>SR</given-names></name><etal></etal></person-group>
<article-title>The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial</article-title>. <source/>J Am Acad Dermatol (<year>2010</year>) <volume>62</volume>(<issue>5</issue>):<page-range>812–8</page-range>. <pub-id pub-id-type="doi">10.1016/j.jaad.2009.07.022</pub-id>
</mixed-citation>
</ref>
<ref id="B94">
<label>94</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tyring</surname><given-names>S</given-names></name><name><surname>Gottlieb</surname><given-names>A</given-names></name><name><surname>Papp</surname><given-names>K</given-names></name><name><surname>Gordon</surname><given-names>K</given-names></name><name><surname>Leonardi</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial</article-title>. <source/>Lancet (<year>2006</year>) <volume>367</volume>(<issue>9504</issue>):<fpage>29</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(05)67763-X</pub-id>
<pub-id pub-id-type="pmid">16399150</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kridin</surname><given-names>K</given-names></name><name><surname>Zelber-Sagi</surname><given-names>S</given-names></name><name><surname>Comaneshter</surname><given-names>D</given-names></name><name><surname>Cohen</surname><given-names>AD</given-names></name></person-group>
<article-title>Bipolar disorder associated with another autoimmune disease-pemphigus: a population-based study</article-title>. <source/>Can J Psychiatry (<year>2017</year>) <volume>63</volume>(<issue>7</issue>):<page-range>474–80</page-range>. <pub-id pub-id-type="doi">10.1177/0706743717740344</pub-id>
</mixed-citation>
</ref>
<ref id="B96">
<label>96</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benros</surname><given-names>ME</given-names></name><name><surname>Nielsen</surname><given-names>PR</given-names></name><name><surname>Nordentoft</surname><given-names>M</given-names></name><name><surname>Eaton</surname><given-names>WW</given-names></name><name><surname>Dalton</surname><given-names>SO</given-names></name><name><surname>Mortensen</surname><given-names>PB</given-names></name></person-group>
<article-title>Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study</article-title>. <source/>Am J Psychiatry (<year>2011</year>) <volume>168</volume>(<issue>12</issue>):<page-range>1303–10</page-range>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2011.11030516</pub-id>
</mixed-citation>
</ref>
<ref id="B97">
<label>97</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harris</surname><given-names>RC</given-names></name><name><surname>McKanna</surname><given-names>JA</given-names></name><name><surname>Akai</surname><given-names>Y</given-names></name><name><surname>Jacobson</surname><given-names>HR</given-names></name><name><surname>Dubois</surname><given-names>RN</given-names></name><name><surname>Breyer</surname><given-names>MD</given-names></name></person-group>
<article-title>Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction</article-title>. <source/>J Clin Invest (<year>1994</year>) <volume>94</volume>(<issue>6</issue>):<page-range>2504–10</page-range>. <pub-id pub-id-type="doi">10.1172/JCI117620</pub-id>
</mixed-citation>
</ref>
<ref id="B98">
<label>98</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hirst</surname><given-names>JJ</given-names></name><name><surname>Teixeira</surname><given-names>FJ</given-names></name><name><surname>Zakar</surname><given-names>T</given-names></name><name><surname>Olson</surname><given-names>DM</given-names></name></person-group>
<article-title>Prostaglandin endoperoxide-H synthase-1 and -2 messenger ribonucleic acid levels in human amnion with spontaneous labor onset</article-title>. <source/>J Clin Endocrinol Metab (<year>1995</year>) <volume>80</volume>(<issue>2</issue>):<page-range>517–23</page-range>. <pub-id pub-id-type="doi">10.1210/jc.80.2.517</pub-id>
</mixed-citation>
</ref>
<ref id="B99">
<label>99</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirkby</surname><given-names>NS</given-names></name><name><surname>Zaiss</surname><given-names>AK</given-names></name><name><surname>Urquhart</surname><given-names>P</given-names></name><name><surname>Jiao</surname><given-names>J</given-names></name><name><surname>Austin</surname><given-names>PJ</given-names></name><name><surname>Al-Yamani</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression</article-title>. <source/>PLoS One (<year>2013</year>) <volume>8</volume>(<issue>7</issue>):<elocation-id>e69524</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0069524</pub-id>
<pub-id pub-id-type="pmid">23874970</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>CS</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>DuBois</surname><given-names>RN</given-names></name></person-group>
<article-title>The role of cyclooxygenases in inflammation, cancer, and development</article-title>. <source/>Oncogene (<year>1999</year>) <volume>18</volume>:<fpage>7908</fpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1203286</pub-id>
<pub-id pub-id-type="pmid">10630643</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Coyne</surname><given-names>DW</given-names></name><name><surname>Nickols</surname><given-names>M</given-names></name><name><surname>Bertrand</surname><given-names>W</given-names></name><name><surname>Morrison</surname><given-names>AR</given-names></name></person-group>
<article-title>Regulation of mesangial cell cyclooxygenase synthesis by cytokines and glucocorticoids</article-title>. <source/>Am J Physiol (<year>1992</year>) <volume>263</volume>(1 <issue>Pt 2</issue>):<page-range>F97–102</page-range>. <pub-id pub-id-type="doi">10.1152/ajprenal.1992.263.1.F97</pub-id>
</mixed-citation>
</ref>
<ref id="B102">
<label>102</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DeWitt</surname><given-names>DL</given-names></name><name><surname>Meade</surname><given-names>EA</given-names></name><name><surname>Smith</surname><given-names>WL</given-names></name></person-group>
<article-title>PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs</article-title>. <source/>Am J Med (<year>1993</year>) <volume>95</volume>(<issue>2a</issue>):<page-range>40s–4s</page-range>. <pub-id pub-id-type="doi">10.1016/0002-9343(93)90396-7</pub-id>
</mixed-citation>
</ref>
<ref id="B103">
<label>103</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fu</surname><given-names>JY</given-names></name><name><surname>Masferrer</surname><given-names>JL</given-names></name><name><surname>Seibert</surname><given-names>K</given-names></name><name><surname>Raz</surname><given-names>A</given-names></name><name><surname>Needleman</surname><given-names>P</given-names></name></person-group>
<article-title>The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes</article-title>. <source/>J Biol Chem (<year>1990</year>) <volume>265</volume>(<issue>28</issue>):<page-range>16737–40</page-range>.</mixed-citation>
</ref>
<ref id="B104">
<label>104</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Geng</surname><given-names>Y</given-names></name><name><surname>Blanco</surname><given-names>FJ</given-names></name><name><surname>Cornelisson</surname><given-names>M</given-names></name><name><surname>Lotz</surname><given-names>M</given-names></name></person-group>
<article-title>Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes</article-title>. <source/>J Immunol (<year>1995</year>) <volume>155</volume>(<issue>2</issue>):<fpage>796</fpage>–<lpage>801</lpage>.<pub-id pub-id-type="pmid">7608556</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>DA</given-names></name><name><surname>Carlton</surname><given-names>DP</given-names></name><name><surname>McIntyre</surname><given-names>TM</given-names></name><name><surname>Zimmerman</surname><given-names>GA</given-names></name><name><surname>Prescott</surname><given-names>SM</given-names></name></person-group>
<article-title>Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines</article-title>. <source/>J Biol Chem (<year>1993</year>) <volume>268</volume>(<issue>12</issue>):<page-range>9049–54</page-range>.</mixed-citation>
</ref>
<ref id="B106">
<label>106</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Soyoola</surname><given-names>E</given-names></name><name><surname>Chanmugam</surname><given-names>P</given-names></name><name><surname>Hart</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide</article-title>. <source/>J Biol Chem (<year>1992</year>) <volume>267</volume>(<issue>36</issue>):<page-range>25934–8</page-range>.</mixed-citation>
</ref>
<ref id="B107">
<label>107</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O’Sullivan</surname><given-names>MG</given-names></name><name><surname>Huggins</surname><given-names>EM</given-names><suffix>Jr.</suffix></name><name><surname>Meade</surname><given-names>EA</given-names></name><name><surname>DeWitt</surname><given-names>DL</given-names></name><name><surname>McCall</surname><given-names>CE</given-names></name></person-group>
<article-title>Lipopolysaccharide induces prostaglandin H synthase-2 in alveolar macrophages</article-title>. <source/>Biochem Biophys Res Commun (<year>1992</year>) <volume>187</volume>(<issue>2</issue>):<page-range>1123–7</page-range>. <pub-id pub-id-type="doi">10.1016/0006-291X(92)91313-F</pub-id>
</mixed-citation>
</ref>
<ref id="B108">
<label>108</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riese</surname><given-names>J</given-names></name><name><surname>Hoff</surname><given-names>T</given-names></name><name><surname>Nordhoff</surname><given-names>A</given-names></name><name><surname>DeWitt</surname><given-names>DL</given-names></name><name><surname>Resch</surname><given-names>K</given-names></name><name><surname>Kaever</surname><given-names>V</given-names></name></person-group>
<article-title>Transient expression of prostaglandin endoperoxide synthase-2 during mouse macrophage activation</article-title>. <source/>J Leukoc Biol (<year>1994</year>) <volume>55</volume>(<issue>4</issue>):<page-range>476–82</page-range>. <pub-id pub-id-type="doi">10.1002/jlb.55.4.476</pub-id>
</mixed-citation>
</ref>
<ref id="B109">
<label>109</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maes</surname><given-names>M</given-names></name></person-group>
<article-title>Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression</article-title>. <source/>Metab Brain Dis (<year>2012</year>) <volume>27</volume>(<issue>4</issue>):<page-range>405–13</page-range>. <pub-id pub-id-type="doi">10.1007/s11011-012-9326-6</pub-id>
</mixed-citation>
</ref>
<ref id="B110">
<label>110</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Minghetti</surname><given-names>L</given-names></name><name><surname>Greco</surname><given-names>A</given-names></name><name><surname>Potenza</surname><given-names>RL</given-names></name><name><surname>Pezzola</surname><given-names>A</given-names></name><name><surname>Blum</surname><given-names>D</given-names></name><name><surname>Bantubungi</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration</article-title>. <source/>J Neuropathol Exp Neurol (<year>2007</year>) <volume>66</volume>(<issue>5</issue>):<page-range>363–71</page-range>. <pub-id pub-id-type="doi">10.1097/nen.0b013e3180517477</pub-id>
</mixed-citation>
</ref>
<ref id="B111">
<label>111</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Bonaccorso</surname><given-names>S</given-names></name><name><surname>Heide</surname><given-names>C</given-names></name><name><surname>Verkerk</surname><given-names>R</given-names></name><name><surname>Kenis</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression</article-title>. <source/>J Affect Disord (<year>1998</year>) <volume>49</volume>(<issue>3</issue>):<page-range>211–9</page-range>. <pub-id pub-id-type="doi">10.1016/S0165-0327(98)00025-1</pub-id>
</mixed-citation>
</ref>
<ref id="B112">
<label>112</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rapoport</surname><given-names>SI</given-names></name></person-group>
<article-title>Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade</article-title>. <source/>ACS Chem Neurosci (<year>2014</year>) <volume>5</volume>(<issue>6</issue>):<page-range>459–67</page-range>. <pub-id pub-id-type="doi">10.1021/cn500058v</pub-id>
</mixed-citation>
</ref>
<ref id="B113">
<label>113</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Tanabe</surname><given-names>T</given-names></name><name><surname>Umesono</surname><given-names>K</given-names></name></person-group>
<article-title>Feedback control of cyclooxygenase-2 expression through PPARgamma</article-title>. <source/>J Biol Chem (<year>2000</year>) <volume>275</volume>(<issue>36</issue>):<page-range>28028–32</page-range>. <pub-id pub-id-type="doi">10.1074/jbc.M001387200</pub-id>
</mixed-citation>
</ref>
<ref id="B114">
<label>114</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sales</surname><given-names>KJ</given-names></name><name><surname>Grant</surname><given-names>V</given-names></name><name><surname>Jabbour</surname><given-names>HN</given-names></name></person-group>
<article-title>Prostaglandin E2 and F2alpha activate the FP receptor and up-regulate cyclooxygenase-2 expression <italic>via</italic> the cyclic AMP response element</article-title>. <source/>Mol Cell Endocrinol (<year>2008</year>) <volume>285</volume>(<issue>1–2</issue>):<fpage>51</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2008.01.016</pub-id>
<pub-id pub-id-type="pmid">18316157</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Müller</surname><given-names>N</given-names></name></person-group>
<article-title>Immunological aspects of the treatment of depression and schizophrenia</article-title>. <source/>Dialogues Clin Neurosci (<year>2017</year>) <volume>19</volume>(<issue>1</issue>):<fpage>55</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">28566947</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Langenbach</surname><given-names>R</given-names></name><name><surname>Bosetti</surname><given-names>F</given-names></name></person-group>
<article-title>Cyclooxygenase-1 and -2 enzymes differentially regulate the brain upstream NF-kappa B pathway and downstream enzymes involved in prostaglandin biosynthesis</article-title>. <source/>J Neurochem (<year>2006</year>) <volume>98</volume>(<issue>3</issue>):<page-range>801–11</page-range>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.03926.x</pub-id>
</mixed-citation>
</ref>
<ref id="B117">
<label>117</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rao</surname><given-names>JS</given-names></name><name><surname>Langenbach</surname><given-names>R</given-names></name><name><surname>Bosetti</surname><given-names>F</given-names></name></person-group>
<article-title>Down-regulation of brain nuclear factor-kappa B pathway in the cyclooxygenase-2 knockout mouse</article-title>. <source/>Brain Res Mol Brain Res (<year>2005</year>) <volume>139</volume>(<issue>2</issue>):<page-range>217–24</page-range>. <pub-id pub-id-type="doi">10.1016/j.molbrainres.2005.05.008</pub-id>
</mixed-citation>
</ref>
<ref id="B118">
<label>118</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hawkey</surname><given-names>CJ</given-names></name></person-group>
<article-title>COX-2 chronology</article-title>. <source/>Gut (<year>2005</year>) <volume>54</volume>(<issue>11</issue>):<fpage>1509</fpage>. <pub-id pub-id-type="doi">10.1136/gut.2005.065003</pub-id>
<pub-id pub-id-type="pmid">16227351</pub-id></mixed-citation>
</ref>
<ref id="B119">
<label>119</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>FitzGerald</surname><given-names>GA</given-names></name><name><surname>Patrono</surname><given-names>C</given-names></name></person-group>
<article-title>The coxibs, selective inhibitors of cyclooxygenase-2</article-title>. <source/>N Engl J Med (<year>2001</year>) <volume>345</volume>(<issue>6</issue>):<page-range>433–42</page-range>. <pub-id pub-id-type="doi">10.1056/NEJM200108093450607</pub-id>
</mixed-citation>
</ref>
<ref id="B120">
<label>120</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Laine</surname><given-names>L</given-names></name><name><surname>Reicin</surname><given-names>A</given-names></name><name><surname>Shapiro</surname><given-names>D</given-names></name><name><surname>Burgos-Vargas</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis</article-title>. <source/>N Engl J Med (<year>2000</year>) <volume>343</volume>(<issue>21</issue>):<page-range>1520–8</page-range>. <pub-id pub-id-type="doi">10.1056/NEJM200011233432103</pub-id>
</mixed-citation>
</ref>
<ref id="B121">
<label>121</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bresalier</surname><given-names>RS</given-names></name><name><surname>Sandler</surname><given-names>RS</given-names></name><name><surname>Quan</surname><given-names>H</given-names></name><name><surname>Bolognese</surname><given-names>JA</given-names></name><name><surname>Oxenius</surname><given-names>B</given-names></name><name><surname>Horgan</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial</article-title>. <source/>N Engl J Med (<year>2005</year>) <volume>352</volume>(<issue>11</issue>):<page-range>1092–102</page-range>. <pub-id pub-id-type="doi">10.1056/NEJMoa050493</pub-id>
</mixed-citation>
</ref>
<ref id="B122">
<label>122</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Farkouh</surname><given-names>ME</given-names></name><name><surname>Kirshner</surname><given-names>H</given-names></name><name><surname>Harrington</surname><given-names>RA</given-names></name><name><surname>Ruland</surname><given-names>S</given-names></name><name><surname>Verheugt</surname><given-names>FW</given-names></name><name><surname>Schnitzer</surname><given-names>TJ</given-names></name><etal></etal></person-group>
<article-title>‘Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial</article-title>. <source/>Lancet (<year>2004</year>) <volume>364</volume>(<issue>9435</issue>):<page-range>675–84</page-range>. <pub-id pub-id-type="doi">10.1016/S0140-6736(04)16894-3</pub-id>
</mixed-citation>
</ref>
<ref id="B123">
<label>123</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schnitzer</surname><given-names>TJ</given-names></name><name><surname>Burmester</surname><given-names>GR</given-names></name><name><surname>Mysler</surname><given-names>E</given-names></name><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Ehrsam</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial</article-title>. <source/>Lancet (<year>2004</year>) <volume>364</volume>(<issue>9435</issue>):<page-range>665–74</page-range>. <pub-id pub-id-type="doi">10.1016/S0140-6736(04)16893-1</pub-id>
</mixed-citation>
</ref>
<ref id="B124">
<label>124</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scarpignato</surname><given-names>C</given-names></name><name><surname>Lanas</surname><given-names>A</given-names></name><name><surname>Blandizzi</surname><given-names>C</given-names></name><name><surname>Lems</surname><given-names>WF</given-names></name><name><surname>Hermann</surname><given-names>M</given-names></name><name><surname>Hunt</surname><given-names>RH</given-names></name></person-group>
<article-title>Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis—an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks</article-title>. <source/>BMC Med (<year>2015</year>) <volume>13</volume>:<fpage>55</fpage>. <pub-id pub-id-type="doi">10.1186/s12916-015-0285-8</pub-id>
<pub-id pub-id-type="pmid">25857826</pub-id></mixed-citation>
</ref>
<ref id="B125">
<label>125</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sandrini</surname><given-names>M</given-names></name><name><surname>Vitale</surname><given-names>G</given-names></name><name><surname>Pini</surname><given-names>LA</given-names></name></person-group>
<article-title>Effect of rofecoxib on nociception and the serotonin system in the rat brain</article-title>. <source/>Inflamm Res (<year>2002</year>) <volume>51</volume>(<issue>3</issue>):<page-range>154–9</page-range>. <pub-id pub-id-type="doi">10.1007/PL00000287</pub-id>
</mixed-citation>
</ref>
<ref id="B126">
<label>126</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johansson</surname><given-names>D</given-names></name><name><surname>Falk</surname><given-names>A</given-names></name><name><surname>Marcus</surname><given-names>MM</given-names></name><name><surname>Svensson</surname><given-names>TH</given-names></name></person-group>
<article-title>Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry (<year>2012</year>) <volume>39</volume>(<issue>1</issue>):<page-range>143–8</page-range>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2012.06.003</pub-id>
</mixed-citation>
</ref>
<ref id="B127">
<label>127</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi</surname><given-names>S-H</given-names></name><name><surname>Aid</surname><given-names>S</given-names></name><name><surname>Bosetti</surname><given-names>F</given-names></name></person-group>
<article-title>The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research</article-title>. <source/>Trends Pharmacol Sci (<year>2009</year>) <volume>30</volume>(<issue>4</issue>):<page-range>174–81</page-range>. <pub-id pub-id-type="doi">10.1016/j.tips.2009.01.002</pub-id>
</mixed-citation>
</ref>
<ref id="B128">
<label>128</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Minghetti</surname><given-names>L</given-names></name><name><surname>Pocchiari</surname><given-names>M</given-names></name></person-group>
<article-title>Cyclooxygenase-2, prostaglandin E2, and microglial activation in prion diseases</article-title>. <source/>Int Rev Neurobiol (<year>2007</year>) <volume>82</volume>:<page-range>265–75</page-range>. <pub-id pub-id-type="doi">10.1016/S0074-7742(07)82014-9</pub-id>
</mixed-citation>
</ref>
<ref id="B129">
<label>129</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gilroy</surname><given-names>DW</given-names></name><name><surname>Stables</surname><given-names>M</given-names></name><name><surname>Newson</surname><given-names>J</given-names></name></person-group>
<article-title><italic>In vivo</italic> models to study cyclooxygenase products in health and disease: introduction to part III</article-title>. <source/>Methods Mol Biol (<year>2010</year>) <volume>644</volume>:<page-range>181–8</page-range>. <pub-id pub-id-type="doi">10.1007/978-1-59745-364-6_15</pub-id>
</mixed-citation>
</ref>
<ref id="B130">
<label>130</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dinchuk</surname><given-names>JE</given-names></name><name><surname>Car</surname><given-names>BD</given-names></name><name><surname>Focht</surname><given-names>RJ</given-names></name><name><surname>Johnston</surname><given-names>JJ</given-names></name><name><surname>Jaffee</surname><given-names>BD</given-names></name><name><surname>Covington</surname><given-names>MB</given-names></name><etal></etal></person-group>
<article-title>Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II</article-title>. <source/>Nature (<year>1995</year>) <volume>378</volume>(<issue>6555</issue>):<page-range>406–9</page-range>. <pub-id pub-id-type="doi">10.1038/378406a0</pub-id>
</mixed-citation>
</ref>
<ref id="B131">
<label>131</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morham</surname><given-names>SG</given-names></name><name><surname>Langenbach</surname><given-names>R</given-names></name><name><surname>Loftin</surname><given-names>CD</given-names></name><name><surname>Tiano</surname><given-names>HF</given-names></name><name><surname>Vouloumanos</surname><given-names>N</given-names></name><name><surname>Jennette</surname><given-names>JC</given-names></name><etal></etal></person-group>
<article-title>Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse</article-title>. <source/>Cell (<year>1995</year>) <volume>83</volume>(<issue>3</issue>):<page-range>473–82</page-range>. <pub-id pub-id-type="doi">10.1016/0092-8674(95)90125-6</pub-id>
</mixed-citation>
</ref>
<ref id="B132">
<label>132</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aid</surname><given-names>S</given-names></name><name><surname>Silva</surname><given-names>AC</given-names></name><name><surname>Candelario-Jalil</surname><given-names>E</given-names></name><name><surname>Choi</surname><given-names>SH</given-names></name><name><surname>Rosenberg</surname><given-names>GA</given-names></name><name><surname>Bosetti</surname><given-names>F</given-names></name></person-group>
<article-title>Cyclooxygenase-1 and -2 differentially modulate lipopolysaccharide-induced blood–brain barrier disruption through matrix metalloproteinase activity</article-title>. <source/>J Cereb Blood Flow Metab (<year>2010</year>) <volume>30</volume>(<issue>2</issue>):<page-range>370–80</page-range>. <pub-id pub-id-type="doi">10.1038/jcbfm.2009.223</pub-id>
</mixed-citation>
</ref>
<ref id="B133">
<label>133</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gilroy</surname><given-names>DW</given-names></name><name><surname>Colville-Nash</surname><given-names>PR</given-names></name><name><surname>Willis</surname><given-names>D</given-names></name><name><surname>Chivers</surname><given-names>J</given-names></name><name><surname>Paul-Clark</surname><given-names>MJ</given-names></name><name><surname>Willoughby</surname><given-names>DA</given-names></name></person-group>
<article-title>Inducible cyclooxygenase may have anti-inflammatory properties</article-title>. <source/>Nat Med (<year>1999</year>) <volume>5</volume>(<issue>6</issue>):<fpage>698</fpage>–<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1038/9550</pub-id>
<pub-id pub-id-type="pmid">10371510</pub-id></mixed-citation>
</ref>
<ref id="B134">
<label>134</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Iwase</surname><given-names>M</given-names></name><name><surname>Kondo</surname><given-names>G</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Ohashi</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Suppressive effect of selective cyclooxygenase-2 inhibitor on cytokine release in human neutrophils</article-title>. <source/>Int Immunopharmacol (<year>2003</year>) <volume>3</volume>(<issue>10–11</issue>):<page-range>1519–28</page-range>. <pub-id pub-id-type="doi">10.1016/S1567-5769(03)00179-6</pub-id>
</mixed-citation>
</ref>
<ref id="B135">
<label>135</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Strauss</surname><given-names>KI</given-names></name><name><surname>Marini</surname><given-names>AM</given-names></name></person-group>
<article-title>Cyclooxygenase-2 inhibition protects cultured cerebellar granule neurons from glutamate-mediated cell death</article-title>. <source/>J Neurotrauma (<year>2002</year>) <volume>19</volume>(<issue>5</issue>):<page-range>627–38</page-range>. <pub-id pub-id-type="doi">10.1089/089771502753754091</pub-id>
</mixed-citation>
</ref>
<ref id="B136">
<label>136</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Izquierdo</surname><given-names>LA</given-names></name><name><surname>Barros</surname><given-names>DM</given-names></name><name><surname>Ardenghi</surname><given-names>PG</given-names></name><name><surname>Pereira</surname><given-names>P</given-names></name><name><surname>Rodrigues</surname><given-names>C</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Different hippocampal molecular requirements for short- and long-term retrieval of one-trial avoidance learning</article-title>. <source/>Behav Brain Res (<year>2000</year>) <volume>111</volume>(<issue>1–2</issue>):<page-range>93–8</page-range>. <pub-id pub-id-type="doi">10.1016/S0166-4328(00)00137-6</pub-id>
</mixed-citation>
</ref>
<ref id="B137">
<label>137</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zagulska-Szymczak</surname><given-names>S</given-names></name><name><surname>Filipkowski</surname><given-names>RK</given-names></name><name><surname>Kaczmarek</surname><given-names>L</given-names></name></person-group>
<article-title>Kainate-induced genes in the hippocampus: lessons from expression patterns</article-title>. <source/>Neurochem Int (<year>2001</year>) <volume>38</volume>(<issue>6</issue>):<fpage>485</fpage>–<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1016/S0197-0186(00)00101-7</pub-id>
<pub-id pub-id-type="pmid">11248397</pub-id></mixed-citation>
</ref>
<ref id="B138">
<label>138</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X-Y</given-names></name><name><surname>Zhang</surname><given-names>H-L</given-names></name><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name></person-group>
<article-title>Kainic acid-induced neurodegenerative model: potentials and limitations</article-title>. <source/>J Biomed Biotechnol (<year>2011</year>) <volume>2011</volume>:<fpage>457079</fpage>. <pub-id pub-id-type="doi">10.1155/2011/457079</pub-id>
<pub-id pub-id-type="pmid">21127706</pub-id></mixed-citation>
</ref>
<ref id="B139">
<label>139</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ciceri</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Shaffer</surname><given-names>AF</given-names></name><name><surname>Leahy</surname><given-names>KM</given-names></name><name><surname>Woerner</surname><given-names>MB</given-names></name><name><surname>Smith</surname><given-names>WG</given-names></name><etal></etal></person-group>
<article-title>Pharmacology of celecoxib in rat brain after kainate administration</article-title>. <source/>J Pharmacol Exp Ther (<year>2002</year>) <volume>302</volume>(<issue>3</issue>):<fpage>846</fpage>. <pub-id pub-id-type="doi">10.1124/jpet.302.3.846</pub-id>
<pub-id pub-id-type="pmid">12183639</pub-id></mixed-citation>
</ref>
<ref id="B140">
<label>140</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Byun</surname><given-names>J-S</given-names></name><name><surname>Cho</surname><given-names>S-Y</given-names></name><name><surname>Kim</surname><given-names>S-I</given-names></name><name><surname>Kwon</surname><given-names>Y-S</given-names></name><name><surname>Jeon</surname><given-names>S-H</given-names></name><name><surname>Kim</surname><given-names>M-J</given-names></name><etal></etal></person-group>
<article-title>Celecoxib attenuates kainic acid-induced neuronal cell death through suppression of microglial c-Jun N-terminal kinase phosphorylation</article-title>. <source/>Exp Neurobiol (<year>2009</year>) <volume>18</volume>(<issue>1</issue>):<page-range>13–8</page-range>. <pub-id pub-id-type="doi">10.5607/en.2009.18.1.13</pub-id>
</mixed-citation>
</ref>
<ref id="B141">
<label>141</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baik</surname><given-names>EJ</given-names></name><name><surname>Kim</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Moon</surname><given-names>C-H</given-names></name></person-group>
<article-title>Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus</article-title>. <source/>Brain Res (<year>1999</year>) <volume>843</volume>(<issue>1</issue>):<page-range>118–29</page-range>. <pub-id pub-id-type="doi">10.1016/S0006-8993(99)01797-7</pub-id>
</mixed-citation>
</ref>
<ref id="B142">
<label>142</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nogawa</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Ross</surname><given-names>ME</given-names></name><name><surname>Iadecola</surname><given-names>C</given-names></name></person-group>
<article-title>Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage</article-title>. <source/>J Neurosci (<year>1997</year>) <volume>17</volume>(<issue>8</issue>):<page-range>2746–55</page-range>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.17-08-02746.1997</pub-id>
</mixed-citation>
</ref>
<ref id="B143">
<label>143</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SF</given-names></name><name><surname>Hester</surname><given-names>L</given-names></name><name><surname>Snyder</surname><given-names>SH</given-names></name></person-group>
<article-title>S-nitrosylation/activation of COX-2 mediates NMDA neurotoxicity</article-title>. <source/>Proc Natl Acad Sci U S A (<year>2008</year>) <volume>105</volume>(<issue>30</issue>):<page-range>10537–40</page-range>. <pub-id pub-id-type="doi">10.1073/pnas.0804852105</pub-id>
</mixed-citation>
</ref>
<ref id="B144">
<label>144</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>F</given-names></name><name><surname>Rossetti</surname><given-names>AC</given-names></name><name><surname>Racagni</surname><given-names>G</given-names></name><name><surname>Gass</surname><given-names>P</given-names></name><name><surname>Riva</surname><given-names>MA</given-names></name><name><surname>Molteni</surname><given-names>R</given-names></name></person-group>
<article-title>Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity</article-title>. <source/>Front Cell Neurosci (<year>2014</year>) <volume>8</volume>:<fpage>430</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2014.00430</pub-id>
<pub-id pub-id-type="pmid">25565964</pub-id></mixed-citation>
</ref>
<ref id="B145">
<label>145</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hayley</surname><given-names>S</given-names></name></person-group>
<article-title>The neuroimmune-neuroplasticity interface and brain pathology</article-title>. <source/>Front Cell Neurosci (<year>2014</year>) <volume>8</volume>:<fpage>419</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2014.00419</pub-id>
<pub-id pub-id-type="pmid">25538568</pub-id></mixed-citation>
</ref>
<ref id="B146">
<label>146</label>
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Robertson</surname><given-names>OD</given-names></name><name><surname>Coronado</surname><given-names>NG</given-names></name><name><surname>Sethi</surname><given-names>R</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name><name><surname>Dodd</surname><given-names>S</given-names></name></person-group>
. <article-title>Putative neuroprotective pharmacotherapies to target the staged progression of mental illness</article-title>. <source/>Early Intervention in Psychiatry (<year>2019</year>) <fpage>1</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1111/eip.12775</pub-id>
</mixed-citation>
</ref>
<ref id="B147">
<label>147</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Capuron</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>AH</given-names></name></person-group>
<article-title>Immune system to brain signaling: neuropsychopharmacological implications</article-title>. <source/>Pharmacol Ther (<year>2011</year>) <volume>130</volume>(<issue>2</issue>):<page-range>226–38</page-range>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2011.01.014</pub-id>
</mixed-citation>
</ref>
<ref id="B148">
<label>148</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>AH</given-names></name><name><surname>Haroon</surname><given-names>E</given-names></name><name><surname>Raison</surname><given-names>CL</given-names></name><name><surname>Felger</surname><given-names>JC</given-names></name></person-group>
<article-title>Cytokine targets in the brain: impact on neurotransmitters and neurocircuits</article-title>. <source/>Depress Anxiety (<year>2013</year>) <volume>30</volume>(<issue>4</issue>):<fpage>297</fpage>–<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1002/da.22084</pub-id>
<pub-id pub-id-type="pmid">23468190</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peters</surname><given-names>JC</given-names></name></person-group>
<article-title>Tryptophan nutrition and metabolism: an overview</article-title>. <source/>Adv Exp Med Biol (<year>1991</year>) <volume>294</volume>:<page-range>345–58</page-range>. <pub-id pub-id-type="doi">10.1007/978-1-4684-5952-4_32</pub-id>
</mixed-citation>
</ref>
<ref id="B150">
<label>150</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hirschfeld</surname><given-names>RM</given-names></name></person-group>
<article-title>History and evolution of the monoamine hypothesis of depression</article-title>. <source/>J Clin Psychiatry (<year>2000</year>) <volume>61</volume>(<issue>Suppl 6</issue>):<fpage>4</fpage>–<lpage>6</lpage>.</mixed-citation>
</ref>
<ref id="B151">
<label>151</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maes</surname><given-names>M</given-names></name></person-group>
<article-title>The cytokine hypothesis of depression: inflammation, oxidative &amp; nitrosative stress (IO&amp;NS) and leaky gut as new targets for adjunctive treatments in depression</article-title>. <source/>Neuro Endocrinol Lett (<year>2008</year>) <volume>29</volume>(<issue>3</issue>):<page-range>287–91</page-range>.</mixed-citation>
</ref>
<ref id="B152">
<label>152</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Dunn</surname><given-names>AJ</given-names></name></person-group>
<article-title>Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism</article-title>. <source/>Neurochem Int (<year>1998</year>) <volume>33</volume>(<issue>2</issue>):<page-range>143–54</page-range>. <pub-id pub-id-type="doi">10.1016/S0197-0186(98)00016-3</pub-id>
</mixed-citation>
</ref>
<ref id="B153">
<label>153</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raison</surname><given-names>CL</given-names></name><name><surname>Dantzer</surname><given-names>R</given-names></name><name><surname>Kelley</surname><given-names>KW</given-names></name><name><surname>Lawson</surname><given-names>MA</given-names></name><name><surname>Woolwine</surname><given-names>BJ</given-names></name><name><surname>Vogt</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression</article-title>. <source/>Mol Psychiatry (<year>2010</year>) <volume>15</volume>(<issue>4</issue>):<fpage>393</fpage>–<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2009.116</pub-id>
<pub-id pub-id-type="pmid">19918244</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steiner</surname><given-names>J</given-names></name><name><surname>Walter</surname><given-names>M</given-names></name><name><surname>Gos</surname><given-names>T</given-names></name><name><surname>Guillemin</surname><given-names>GJ</given-names></name><name><surname>Bernstein</surname><given-names>H-G</given-names></name><name><surname>Sarnyai</surname><given-names>Z</given-names></name><etal></etal></person-group>
<article-title>Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission</article-title>? <source/>J Neuroinflammation (<year>2011</year>) <volume>8</volume>(<issue>1</issue>):<fpage>94</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-8-94</pub-id>
<pub-id pub-id-type="pmid">21831269</pub-id></mixed-citation>
</ref>
<ref id="B155">
<label>155</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stone</surname><given-names>TW</given-names></name><name><surname>Darlington</surname><given-names>LG</given-names></name></person-group>
<article-title>Endogenous kynurenines as targets for drug discovery and development</article-title>. <source/>Nat Rev Drug Discov (<year>2002</year>) <volume>1</volume>(<issue>8</issue>):<page-range>609–20</page-range>. <pub-id pub-id-type="doi">10.1038/nrd870</pub-id>
</mixed-citation>
</ref>
<ref id="B156">
<label>156</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stone</surname><given-names>TW</given-names></name><name><surname>Stoy</surname><given-names>N</given-names></name><name><surname>Darlington</surname><given-names>LG</given-names></name></person-group>
<article-title>An expanding range of targets for kynurenine metabolites of tryptophan</article-title>. <source/>Trends Pharmacol Sci (<year>2013</year>) <volume>34</volume>(<issue>2</issue>):<page-range>136–43</page-range>. <pub-id pub-id-type="doi">10.1016/j.tips.2012.09.006</pub-id>
</mixed-citation>
</ref>
<ref id="B157">
<label>157</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beal</surname><given-names>MF</given-names></name><name><surname>Matson</surname><given-names>WR</given-names></name><name><surname>Swartz</surname><given-names>KJ</given-names></name><name><surname>Gamache</surname><given-names>PH</given-names></name><name><surname>Bird</surname><given-names>ED</given-names></name></person-group>
<article-title>Kynurenine pathway measurements in Huntington’s disease striatum: evidence for reduced formation of kynurenic acid</article-title>. <source/>J Neurochem (<year>1990</year>) <volume>55</volume>(<issue>4</issue>):<page-range>1327–39</page-range>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.1990.tb03143.x</pub-id>
</mixed-citation>
</ref>
<ref id="B158">
<label>158</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Irwin</surname><given-names>MR</given-names></name><name><surname>Miller</surname><given-names>AH</given-names></name></person-group>
<article-title>Depressive disorders and immunity: 20 years of progress and discovery</article-title>. <source/>Brain Behav Immun (<year>2007</year>) <volume>21</volume>(<issue>4</issue>):<page-range>374–83</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2007.01.010</pub-id>
</mixed-citation>
</ref>
<ref id="B159">
<label>159</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lugo-Huitrón</surname><given-names>R</given-names></name><name><surname>Muñiz</surname><given-names>U</given-names></name><name><surname>Pineda</surname><given-names>B</given-names></name><name><surname>Pedraza-Chaverrí</surname><given-names>J</given-names></name><name><surname>Ríos</surname><given-names>C</given-names></name><name><surname>Pérez-de la Cruz</surname><given-names>V</given-names></name></person-group>
<article-title>Quinolinic acid: an endogenous neurotoxin with multiple targets</article-title>. <source/>Oxid Med Cell Longev (<year>2013</year>) <volume>2013</volume>:<fpage>14</fpage>. <pub-id pub-id-type="doi">10.1155/2013/104024</pub-id>
</mixed-citation>
</ref>
<ref id="B160">
<label>160</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>AH</given-names></name></person-group>
<article-title>Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression</article-title>. <source/>Neuropsychopharmacology (<year>2013</year>) <volume>38</volume>(<issue>9</issue>):<page-range>1607–8</page-range>. <pub-id pub-id-type="doi">10.1038/npp.2013.140</pub-id>
</mixed-citation>
</ref>
<ref id="B161">
<label>161</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwarcz</surname><given-names>R</given-names></name></person-group>
<article-title>‘The kynurenine pathway of tryptophan degradation as a drug target</article-title>. <source/>Curr Opin Pharmacol (<year>2004</year>) <volume>4</volume>(<issue>1</issue>):<page-range>12–7</page-range>. <pub-id pub-id-type="doi">10.1016/j.coph.2003.10.006</pub-id>
</mixed-citation>
</ref>
<ref id="B162">
<label>162</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herman</surname><given-names>JP</given-names></name><name><surname>McKlveen</surname><given-names>JM</given-names></name><name><surname>Ghosal</surname><given-names>S</given-names></name><name><surname>Kopp</surname><given-names>B</given-names></name><name><surname>Wulsin</surname><given-names>A</given-names></name><name><surname>Makinson</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Regulation of the hypothalamic–pituitary–adrenocortical stress response</article-title>. <source/>Compr Physiol (<year>2016</year>) <volume>6</volume>(<issue>2</issue>):<page-range>603–21</page-range>. <pub-id pub-id-type="doi">10.1002/cphy.c150015</pub-id>
</mixed-citation>
</ref>
<ref id="B163">
<label>163</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McKay</surname><given-names>MS</given-names></name><name><surname>Zakzanis</surname><given-names>KK</given-names></name></person-group>
<article-title>The impact of treatment on HPA axis activity in unipolar major depression</article-title>. <source/>J Psychiatr Res (<year>2010</year>) <volume>44</volume>(<issue>3</issue>):<page-range>183–92</page-range>. <pub-id pub-id-type="doi">10.1016/j.jpsychires.2009.07.012</pub-id>
</mixed-citation>
</ref>
<ref id="B164">
<label>164</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beishuizen</surname><given-names>A</given-names></name><name><surname>Thijs</surname><given-names>LG</given-names></name></person-group>
<article-title>Endotoxin and the hypothalamo–pituitary–adrenal (HPA) axis</article-title>. <source/>J Endotoxin Res (<year>2003</year>) <volume>9</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1179/096805103125001298</pub-id>
<pub-id pub-id-type="pmid">12691614</pub-id></mixed-citation>
</ref>
<ref id="B165">
<label>165</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dunn</surname><given-names>AJ</given-names></name></person-group>
<article-title>Cytokine activation of the HPA axis</article-title>. <source/>Ann N Y Acad Sci (<year>2000</year>) <volume>917</volume>:<page-range>608–17</page-range>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb05426.x</pub-id>
</mixed-citation>
</ref>
<ref id="B166">
<label>166</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silverman</surname><given-names>MN</given-names></name><name><surname>Pearce</surname><given-names>BD</given-names></name><name><surname>Biron</surname><given-names>CA</given-names></name><name><surname>Miller</surname><given-names>AH</given-names></name></person-group>
<article-title>Immune modulation of the hypothalamic–pituitary–adrenal (HPA) axis during viral infection</article-title>. <source/>Viral Immunol (<year>2005</year>) <volume>18</volume>(<issue>1</issue>):<fpage>41</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1089/vim.2005.18.41</pub-id>
<pub-id pub-id-type="pmid">15802953</pub-id></mixed-citation>
</ref>
<ref id="B167">
<label>167</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silverman</surname><given-names>MN</given-names></name><name><surname>Sternberg</surname><given-names>EM</given-names></name></person-group>
<article-title>Glucocorticoid regulation of inflammation and its behavioral and metabolic correlates: from HPA axis to glucocorticoid receptor dysfunction</article-title>. <source/>Ann N Y Acad Sci (<year>2012</year>) <volume>1261</volume>:<fpage>55</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06633.x</pub-id>
<pub-id pub-id-type="pmid">22823394</pub-id></mixed-citation>
</ref>
<ref id="B168">
<label>168</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oxenkrug</surname><given-names>GF</given-names></name></person-group>
<article-title>Tryptophan–kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later</article-title>. <source/>Isr J Psychiatry Relat Sci (<year>2010</year>) <volume>47</volume>(<issue>1</issue>):<fpage>56</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">20686200</pub-id></mixed-citation>
</ref>
<ref id="B169">
<label>169</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosenblat</surname><given-names>JD</given-names></name><name><surname>Cha</surname><given-names>DS</given-names></name><name><surname>Mansur</surname><given-names>RB</given-names></name><name><surname>McIntyre</surname><given-names>RS</given-names></name></person-group>
<article-title>‘Inflamed moods: a review of the interactions between inflammation and mood disorders</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry (<year>2014</year>) <volume>53</volume>:<fpage>23</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2014.01.013</pub-id>
<pub-id pub-id-type="pmid">24468642</pub-id></mixed-citation>
</ref>
<ref id="B170">
<label>170</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McQuade</surname><given-names>R</given-names></name><name><surname>Young</surname><given-names>AH</given-names></name></person-group>
<article-title>Future therapeutic targets in mood disorders: the glucocorticoid receptor</article-title>. <source/>Br J Psychiatry (<year>2000</year>) <volume>177</volume>:<page-range>390–5</page-range>. <pub-id pub-id-type="doi">10.1192/bjp.177.5.390</pub-id>
</mixed-citation>
</ref>
<ref id="B171">
<label>171</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raison</surname><given-names>CL</given-names></name><name><surname>Miller</surname><given-names>AH</given-names></name></person-group>
<article-title>When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders</article-title>. <source/>Am J Psychiatry (<year>2003</year>) <volume>160</volume>(<issue>9</issue>):<page-range>1554–65</page-range>. <pub-id pub-id-type="doi">10.1176/appi.ajp.160.9.1554</pub-id>
</mixed-citation>
</ref>
<ref id="B172">
<label>172</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adzic</surname><given-names>M</given-names></name><name><surname>Djordjevic</surname><given-names>J</given-names></name><name><surname>Djordjevic</surname><given-names>A</given-names></name><name><surname>Niciforovic</surname><given-names>A</given-names></name><name><surname>Demonacos</surname><given-names>C</given-names></name><name><surname>Radojcic</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Acute or chronic stress induce cell compartment-specific phosphorylation of glucocorticoid receptor and alter its transcriptional activity in Wistar rat brain</article-title>. <source/>J Endocrinol (<year>2009</year>) <volume>202</volume>(<issue>1</issue>):<fpage>87</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1677/JOE-08-0509</pub-id>
<pub-id pub-id-type="pmid">19406955</pub-id></mixed-citation>
</ref>
<ref id="B173">
<label>173</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anacker</surname><given-names>C</given-names></name><name><surname>Zunszain</surname><given-names>PA</given-names></name><name><surname>Carvalho</surname><given-names>LA</given-names></name><name><surname>Pariante</surname><given-names>CM</given-names></name></person-group>
<article-title>The glucocorticoid receptor: pivot of depression and of antidepressant treatment</article-title>? <source/>Psychoneuroendocrinology (<year>2011</year>) <volume>36</volume>(<issue>3</issue>):<page-range>415–25</page-range>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2010.03.007</pub-id>
</mixed-citation>
</ref>
<ref id="B174">
<label>174</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pariante</surname><given-names>CM</given-names></name></person-group>
<article-title>Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids</article-title>. <source/>Ann N Y Acad Sci (<year>2009</year>) <volume>1179</volume>:<page-range>144–52</page-range>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.04978.x</pub-id>
</mixed-citation>
</ref>
<ref id="B175">
<label>175</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Atmaca</surname><given-names>M</given-names></name><name><surname>Yildirim</surname><given-names>H</given-names></name><name><surname>Ozler</surname><given-names>S</given-names></name><name><surname>Koc</surname><given-names>M</given-names></name><name><surname>Kara</surname><given-names>B</given-names></name><name><surname>Sec</surname><given-names>S</given-names></name></person-group>
<article-title>Smaller pituitary volume in adult patients with obsessive-compulsive disorder</article-title>. <source/>Psychiatry Clin Neurosci (<year>2009</year>) <volume>63</volume>(<issue>4</issue>):<page-range>516–20</page-range>. <pub-id pub-id-type="doi">10.1111/j.1440-1819.2009.01981.x</pub-id>
</mixed-citation>
</ref>
<ref id="B176">
<label>176</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clark</surname><given-names>IA</given-names></name><name><surname>Mackay</surname><given-names>CE</given-names></name><name><surname>Goodwin</surname><given-names>GM</given-names></name></person-group>
<article-title>‘Pituitary gland volumes in bipolar disorder</article-title>. <source/>J Affect Disord (<year>2014</year>) <volume>169</volume>:<fpage>197</fpage>–<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2014.08.022</pub-id>
<pub-id pub-id-type="pmid">25212995</pub-id></mixed-citation>
</ref>
<ref id="B177">
<label>177</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nemeroff</surname><given-names>CB</given-names></name><name><surname>Vale</surname><given-names>WW</given-names></name></person-group>
<article-title>The neurobiology of depression: inroads to treatment and new drug discovery</article-title>. <source/>J Clin Psychiatry (<year>2005</year>) <volume>66</volume>(<issue>Suppl 7</issue>):<fpage>5</fpage>–<lpage>13</lpage>.</mixed-citation>
</ref>
<ref id="B178">
<label>178</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nordholm</surname><given-names>D</given-names></name><name><surname>Krogh</surname><given-names>J</given-names></name><name><surname>Mondelli</surname><given-names>V</given-names></name><name><surname>Dazzan</surname><given-names>P</given-names></name><name><surname>Pariante</surname><given-names>C</given-names></name><name><surname>Nordentoft</surname><given-names>M</given-names></name></person-group>
<article-title>Pituitary gland volume in patients with schizophrenia, subjects at ultra high-risk of developing psychosis and healthy controls: a systematic review and meta-analysis</article-title>. <source/>Psychoneuroendocrinology (<year>2013</year>) <volume>38</volume>(<issue>11</issue>):<page-range>2394–404</page-range>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2013.06.030</pub-id>
</mixed-citation>
</ref>
<ref id="B179">
<label>179</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pavon</surname><given-names>L</given-names></name><name><surname>Sandoval-Lopez</surname><given-names>G</given-names></name><name><surname>Eugenia Hernandez</surname><given-names>M</given-names></name><name><surname>Loria</surname><given-names>F</given-names></name><name><surname>Estrada</surname><given-names>I</given-names></name><name><surname>Perez</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Th2 cytokine response in major depressive disorder patients before treatment</article-title>. <source/>J Neuroimmunol (<year>2006</year>) <volume>172</volume>(<issue>1–2</issue>):<page-range>156–65</page-range>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2005.08.014</pub-id>
</mixed-citation>
</ref>
<ref id="B180">
<label>180</label>
<mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Bocharova</surname><given-names>M</given-names></name><name><surname>Agustini</surname><given-names>B</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Juruena</surname><given-names>MF</given-names></name></person-group>
<article-title>HPA axis function as biomarker for atypical and melancholic depression</article-title>. <source/>Front Psychiatry (<year>2019</year>). <pub-id pub-id-type="doi">10.3389/conf.fpsyt.2017.48.00006</pub-id>
</mixed-citation>
</ref>
<ref id="B181">
<label>181</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lamers</surname><given-names>F</given-names></name><name><surname>Vogelzangs</surname><given-names>N</given-names></name><name><surname>Merikangas</surname><given-names>KR</given-names></name><name><surname>de Jonge</surname><given-names>P</given-names></name><name><surname>Beekman</surname><given-names>AT</given-names></name><name><surname>Penninx</surname><given-names>BW</given-names></name></person-group>
<article-title>Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression</article-title>. <source/>Mol Psychiatry (<year>2013</year>) <volume>18</volume>(<issue>6</issue>):<page-range>692–9</page-range>. <pub-id pub-id-type="doi">10.1038/mp.2012.144</pub-id>
</mixed-citation>
</ref>
<ref id="B182">
<label>182</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Girshkin</surname><given-names>L</given-names></name><name><surname>Matheson</surname><given-names>SL</given-names></name><name><surname>Shepherd</surname><given-names>AM</given-names></name><name><surname>Green</surname><given-names>MJ</given-names></name></person-group>
<article-title>Morning cortisol levels in schizophrenia and bipolar disorder: a meta-analysis</article-title>. <source/>Psychoneuroendocrinology (<year>2014</year>) <volume>49</volume>:<fpage>187</fpage>–<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2014.07.013</pub-id>
<pub-id pub-id-type="pmid">25108162</pub-id></mixed-citation>
</ref>
<ref id="B183">
<label>183</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Russo</surname><given-names>MV</given-names></name><name><surname>McGavern</surname><given-names>DB</given-names></name></person-group>
<article-title>Inflammatory neuroprotection following traumatic brain injury</article-title>. <source/>Science (<year>2016</year>) <volume>353</volume>(<issue>6301</issue>):<page-range>783–5</page-range>. <pub-id pub-id-type="doi">10.1126/science.aaf6260</pub-id>
</mixed-citation>
</ref>
<ref id="B184">
<label>184</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paolicelli</surname><given-names>RC</given-names></name><name><surname>Bolasco</surname><given-names>G</given-names></name><name><surname>Pagani</surname><given-names>F</given-names></name><name><surname>Maggi</surname><given-names>L</given-names></name><name><surname>Scianni</surname><given-names>M</given-names></name><name><surname>Panzanelli</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Synaptic pruning by microglia is necessary for normal brain development</article-title>. <source/>Science (<year>2011</year>) <volume>333</volume>(<issue>6048</issue>):<page-range>1456–8</page-range>. <pub-id pub-id-type="doi">10.1126/science.1202529</pub-id>
</mixed-citation>
</ref>
<ref id="B185">
<label>185</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="editor"><name><surname>Keshavan</surname><given-names>MS</given-names></name><name><surname>Anderson</surname><given-names>S</given-names></name><name><surname>Pettergrew</surname><given-names>JW</given-names></name></person-group>
<article-title>Is Schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited</article-title>. <source/>J Psychiatr Res (<year>1994</year>) <volume>28</volume>(<issue>3</issue>):<page-range>239–65</page-range>. <pub-id pub-id-type="doi">10.1016/0022-3956(94)90009-4</pub-id>
</mixed-citation>
</ref>
<ref id="B186">
<label>186</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Cho</surname><given-names>MH</given-names></name><name><surname>Shim</surname><given-names>WH</given-names></name><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Jeon</surname><given-names>EY</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><etal></etal></person-group>
<article-title>Deficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects</article-title>. <source/>Mol Psychiatry (<year>2016</year>) <volume>22</volume>:<fpage>1576</fpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.103</pub-id>
<pub-id pub-id-type="pmid">27400854</pub-id></mixed-citation>
</ref>
<ref id="B187">
<label>187</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stertz</surname><given-names>L</given-names></name><name><surname>Magalhaes</surname><given-names>PV</given-names></name><name><surname>Kapczinski</surname><given-names>F</given-names></name></person-group>
<article-title>Is bipolar disorder an inflammatory condition? The relevance of microglial activation</article-title>. <source/>Curr Opin Psychiatry (<year>2013</year>) <volume>26</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1097/YCO.0b013e32835aa4b4</pub-id>
<pub-id pub-id-type="pmid">23196997</pub-id></mixed-citation>
</ref>
<ref id="B188">
<label>188</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ekdahl</surname><given-names>CT</given-names></name></person-group>
<article-title>Microglial activation—tuning and pruning adult neurogenesis</article-title>. <source/>Front Pharmacol (<year>2012</year>) <volume>3</volume>:<fpage>41</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2012.00041</pub-id>
<pub-id pub-id-type="pmid">22408626</pub-id></mixed-citation>
</ref>
<ref id="B189">
<label>189</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kraft</surname><given-names>AD</given-names></name><name><surname>Harry</surname><given-names>GJ</given-names></name></person-group>
<article-title>Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity</article-title>. <source/>Int J Environ Res Public Health (<year>2011</year>) <volume>8</volume>(<issue>7</issue>):<fpage>2980</fpage>–<lpage>3018</lpage>. <pub-id pub-id-type="doi">10.3390/ijerph8072980</pub-id>
<pub-id pub-id-type="pmid">21845170</pub-id></mixed-citation>
</ref>
<ref id="B190">
<label>190</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paradise</surname><given-names>MB</given-names></name><name><surname>Naismith</surname><given-names>SL</given-names></name><name><surname>Norrie</surname><given-names>LM</given-names></name><name><surname>Graeber</surname><given-names>MB</given-names></name><name><surname>Hickie</surname><given-names>IB</given-names></name></person-group>
<article-title>The role of glia in late-life depression</article-title>. <source/>Int Psychogeriatr (<year>2012</year>) <volume>24</volume>(<issue>12</issue>):<page-range>1878–90</page-range>. <pub-id pub-id-type="doi">10.1017/S1041610212000828</pub-id>
</mixed-citation>
</ref>
<ref id="B191">
<label>191</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>KM</given-names></name><name><surname>Bowers</surname><given-names>WJ</given-names></name></person-group>
<article-title>Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction</article-title>. <source/>Cell Signal (<year>2010</year>) <volume>22</volume>(<issue>7</issue>):<page-range>977–83</page-range>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2010.01.010</pub-id>
</mixed-citation>
</ref>
<ref id="B192">
<label>192</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bloomfield</surname><given-names>PS</given-names></name><name><surname>Selvaraj</surname><given-names>S</given-names></name><name><surname>Veronese</surname><given-names>M</given-names></name><name><surname>Rizzo</surname><given-names>G</given-names></name><name><surname>Bertoldo</surname><given-names>A</given-names></name><name><surname>Owen</surname><given-names>DR</given-names></name><etal></etal></person-group>
<article-title>Microglial activity in people at ultra high risk of psychosis and in schizophrenia; an [(11)C]PBR28 PET brain imaging study</article-title>. <source/>Am J Psychiatry (<year>2016</year>) <volume>173</volume>(<issue>1</issue>):<fpage>44</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2015.14101358</pub-id>
<pub-id pub-id-type="pmid">26472628</pub-id></mixed-citation>
</ref>
<ref id="B193">
<label>193</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Laskaris</surname><given-names>LE</given-names></name><name><surname>Di Biase</surname><given-names>MA</given-names></name><name><surname>Everall</surname><given-names>I</given-names></name><name><surname>Chana</surname><given-names>G</given-names></name><name><surname>Christopoulos</surname><given-names>A</given-names></name><name><surname>Skafidas</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Microglial activation and progressive brain changes in schizophrenia</article-title>. <source/>Br J Pharmacol (<year>2016</year>) <volume>173</volume>(<issue>4</issue>):<page-range>666–80</page-range>. <pub-id pub-id-type="doi">10.1111/bph.13364</pub-id>
</mixed-citation>
</ref>
<ref id="B194">
<label>194</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trépanier</surname><given-names>MO</given-names></name><name><surname>Hopperton</surname><given-names>KE</given-names></name><name><surname>Mizrahi</surname><given-names>R</given-names></name><name><surname>Mechawar</surname><given-names>N</given-names></name><name><surname>Bazinet</surname><given-names>RP</given-names></name></person-group>
<article-title>Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review</article-title>. <source/>Mol Psychiatry (<year>2016</year>) <volume>21</volume>:<fpage>1009</fpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.90</pub-id>
<pub-id pub-id-type="pmid">27271499</pub-id></mixed-citation>
</ref>
<ref id="B195">
<label>195</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katsumoto</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Miranda</surname><given-names>AS</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name></person-group>
<article-title>Ontogeny and functions of central nervous system macrophages</article-title>. <source/>J Immunol (<year>2014</year>) <volume>193</volume>(<issue>6</issue>):<page-range>2615–21</page-range>. <pub-id pub-id-type="doi">10.4049/jimmunol.1400716</pub-id>
</mixed-citation>
</ref>
<ref id="B196">
<label>196</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Brown</surname><given-names>MA</given-names></name></person-group>
<article-title>Innate immunity in the central nervous system</article-title>. <source/>J Clin Invest (<year>2012</year>) <volume>122</volume>(<issue>4</issue>):<page-range>1164–71</page-range>. <pub-id pub-id-type="doi">10.1172/JCI58644</pub-id>
</mixed-citation>
</ref>
<ref id="B197">
<label>197</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bora</surname><given-names>E</given-names></name><name><surname>Fornito</surname><given-names>A</given-names></name><name><surname>Pantelis</surname><given-names>C</given-names></name><name><surname>Yucel</surname><given-names>M</given-names></name></person-group>
<article-title>Gray matter abnormalities in major depressive disorder: a meta-analysis of voxel based morphometry studies</article-title>. <source/>J Affect Disord (<year>2012</year>a) <volume>138</volume>(<issue>1–2</issue>):<fpage>9</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2011.03.049</pub-id>
<pub-id pub-id-type="pmid">21511342</pub-id></mixed-citation>
</ref>
<ref id="B198">
<label>198</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bora</surname><given-names>E</given-names></name><name><surname>Fornito</surname><given-names>A</given-names></name><name><surname>Yucel</surname><given-names>M</given-names></name><name><surname>Pantelis</surname><given-names>C</given-names></name></person-group>
<article-title>Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder</article-title>. <source/>Biol Psychiatry (<year>2010</year>) <volume>67</volume>(<issue>11</issue>):<page-range>1097–105</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2010.01.020</pub-id>
</mixed-citation>
</ref>
<ref id="B199">
<label>199</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bora</surname><given-names>E</given-names></name><name><surname>Harrison</surname><given-names>BJ</given-names></name><name><surname>Davey</surname><given-names>CG</given-names></name><name><surname>Yucel</surname><given-names>M</given-names></name><name><surname>Pantelis</surname><given-names>C</given-names></name></person-group>
<article-title>Meta-analysis of volumetric abnormalities in cortico-striatal-pallidal-thalamic circuits in major depressive disorder</article-title>. <source/>Psychol Med (<year>2012</year>b) <volume>42</volume>(<issue>4</issue>):<page-range>671–81</page-range>. <pub-id pub-id-type="doi">10.1017/S0033291711001668</pub-id>
</mixed-citation>
</ref>
<ref id="B200">
<label>200</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goodkind</surname><given-names>M</given-names></name><name><surname>Eickhoff</surname><given-names>SB</given-names></name><name><surname>Oathes</surname><given-names>DJ</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>A</given-names></name><name><surname>Jones-Hagata</surname><given-names>LB</given-names></name><etal></etal></person-group>
<article-title>Identification of a common neurobiological substrate for mental illness</article-title>. <source/>JAMA Psychiatry (<year>2015</year>) <volume>72</volume>(<issue>4</issue>):<page-range>305–15</page-range>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.2206</pub-id>
</mixed-citation>
</ref>
<ref id="B201">
<label>201</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Yucel</surname><given-names>M</given-names></name><name><surname>Lorenzetti</surname><given-names>V</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Whittle</surname><given-names>S</given-names></name><name><surname>Walterfang</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Midline brain structures in patients with current and remitted major depression</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry (<year>2009</year>) <volume>33</volume>(<issue>6</issue>):<page-range>1058–63</page-range>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2009.05.020</pub-id>
</mixed-citation>
</ref>
<ref id="B202">
<label>202</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dodd</surname><given-names>S</given-names></name><name><surname>Maes</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>G</given-names></name><name><surname>Dean</surname><given-names>OM</given-names></name><name><surname>Moylan</surname><given-names>S</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name></person-group>
<article-title>Putative neuroprotective agents in neuropsychiatric disorders</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry (<year>2013</year>) <volume>42</volume>:<page-range>135–45</page-range>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2012.11.007</pub-id>
</mixed-citation>
</ref>
<ref id="B203">
<label>203</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kessler</surname><given-names>RC</given-names></name><name><surname>Ormel</surname><given-names>J</given-names></name><name><surname>Petukhova</surname><given-names>M</given-names></name><name><surname>McLaughlin</surname><given-names>KA</given-names></name><name><surname>Green</surname><given-names>JG</given-names></name><name><surname>Russo</surname><given-names>LJ</given-names></name><etal></etal></person-group>
<article-title>Development of lifetime comorbidity in the World Health Organization world mental health surveys</article-title>. <source/>Arch Gen Psychiatry (<year>2011</year>) <volume>68</volume>(<issue>1</issue>):<fpage>90</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2010.180</pub-id>
<pub-id pub-id-type="pmid">21199968</pub-id></mixed-citation>
</ref>
<ref id="B204">
<label>204</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dowlati</surname><given-names>Y</given-names></name><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Swardfager</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Sham</surname><given-names>L</given-names></name><name><surname>Reim</surname><given-names>EK</given-names></name><etal></etal></person-group>
<article-title>A meta-analysis of cytokines in major depression</article-title>. <source/>Biol Psychiatry (<year>2010</year>) <volume>67</volume>(<issue>5</issue>):<page-range>446–57</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2009.09.033</pub-id>
</mixed-citation>
</ref>
<ref id="B205">
<label>205</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Howren</surname><given-names>MB</given-names></name><name><surname>Lamkin</surname><given-names>DM</given-names></name><name><surname>Suls</surname><given-names>J</given-names></name></person-group>
<article-title>Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis</article-title>. <source/>Psychosom Med (<year>2009</year>) <volume>71</volume>(<issue>2</issue>):<page-range>171–86</page-range>. <pub-id pub-id-type="doi">10.1097/PSY.0b013e3181907c1b</pub-id>
</mixed-citation>
</ref>
<ref id="B206">
<label>206</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lanquillon</surname><given-names>S</given-names></name><name><surname>Krieg</surname><given-names>JC</given-names></name><name><surname>Bening-Abu-Shach</surname><given-names>U</given-names></name><name><surname>Vedder</surname><given-names>H</given-names></name></person-group>
<article-title>Cytokine production and treatment response in major depressive disorder</article-title>. <source/>Neuropsychopharmacology (<year>2000</year>) <volume>22</volume>(<issue>4</issue>):<page-range>370–9</page-range>. <pub-id pub-id-type="doi">10.1016/S0893-133X(99)00134-7</pub-id>
</mixed-citation>
</ref>
<ref id="B207">
<label>207</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O’Brien</surname><given-names>SM</given-names></name><name><surname>Scully</surname><given-names>P</given-names></name><name><surname>Fitzgerald</surname><given-names>P</given-names></name><name><surname>Scott</surname><given-names>LV</given-names></name><name><surname>Dinan</surname><given-names>TG</given-names></name></person-group>
<article-title>Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy</article-title>. <source/>J Psychiatr Res (<year>2007</year>) <volume>41</volume>(<issue>3–4</issue>):<page-range>326–31</page-range>. <pub-id pub-id-type="doi">10.1016/j.jpsychires.2006.05.013</pub-id>
</mixed-citation>
</ref>
<ref id="B208">
<label>208</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khandaker</surname><given-names>GM</given-names></name><name><surname>Pearson</surname><given-names>RM</given-names></name><name><surname>Zammit</surname><given-names>S</given-names></name><name><surname>Lewis</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>PB</given-names></name></person-group>
<article-title>Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study</article-title>. <source/>JAMA Psychiatry (<year>2014</year>) <volume>71</volume>(<issue>10</issue>):<page-range>1121–8</page-range>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.1332</pub-id>
</mixed-citation>
</ref>
<ref id="B209">
<label>209</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Penninx</surname><given-names>BW</given-names></name><name><surname>Beekman</surname><given-names>AT</given-names></name><name><surname>Smit</surname><given-names>JH</given-names></name><name><surname>Zitman</surname><given-names>FG</given-names></name><name><surname>Nolen</surname><given-names>WA</given-names></name><name><surname>Spinhoven</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods</article-title>. <source/>Int J Methods Psychiatr Res (<year>2008</year>) <volume>17</volume>(<issue>3</issue>):<page-range>121–40</page-range>. <pub-id pub-id-type="doi">10.1002/mpr.256</pub-id>
</mixed-citation>
</ref>
<ref id="B210">
<label>210</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Savitz</surname><given-names>J</given-names></name><name><surname>Drevets</surname><given-names>WC</given-names></name><name><surname>Wurfel</surname><given-names>BE</given-names></name><name><surname>Ford</surname><given-names>BN</given-names></name><name><surname>Bellgowan</surname><given-names>PS</given-names></name><name><surname>Victor</surname><given-names>TA</given-names></name><etal></etal></person-group>
<article-title>Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder</article-title>. <source/>Brain Behav Immun (<year>2015</year>) <volume>46</volume>:<page-range>55–9</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2015.02.007</pub-id>
</mixed-citation>
</ref>
<ref id="B211">
<label>211</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krause</surname><given-names>D</given-names></name><name><surname>Myint</surname><given-names>AM</given-names></name><name><surname>Schuett</surname><given-names>C</given-names></name><name><surname>Musil</surname><given-names>R</given-names></name><name><surname>Dehning</surname><given-names>S</given-names></name><name><surname>Cerovecki</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>High kynurenine (a tryptophan metabolite) predicts remission in patients with major depression to add-on treatment with celecoxib</article-title>. <source/>Front Psychiatry (<year>2017</year>) <volume>8</volume>:<fpage>16</fpage>. <pub-id pub-id-type="doi">10.3389/fpsyt.2017.00016</pub-id>
<pub-id pub-id-type="pmid">28243208</pub-id></mixed-citation>
</ref>
<ref id="B212">
<label>212</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gałecki</surname><given-names>P</given-names></name><name><surname>Galecka</surname><given-names>E</given-names></name><name><surname>Maes</surname><given-names>M</given-names></name><name><surname>Chamielec</surname><given-names>M</given-names></name><name><surname>Orzechowska</surname><given-names>A</given-names></name><name><surname>Bobinska</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder</article-title>. <source/>J Affect Disord (<year>2012</year>) <volume>138</volume>(<issue>3</issue>):<page-range>360–6</page-range>. <pub-id pub-id-type="doi">10.1016/j.jad.2012.01.016</pub-id>
</mixed-citation>
</ref>
<ref id="B213">
<label>213</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Choi</surname><given-names>HK</given-names></name><name><surname>Lee</surname><given-names>KJ</given-names></name><name><surname>Jung</surname><given-names>JY</given-names></name><name><surname>Hur</surname><given-names>GY</given-names></name><name><surname>Jung</surname><given-names>KH</given-names></name><etal></etal></person-group>
<article-title>The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells</article-title>. <source/>J Immunother (<year>2009</year>) <volume>32</volume>(<issue>1</issue>):<page-range>22–8</page-range>. <pub-id pub-id-type="doi">10.1097/CJI.0b013e31818ac2f7</pub-id>
</mixed-citation>
</ref>
<ref id="B214">
<label>214</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>AH</given-names></name><name><surname>Maletic</surname><given-names>V</given-names></name><name><surname>Raison</surname><given-names>CL</given-names></name></person-group>
<article-title>Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression</article-title>. <source/>Biol Psychiatry (<year>2009</year>) <volume>65</volume>(<issue>9</issue>):<page-range>732–41</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.11.029</pub-id>
</mixed-citation>
</ref>
<ref id="B215">
<label>215</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Pace</surname><given-names>TWW</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>AH</given-names></name></person-group>
<article-title>Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function</article-title>. <source/>Mol Psychiatry (<year>2005</year>) <volume>10</volume>(<issue>5</issue>):<page-range>426–8</page-range>. <pub-id pub-id-type="doi">10.1038/sj.mp.4001644</pub-id>
</mixed-citation>
</ref>
<ref id="B216">
<label>216</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Manku</surname><given-names>M</given-names></name></person-group>
<article-title>Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment</article-title>. <source/>J Neurosci (<year>2009</year>a) <volume>29</volume>(<issue>1</issue>):<fpage>14</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3569-08.2009</pub-id>
<pub-id pub-id-type="pmid">19129380</pub-id></mixed-citation>
</ref>
<ref id="B217">
<label>217</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hillier</surname><given-names>K</given-names></name><name><surname>Templeton</surname><given-names>WW</given-names></name></person-group>
<article-title>Regulation of noradrenaline overflow in rat cerebral cortex by prostaglandin E2</article-title>. <source/>Br J Pharmacol (<year>1980</year>) <volume>70</volume>(<issue>3</issue>):<page-range>469–73</page-range>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.1980.tb08725.x</pub-id>
</mixed-citation>
</ref>
<ref id="B218">
<label>218</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Casolini</surname><given-names>P</given-names></name><name><surname>Catalani</surname><given-names>A</given-names></name><name><surname>Zuena</surname><given-names>AR</given-names></name><name><surname>Angelucci</surname><given-names>L</given-names></name></person-group>
<article-title>Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat</article-title>. <source/>J Neurosci Res (<year>2002</year>) <volume>68</volume>(<issue>3</issue>):<page-range>337–43</page-range>. <pub-id pub-id-type="doi">10.1002/jnr.10192</pub-id>
</mixed-citation>
</ref>
<ref id="B219">
<label>219</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konsman</surname><given-names>JP</given-names></name><name><surname>Parnet</surname><given-names>P</given-names></name><name><surname>Dantzer</surname><given-names>R</given-names></name></person-group>
<article-title>Cytokine-induced sickness behaviour: mechanisms and implications</article-title>. <source/>Trends Neurosci (<year>2002</year>) <volume>25</volume>(<issue>3</issue>):<page-range>154–9</page-range>. <pub-id pub-id-type="doi">10.1016/S0166-2236(00)02088-9</pub-id>
</mixed-citation>
</ref>
<ref id="B220">
<label>220</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schiepers</surname><given-names>OJ</given-names></name><name><surname>Wichers</surname><given-names>MC</given-names></name><name><surname>Maes</surname><given-names>M</given-names></name></person-group>
<article-title>Cytokines and major depression</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry (<year>2005</year>) <volume>29</volume>(<issue>2</issue>):<page-range>201–17</page-range>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2004.11.003</pub-id>
</mixed-citation>
</ref>
<ref id="B221">
<label>221</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Myint</surname><given-names>AM</given-names></name><name><surname>Kim</surname><given-names>YK</given-names></name><name><surname>Verkerk</surname><given-names>R</given-names></name><name><surname>Scharpe</surname><given-names>S</given-names></name><name><surname>Steinbusch</surname><given-names>H</given-names></name><name><surname>Leonard</surname><given-names>B</given-names></name></person-group>
<article-title>Kynurenine pathway in major depression: evidence of impaired neuroprotection</article-title>. <source/>J Affect Disord (<year>2007</year>) <volume>98</volume>(<issue>1–2</issue>):<page-range>143–51</page-range>. <pub-id pub-id-type="doi">10.1016/j.jad.2006.07.013</pub-id>
</mixed-citation>
</ref>
<ref id="B222">
<label>222</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brunello</surname><given-names>N</given-names></name><name><surname>Alboni</surname><given-names>S</given-names></name><name><surname>Capone</surname><given-names>G</given-names></name><name><surname>Benatti</surname><given-names>C</given-names></name><name><surname>Blom</surname><given-names>JM</given-names></name><name><surname>Tascedda</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression</article-title>. <source/>Int Clin Psychopharmacol (<year>2006</year>) <volume>21</volume>(<issue>4</issue>):<page-range>219–25</page-range>. <pub-id pub-id-type="doi">10.1097/00004850-200607000-00004</pub-id>
</mixed-citation>
</ref>
<ref id="B223">
<label>223</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kohler</surname><given-names>O</given-names></name><name><surname>Benros</surname><given-names>ME</given-names></name><name><surname>Nordentoft</surname><given-names>M</given-names></name><name><surname>Farkouh</surname><given-names>ME</given-names></name><name><surname>Iyengar</surname><given-names>RL</given-names></name><name><surname>Mors</surname><given-names>O</given-names></name><etal></etal></person-group>
<article-title>Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials</article-title>. <source/>JAMA Psychiatry (<year>2014</year>) <volume>71</volume>(<issue>12</issue>):<page-range>1381–91</page-range>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.1611</pub-id>
</mixed-citation>
</ref>
<ref id="B224">
<label>224</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Na</surname><given-names>KS</given-names></name><name><surname>Lee</surname><given-names>KJ</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Cho</surname><given-names>YS</given-names></name><name><surname>Jung</surname><given-names>HY</given-names></name></person-group>
<article-title>Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry (<year>2014</year>) <volume>48</volume>:<fpage>79</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2013.09.006</pub-id>
<pub-id pub-id-type="pmid">24056287</pub-id></mixed-citation>
</ref>
<ref id="B225">
<label>225</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eyre</surname><given-names>HA</given-names></name><name><surname>Air</surname><given-names>T</given-names></name><name><surname>Pradhan</surname><given-names>A</given-names></name><name><surname>Johnston</surname><given-names>J</given-names></name><name><surname>Lavretsky</surname><given-names>H</given-names></name><name><surname>Stuart</surname><given-names>MJ</given-names></name><etal></etal></person-group>
<article-title>A meta-analysis of chemokines in major depression</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry (<year>2016</year>) <volume>68</volume>:<fpage>1</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2016.02.006</pub-id>
<pub-id pub-id-type="pmid">26903140</pub-id></mixed-citation>
</ref>
<ref id="B226">
<label>226</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Huh</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>SB</given-names></name><name><surname>Han</surname><given-names>SK</given-names></name><etal></etal></person-group>
<article-title>Standardization of the Korean version of the Geriatric Depression Scale: reliability, validity, and factor structure</article-title>. <source/>Psychiatry Investig (<year>2008</year>) <volume>5</volume>(<issue>4</issue>):<page-range>232–8</page-range>. <pub-id pub-id-type="doi">10.4306/pi.2008.5.4.232</pub-id>
</mixed-citation>
</ref>
<ref id="B227">
<label>227</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baldi</surname><given-names>PC</given-names></name><name><surname>Giambartolomei</surname><given-names>GH</given-names></name></person-group>
<article-title>Immunopathology of Brucella infection</article-title>. <source/>Recent Pat Antiinfect Drug Discov (<year>2013</year>a) <volume>8</volume>(<issue>1</issue>):<fpage>18</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.2174/1574891X11308010005</pub-id>
<pub-id pub-id-type="pmid">22812614</pub-id></mixed-citation>
</ref>
<ref id="B228">
<label>228</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baldi</surname><given-names>PC</given-names></name><name><surname>Giambartolomei</surname><given-names>GH</given-names></name></person-group>
<article-title>Pathogenesis and pathobiology of zoonotic brucellosis in humans</article-title>. <source/>Rev Sci Tech (<year>2013</year>b) <volume>32</volume>(<issue>1</issue>):<page-range>117–25</page-range>. <pub-id pub-id-type="doi">10.20506/rst.32.1.2192</pub-id>
</mixed-citation>
</ref>
<ref id="B229">
<label>229</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iyengar</surname><given-names>RL</given-names></name><name><surname>Gandhi</surname><given-names>S</given-names></name><name><surname>Aneja</surname><given-names>A</given-names></name><name><surname>Thorpe</surname><given-names>K</given-names></name><name><surname>Razzouk</surname><given-names>L</given-names></name><name><surname>Greenberg</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>NSAIDs are associated with lower depression scores in patients with osteoarthritis</article-title>. <source/>Am J Med (<year>2013</year>) <volume>126</volume>(<issue>11</issue>):<page-range>1017.e11–8</page-range>. <pub-id pub-id-type="doi">10.1016/j.amjmed.2013.02.037</pub-id>
</mixed-citation>
</ref>
<ref id="B230">
<label>230</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lai</surname><given-names>V</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Richey</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Cannon</surname><given-names>T</given-names></name><name><surname>Shores</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract</article-title>. <source/>Head Neck (<year>2008</year>) <volume>30</volume>(<issue>1</issue>):<fpage>67</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1002/hed.20662</pub-id>
<pub-id pub-id-type="pmid">17615567</pub-id></mixed-citation>
</ref>
<ref id="B231">
<label>231</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lundholm</surname><given-names>K</given-names></name><name><surname>Daneryd</surname><given-names>P</given-names></name><name><surname>Korner</surname><given-names>U</given-names></name><name><surname>Hyltander</surname><given-names>A</given-names></name><name><surname>Bosaeus</surname><given-names>I</given-names></name></person-group>
<article-title>Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia</article-title>. <source/>Int J Oncol (<year>2004</year>) <volume>24</volume>(<issue>3</issue>):<page-range>505–12</page-range>. <pub-id pub-id-type="doi">10.3892/ijo.24.3.505</pub-id>
</mixed-citation>
</ref>
<ref id="B232">
<label>232</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>CB</given-names></name><name><surname>Mors</surname><given-names>O</given-names></name><name><surname>Bertelsen</surname><given-names>A</given-names></name><name><surname>Waltoft</surname><given-names>BL</given-names></name><name><surname>Agerbo</surname><given-names>E</given-names></name><name><surname>McGrath</surname><given-names>JJ</given-names></name><etal></etal></person-group>
<article-title>A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders</article-title>. <source/>JAMA Psychiatry (<year>2014</year>) <volume>71</volume>(<issue>5</issue>):<page-range>573–81</page-range>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.16</pub-id>
</mixed-citation>
</ref>
<ref id="B233">
<label>233</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Malhi</surname><given-names>GS</given-names></name><name><surname>Ivanovski</surname><given-names>B</given-names></name><name><surname>Hadzi-Pavlovic</surname><given-names>D</given-names></name><name><surname>Mitchell</surname><given-names>PB</given-names></name><name><surname>Vieta</surname><given-names>E</given-names></name><name><surname>Sachdev</surname><given-names>P</given-names></name></person-group>
<article-title>Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia</article-title>. <source/>Bipolar Disord (<year>2007</year>) <volume>9</volume>(<issue>1–2</issue>):<page-range>114–25</page-range>. <pub-id pub-id-type="doi">10.1111/j.1399-5618.2007.00324.x</pub-id>
</mixed-citation>
</ref>
<ref id="B234">
<label>234</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marotta</surname><given-names>A</given-names></name><name><surname>Chiaie</surname><given-names>RD</given-names></name><name><surname>Spagna</surname><given-names>A</given-names></name><name><surname>Bernabei</surname><given-names>L</given-names></name><name><surname>Sciarretta</surname><given-names>M</given-names></name><name><surname>Roca</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Impaired conflict resolution and vigilance in euthymic bipolar disorder</article-title>. <source/>Psychiatry Res (<year>2015</year>) <volume>229</volume>(<issue>1–2</issue>):<page-range>490–6</page-range>. <pub-id pub-id-type="doi">10.1016/j.psychres.2015.06.026</pub-id>
</mixed-citation>
</ref>
<ref id="B235">
<label>235</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baumeister</surname><given-names>D</given-names></name><name><surname>Russell</surname><given-names>A</given-names></name><name><surname>Pariante</surname><given-names>CM</given-names></name><name><surname>Mondelli</surname><given-names>V</given-names></name></person-group>
<article-title>Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors</article-title>. <source/>Soc Psychiatry Psychiatr Epidemiol (<year>2014</year>) <volume>49</volume>(<issue>6</issue>):<page-range>841–9</page-range>. <pub-id pub-id-type="doi">10.1007/s00127-014-0887-z</pub-id>
</mixed-citation>
</ref>
<ref id="B236">
<label>236</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Drexhage</surname><given-names>RC</given-names></name><name><surname>van der Heul-Nieuwenhuijsen</surname><given-names>L</given-names></name><name><surname>Padmos</surname><given-names>RC</given-names></name><name><surname>van Beveren</surname><given-names>N</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name><name><surname>Versnel</surname><given-names>MA</given-names></name><etal></etal></person-group>
<article-title>Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients</article-title>. <source/>Int J Neuropsychopharmacol (<year>2010</year>b) <volume>13</volume>(<issue>10</issue>):<page-range>1369–81</page-range>. <pub-id pub-id-type="doi">10.1017/S1461145710000799</pub-id>
</mixed-citation>
</ref>
<ref id="B237">
<label>237</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dargel</surname><given-names>AA</given-names></name><name><surname>Godin</surname><given-names>O</given-names></name><name><surname>Kapczinski</surname><given-names>F</given-names></name><name><surname>Kupfer</surname><given-names>DJ</given-names></name><name><surname>Leboyer</surname><given-names>M</given-names></name></person-group>
<article-title>C-reactive protein alterations in bipolar disorder: a meta-analysis</article-title>. <source/>J Clin Psychiatry (<year>2015</year>) <volume>76</volume>(<issue>2</issue>):<page-range>142–50</page-range>. <pub-id pub-id-type="doi">10.4088/JCP.14r09007</pub-id>
</mixed-citation>
</ref>
<ref id="B238">
<label>238</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Munkholm</surname><given-names>K</given-names></name><name><surname>Brauner</surname><given-names>JV</given-names></name><name><surname>Kessing</surname><given-names>LV</given-names></name><name><surname>Vinberg</surname><given-names>M</given-names></name></person-group>
<article-title>‘Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis</article-title>. <source/>J Psychiatr Res (<year>2013</year>a) <volume>47</volume>(<issue>9</issue>):<page-range>1119–33</page-range>. <pub-id pub-id-type="doi">10.1016/j.jpsychires.2013.05.018</pub-id>
</mixed-citation>
</ref>
<ref id="B239">
<label>239</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barbosa</surname><given-names>IG</given-names></name><name><surname>Bauer</surname><given-names>ME</given-names></name><name><surname>Machado-Vieira</surname><given-names>R</given-names></name><name><surname>Teixeira</surname><given-names>AL</given-names></name></person-group>
<article-title>Cytokines in bipolar disorder: paving the way for neuroprogression</article-title>. <source/>Neural Plast (<year>2014</year>a) <volume>2014</volume>:<fpage>360481</fpage>. <pub-id pub-id-type="doi">10.1155/2014/360481</pub-id>
<pub-id pub-id-type="pmid">25313338</pub-id></mixed-citation>
</ref>
<ref id="B240">
<label>240</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barbosa</surname><given-names>IG</given-names></name><name><surname>Machado-Vieira</surname><given-names>R</given-names></name><name><surname>Soares</surname><given-names>JC</given-names></name><name><surname>Teixeira</surname><given-names>AL</given-names></name></person-group>
<article-title>The immunology of bipolar disorder</article-title>. <source/>Neuroimmunomodulation (<year>2014</year>b) <volume>21</volume>(<issue>2-3</issue>):<page-range>117–22</page-range>. <pub-id pub-id-type="doi">10.1159/000356539</pub-id>
</mixed-citation>
</ref>
<ref id="B241">
<label>241</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haarman</surname><given-names>BC</given-names></name><name><surname>Riemersma-Van der Lek</surname><given-names>RF</given-names></name><name><surname>de Groot</surname><given-names>JC</given-names></name><name><surname>Ruhe</surname><given-names>HG</given-names></name><name><surname>Klein</surname><given-names>HC</given-names></name><name><surname>Zandstra</surname><given-names>TE</given-names></name><etal></etal></person-group>
<article-title>Neuroinflammation in bipolar disorder - A [(11)C]-(R)-PK11195 positron emission tomography study</article-title>. <source/>Brain Behav Immun (<year>2014</year>) <volume>40</volume>:<page-range>219–25</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2014.03.016</pub-id>
</mixed-citation>
</ref>
<ref id="B242">
<label>242</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jakobsson</surname><given-names>J</given-names></name><name><surname>Bjerke</surname><given-names>M</given-names></name><name><surname>Sahebi</surname><given-names>S</given-names></name><name><surname>Isgren</surname><given-names>A</given-names></name><name><surname>Ekman</surname><given-names>CJ</given-names></name><name><surname>Sellgren</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Monocyte and microglial activation in patients with mood-stabilized bipolar disorder</article-title>. <source/>J Psychiatry Neurosci (<year>2015</year>) <volume>40</volume>(<issue>4</issue>):<page-range>250–8</page-range>. <pub-id pub-id-type="doi">10.1503/jpn.140183</pub-id>
</mixed-citation>
</ref>
<ref id="B243">
<label>243</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rao</surname><given-names>JS</given-names></name><name><surname>Harry</surname><given-names>GJ</given-names></name><name><surname>Rapoport</surname><given-names>SI</given-names></name><name><surname>Kim</surname><given-names>HW</given-names></name></person-group>
<article-title>Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients</article-title>. <source/>Mol Psychiatry (<year>2010</year>) <volume>15</volume>(<issue>4</issue>):<page-range>384–92</page-range>. <pub-id pub-id-type="doi">10.1038/mp.2009.47</pub-id>
</mixed-citation>
</ref>
<ref id="B244">
<label>244</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schneider</surname><given-names>MR</given-names></name><name><surname>DelBello</surname><given-names>MP</given-names></name><name><surname>McNamara</surname><given-names>RK</given-names></name><name><surname>Strakowski</surname><given-names>SM</given-names></name><name><surname>Adler</surname><given-names>CM</given-names></name></person-group>
<article-title>Neuroprogression in bipolar disorder</article-title>. <source/>Bipolar Disord (<year>2012</year>) <volume>14</volume>(<issue>4</issue>):<page-range>356–74</page-range>. <pub-id pub-id-type="doi">10.1111/j.1399-5618.2012.01024.x</pub-id>
</mixed-citation>
</ref>
<ref id="B245">
<label>245</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Strakowski</surname><given-names>SM</given-names></name><name><surname>Adler</surname><given-names>CM</given-names></name><name><surname>Almeida</surname><given-names>J</given-names></name><name><surname>Altshuler</surname><given-names>LL</given-names></name><name><surname>Blumberg</surname><given-names>HP</given-names></name><name><surname>Chang</surname><given-names>KD</given-names></name><etal></etal></person-group>
<article-title>The functional neuroanatomy of bipolar disorder: a consensus model</article-title>. <source/>Bipolar Disord (<year>2012</year>) <volume>14</volume>(<issue>4</issue>):<page-range>313–25</page-range>. <pub-id pub-id-type="doi">10.1111/j.1399-5618.2012.01022.x</pub-id>
</mixed-citation>
</ref>
<ref id="B246">
<label>246</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boufidou</surname><given-names>F</given-names></name><name><surname>Nikolaou</surname><given-names>C</given-names></name><name><surname>Alevizos</surname><given-names>B</given-names></name><name><surname>Liappas</surname><given-names>IA</given-names></name><name><surname>Christodoulou</surname><given-names>GN</given-names></name></person-group>
<article-title>Cytokine production in bipolar affective disorder patients under lithium treatment</article-title>. <source/>J Affect Disord (<year>2004</year>) <volume>82</volume>(<issue>2</issue>):<page-range>309–13</page-range>. <pub-id pub-id-type="doi">10.1016/j.jad.2004.01.007</pub-id>
</mixed-citation>
</ref>
<ref id="B247">
<label>247</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Basselin</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>H-W</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Rapoport</surname><given-names>SI</given-names></name><name><surname>Murphy</surname><given-names>RC</given-names></name><etal></etal></person-group>
<article-title>Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation</article-title>. <source/>J Lipid Res (<year>2010</year>) <volume>51</volume>(<issue>5</issue>):<page-range>1049–56</page-range>. <pub-id pub-id-type="doi">10.1194/jlr.M002469</pub-id>
</mixed-citation>
</ref>
<ref id="B248">
<label>248</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Breunis</surname><given-names>MN</given-names></name><name><surname>Kupka</surname><given-names>RW</given-names></name><name><surname>Nolen</surname><given-names>WA</given-names></name><name><surname>Suppes</surname><given-names>T</given-names></name><name><surname>Denicoff</surname><given-names>KD</given-names></name><name><surname>Leverich</surname><given-names>GS</given-names></name><etal></etal></person-group>
<article-title>High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder</article-title>. <source/>Biol Psychiatry (<year>2003</year>) <volume>53</volume>(<issue>2</issue>):<page-range>157–65</page-range>. <pub-id pub-id-type="doi">10.1016/S0006-3223(02)01452-X</pub-id>
</mixed-citation>
</ref>
<ref id="B249">
<label>249</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chiu</surname><given-names>CT</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Hunsberger</surname><given-names>JG</given-names></name><name><surname>Chuang</surname><given-names>DM</given-names></name></person-group>
<article-title>Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder</article-title>. <source/>Pharmacol Rev (<year>2013</year>) <volume>65</volume>(<issue>1</issue>):<page-range>105–42</page-range>. <pub-id pub-id-type="doi">10.1124/pr.111.005512</pub-id>
</mixed-citation>
</ref>
<ref id="B250">
<label>250</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knijff</surname><given-names>EM</given-names></name><name><surname>Breunis</surname><given-names>MN</given-names></name><name><surname>Kupka</surname><given-names>RW</given-names></name><name><surname>de Wit</surname><given-names>HJ</given-names></name><name><surname>Ruwhof</surname><given-names>C</given-names></name><name><surname>Akkerhuis</surname><given-names>GW</given-names></name><etal></etal></person-group>
<article-title>An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment</article-title>. <source/>Bipolar Disord (<year>2007</year>) <volume>9</volume>(<issue>7</issue>):<page-range>743–53</page-range>. <pub-id pub-id-type="doi">10.1111/j.1399-5618.2007.00444.x</pub-id>
</mixed-citation>
</ref>
<ref id="B251">
<label>251</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Rao</surname><given-names>JS</given-names></name><name><surname>Rapoport</surname><given-names>SI</given-names></name><name><surname>Bazinet</surname><given-names>RP</given-names></name></person-group>
<article-title>Antimanic therapies target brain arachidonic acid signaling: lessons learned about the regulation of brain fatty acid metabolism</article-title>. <source/>Prostaglandins Leukot Essent Fatty Acids (<year>2007</year>) <volume>77</volume>(<issue>5–6</issue>):<page-range>239–46</page-range>. <pub-id pub-id-type="doi">10.1016/j.plefa.2007.10.018</pub-id>
</mixed-citation>
</ref>
<ref id="B252">
<label>252</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O’Brien</surname><given-names>SM</given-names></name><name><surname>Scully</surname><given-names>P</given-names></name><name><surname>Scott</surname><given-names>LV</given-names></name><name><surname>Dinan</surname><given-names>TG</given-names></name></person-group>
<article-title>Cytokine profiles in bipolar affective disorder: focus on acutely ill patients</article-title>. <source/>J Affect Disord (<year>2006</year>) <volume>90</volume>(<issue>2–3</issue>):<page-range>263–7</page-range>. <pub-id pub-id-type="doi">10.1016/j.jad.2005.11.015</pub-id>
</mixed-citation>
</ref>
<ref id="B253">
<label>253</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rapoport</surname><given-names>SI</given-names></name><name><surname>Bosetti</surname><given-names>F</given-names></name></person-group>
<article-title>Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder</article-title>? <source/>Arch Gen Psychiatry (<year>2002</year>) <volume>59</volume>(<issue>7</issue>):<page-range>592–6</page-range>. <pub-id pub-id-type="doi">10.1001/archpsyc.59.7.592</pub-id>
</mixed-citation>
</ref>
<ref id="B254">
<label>254</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perugi</surname><given-names>G</given-names></name><name><surname>Medda</surname><given-names>P</given-names></name><name><surname>Toni</surname><given-names>C</given-names></name><name><surname>Mariani</surname><given-names>MG</given-names></name><name><surname>Socci</surname><given-names>C</given-names></name><name><surname>Mauri</surname><given-names>M</given-names></name></person-group>
<article-title>The role of electroconvulsive therapy (ect) in bipolar disorder: effectiveness in 522 patients with bipolar depression, mixed-state, mania and catatonic features</article-title>. <source/>Curr Neuropharmacol (<year>2017</year>) <volume>15</volume>(<issue>3</issue>):<page-range>359–71</page-range>. <pub-id pub-id-type="doi">10.2174/1570159X14666161017233642</pub-id>
</mixed-citation>
</ref>
<ref id="B255">
<label>255</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fluitman</surname><given-names>SB</given-names></name><name><surname>Heijnen</surname><given-names>CJ</given-names></name><name><surname>Denys</surname><given-names>DA</given-names></name><name><surname>Nolen</surname><given-names>WA</given-names></name><name><surname>Balk</surname><given-names>FJ</given-names></name><name><surname>Westenberg</surname><given-names>HG</given-names></name></person-group>
<article-title>Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder</article-title>. <source/>J Affect Disord (<year>2011</year>) <volume>131</volume>(<issue>1–3</issue>):<page-range>388–92</page-range>. <pub-id pub-id-type="doi">10.1016/j.jad.2010.11.035</pub-id>
</mixed-citation>
</ref>
<ref id="B256">
<label>256</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hestad</surname><given-names>KA</given-names></name><name><surname>Tonseth</surname><given-names>S</given-names></name><name><surname>Stoen</surname><given-names>CD</given-names></name><name><surname>Ueland</surname><given-names>T</given-names></name><name><surname>Aukrust</surname><given-names>P</given-names></name></person-group>
<article-title>Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy</article-title>. <source/>J ECT (<year>2003</year>) <volume>19</volume>(<issue>4</issue>):<page-range>183–8</page-range>. <pub-id pub-id-type="doi">10.1097/00124509-200312000-00002</pub-id>
</mixed-citation>
</ref>
<ref id="B257">
<label>257</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>S</given-names></name></person-group>
<article-title>Electroconvulsive therapy: a review of history, patient selection, technique, and medication management</article-title>. <source/>South Med J (<year>2007</year>) <volume>100</volume>(<issue>5</issue>):<page-range>494–8</page-range>. <pub-id pub-id-type="doi">10.1097/SMJ.0b013e318038fce0</pub-id>
</mixed-citation>
</ref>
<ref id="B258">
<label>258</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guloksuz</surname><given-names>S</given-names></name><name><surname>Arts</surname><given-names>B</given-names></name><name><surname>Walter</surname><given-names>S</given-names></name><name><surname>Drukker</surname><given-names>M</given-names></name><name><surname>Rodriguez</surname><given-names>L</given-names></name><name><surname>Myint</surname><given-names>AM</given-names></name><etal></etal></person-group>
<article-title>The impact of electroconvulsive therapy on the tryptophan–kynurenine metabolic pathway</article-title>. <source/>Brain Behav Immun (<year>2015</year>) <volume>48</volume>:<fpage>48</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2015.02.029</pub-id>
<pub-id pub-id-type="pmid">25765557</pub-id></mixed-citation>
</ref>
<ref id="B259">
<label>259</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwieler</surname><given-names>L</given-names></name><name><surname>Samuelsson</surname><given-names>M</given-names></name><name><surname>Frye</surname><given-names>MA</given-names></name><name><surname>Bhat</surname><given-names>M</given-names></name><name><surname>Schuppe-Koistinen</surname><given-names>I</given-names></name><name><surname>Jungholm</surname><given-names>O</given-names></name><etal></etal></person-group>
<article-title>Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients</article-title>. <source/>J Neuroinflammation (<year>2016</year>) <volume>13</volume>(<issue>1</issue>):<fpage>51</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-016-0517-7</pub-id>
<pub-id pub-id-type="pmid">26925576</pub-id></mixed-citation>
</ref>
<ref id="B260">
<label>260</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kargar</surname><given-names>M</given-names></name><name><surname>Yousefi</surname><given-names>A</given-names></name><name><surname>Mojtahedzadeh</surname><given-names>M</given-names></name><name><surname>Akhondzadeh</surname><given-names>S</given-names></name><name><surname>Artounian</surname><given-names>V</given-names></name><name><surname>Abdollahi</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study</article-title>. <source/>Swiss Med Wkly (<year>2014</year>) <volume>144</volume>:<fpage>w13880</fpage>. <pub-id pub-id-type="doi">10.4414/smw.2014.13880</pub-id>
<pub-id pub-id-type="pmid">24554598</pub-id></mixed-citation>
</ref>
<ref id="B261">
<label>261</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lehtimaki</surname><given-names>K</given-names></name><name><surname>Keranen</surname><given-names>T</given-names></name><name><surname>Huuhka</surname><given-names>M</given-names></name><name><surname>Palmio</surname><given-names>J</given-names></name><name><surname>Hurme</surname><given-names>M</given-names></name><name><surname>Leinonen</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder</article-title>. <source/>J ECT (<year>2008</year>) <volume>24</volume>(<issue>1</issue>):<fpage>88</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1097/YCT.0b013e3181571abb</pub-id>
<pub-id pub-id-type="pmid">18379341</pub-id></mixed-citation>
</ref>
<ref id="B262">
<label>262</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Husain</surname><given-names>MI</given-names></name><name><surname>Chaudhry</surname><given-names>IB</given-names></name><name><surname>Hamirani</surname><given-names>MM</given-names></name><name><surname>Minhas</surname><given-names>FA</given-names></name><name><surname>Kazmi</surname><given-names>A</given-names></name><name><surname>Hodsoll</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Minocycline and celecoxib as adjunctive treatments for bipolar depression: a study protocol for a multicenter factorial design randomized controlled trial</article-title>. <source/>Neuropsychiatr Dis Treat (<year>2016</year>) <volume>13</volume>:<fpage>1</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.2147/NDT.S115002</pub-id>
<pub-id pub-id-type="pmid">28031712</pub-id></mixed-citation>
</ref>
<ref id="B263">
<label>263</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Os</surname><given-names>J</given-names></name><name><surname>Kapur</surname><given-names>S</given-names></name></person-group>
<article-title>Schizophrenia</article-title>. <source/>Lancet (<year>2009</year>) <volume>374</volume>(<issue>9690</issue>):<page-range>635–45</page-range>. <pub-id pub-id-type="doi">10.1016/S0140-6736(09)60995-8</pub-id>
</mixed-citation>
</ref>
<ref id="B264">
<label>264</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marini</surname><given-names>S</given-names></name><name><surname>De Berardis</surname><given-names>D</given-names></name><name><surname>Vellante</surname><given-names>F</given-names></name><name><surname>Santacroce</surname><given-names>R</given-names></name><name><surname>Orsolini</surname><given-names>L</given-names></name><name><surname>Valchera</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Celecoxib adjunctive treatment to antipsychotics in schizophrenia: a review of randomized clinical add-on trials</article-title>. <source/>Mediators Inflamm (<year>2016</year>) <volume>2016</volume>:<fpage>3476240</fpage>. <pub-id pub-id-type="doi">10.1155/2016/3476240</pub-id>
<pub-id pub-id-type="pmid">27524864</pub-id></mixed-citation>
</ref>
<ref id="B265">
<label>265</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jarskog</surname><given-names>LF</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Wilkie</surname><given-names>MB</given-names></name><name><surname>Lauder</surname><given-names>JM</given-names></name><name><surname>Gilmore</surname><given-names>JH</given-names></name></person-group>
<article-title>Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival <italic>in vitro</italic></article-title>. <source/>Int J Dev Neurosci (<year>1997</year>) <volume>15</volume>(<issue>6</issue>):<page-range>711–6</page-range>. <pub-id pub-id-type="doi">10.1016/S0736-5748(97)00029-4</pub-id>
</mixed-citation>
</ref>
<ref id="B266">
<label>266</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kabiersch</surname><given-names>A</given-names></name><name><surname>Furukawa</surname><given-names>H</given-names></name><name><surname>del Rey</surname><given-names>A</given-names></name><name><surname>Besedovsky</surname><given-names>HO</given-names></name></person-group>
<article-title>Administration of interleukin-1 at birth affects dopaminergic neurons in adult mice</article-title>. <source/>Ann N Y Acad Sci (<year>1998</year>) <volume>840</volume>:<page-range>123–7</page-range>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1998.tb09556.x</pub-id>
</mixed-citation>
</ref>
<ref id="B267">
<label>267</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ling</surname><given-names>ZD</given-names></name><name><surname>Potter</surname><given-names>ED</given-names></name><name><surname>Lipton</surname><given-names>JW</given-names></name><name><surname>Carvey</surname><given-names>PM</given-names></name></person-group>
<article-title>Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines</article-title>. <source/>Exp Neurol (<year>1998</year>) <volume>149</volume>(<issue>2</issue>):<page-range>411–23</page-range>. <pub-id pub-id-type="doi">10.1006/exnr.1998.6715</pub-id>
</mixed-citation>
</ref>
<ref id="B268">
<label>268</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Potter</surname><given-names>ED</given-names></name><name><surname>Ling</surname><given-names>ZD</given-names></name><name><surname>Carvey</surname><given-names>PM</given-names></name></person-group>
<article-title>Cytokine-induced conversion of mesencephalic-derived progenitor cells into dopamine neurons</article-title>. <source/>Cell Tissue Res (<year>1999</year>) <volume>296</volume>(<issue>2</issue>):<page-range>235–46</page-range>. <pub-id pub-id-type="doi">10.1007/s004410051285</pub-id>
</mixed-citation>
</ref>
<ref id="B269">
<label>269</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kegel</surname><given-names>ME</given-names></name><name><surname>Bhat</surname><given-names>M</given-names></name><name><surname>Skogh</surname><given-names>E</given-names></name><name><surname>Samuelsson</surname><given-names>M</given-names></name><name><surname>Lundberg</surname><given-names>K</given-names></name><name><surname>Dahl</surname><given-names>ML</given-names></name><etal></etal></person-group>
<article-title>Imbalanced kynurenine pathway in schizophrenia</article-title>. <source/>Int J Tryptophan Res (<year>2014</year>) <volume>7</volume>:<fpage>15</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.4137/IJTR.S16800</pub-id>
<pub-id pub-id-type="pmid">25288889</pub-id></mixed-citation>
</ref>
<ref id="B270">
<label>270</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zuckerman</surname><given-names>L</given-names></name><name><surname>Weiner</surname><given-names>I</given-names></name></person-group>
<article-title>Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring</article-title>. <source/>J Psychiatr Res (<year>2005</year>) <volume>39</volume>(<issue>3</issue>):<page-range>311–23</page-range>. <pub-id pub-id-type="doi">10.1016/j.jpsychires.2004.08.008</pub-id>
</mixed-citation>
</ref>
<ref id="B271">
<label>271</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>AS</given-names></name></person-group>
<article-title>Prenatal infection as a risk factor for schizophrenia</article-title>. <source/>Schizophr Bull (<year>2006</year>) <volume>32</volume>(<issue>2</issue>):<page-range>200–2</page-range>. <pub-id pub-id-type="doi">10.1093/schbul/sbj052</pub-id>
</mixed-citation>
</ref>
<ref id="B272">
<label>272</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>AS</given-names></name><name><surname>Derkits</surname><given-names>EJ</given-names></name></person-group>
<article-title>Prenatal infection and schizophrenia: a review of epidemiologic and translational studies</article-title>. <source/>Am J Psychiatry (<year>2010</year>) <volume>167</volume>(<issue>3</issue>):<page-range>261–80</page-range>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2009.09030361</pub-id>
</mixed-citation>
</ref>
<ref id="B273">
<label>273</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eaton</surname><given-names>WW</given-names></name><name><surname>Byrne</surname><given-names>M</given-names></name><name><surname>Ewald</surname><given-names>H</given-names></name><name><surname>Mors</surname><given-names>O</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Agerbo</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Association of schizophrenia and autoimmune diseases: linkage of Danish national registers</article-title>. <source/>Am J Psychiatry (<year>2006</year>) <volume>163</volume>(<issue>3</issue>):<page-range>521–8</page-range>. <pub-id pub-id-type="doi">10.1176/appi.ajp.163.3.521</pub-id>
</mixed-citation>
</ref>
<ref id="B274">
<label>274</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Wu</surname><given-names>CY</given-names></name><name><surname>Lin</surname><given-names>MW</given-names></name><name><surname>Chen</surname><given-names>TJ</given-names></name><name><surname>Liao</surname><given-names>KK</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><etal></etal></person-group>
<article-title>Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study</article-title>. <source/>Br J Dermatol (<year>2011</year>) <volume>165</volume>(<issue>3</issue>):<page-range>593–9</page-range>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2011.10386.x</pub-id>
</mixed-citation>
</ref>
<ref id="B275">
<label>275</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eaton</surname><given-names>WW</given-names></name><name><surname>Hayward</surname><given-names>C</given-names></name><name><surname>Ram</surname><given-names>R</given-names></name></person-group>
<article-title>Schizophrenia and rheumatoid arthritis: a review</article-title>. <source/>Schizophr Res (<year>1992</year>) <volume>6</volume>(<issue>3</issue>):<page-range>181–92</page-range>. <pub-id pub-id-type="doi">10.1016/0920-9964(92)90001-L</pub-id>
</mixed-citation>
</ref>
<ref id="B276">
<label>276</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Korschenhausen</surname><given-names>DA</given-names></name><name><surname>Hampel</surname><given-names>HJ</given-names></name><name><surname>Ackenheil</surname><given-names>M</given-names></name><name><surname>Penning</surname><given-names>R</given-names></name><name><surname>Muller</surname><given-names>N</given-names></name></person-group>
<article-title>Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes</article-title>. <source/>Schizophr Res (<year>1996</year>) <volume>19</volume>(<issue>2–3</issue>):<page-range>103–9</page-range>. <pub-id pub-id-type="doi">10.1016/0920-9964(95)00073-9</pub-id>
</mixed-citation>
</ref>
<ref id="B277">
<label>277</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doorduin</surname><given-names>J</given-names></name><name><surname>de Vries</surname><given-names>EF</given-names></name><name><surname>Willemsen</surname><given-names>AT</given-names></name><name><surname>de Groot</surname><given-names>JC</given-names></name><name><surname>Dierckx</surname><given-names>RA</given-names></name><name><surname>Klein</surname><given-names>HC</given-names></name></person-group>
<article-title>Neuroinflammation in schizophrenia-related psychosis: a PET study</article-title>. <source/>J Nucl Med (<year>2009</year>) <volume>50</volume>(<issue>11</issue>):<page-range>1801–7</page-range>. <pub-id pub-id-type="doi">10.2967/jnumed.109.066647</pub-id>
</mixed-citation>
</ref>
<ref id="B278">
<label>278</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Monji</surname><given-names>A</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Kanba</surname><given-names>S</given-names></name></person-group>
<article-title>Cytokines and schizophrenia: microglia hypothesis of schizophrenia</article-title>. <source/>Psychiatry Clin Neurosci (<year>2009</year>) <volume>63</volume>(<issue>3</issue>):<page-range>257–65</page-range>. <pub-id pub-id-type="doi">10.1111/j.1440-1819.2009.01945.x</pub-id>
</mixed-citation>
</ref>
<ref id="B279">
<label>279</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takano</surname><given-names>A</given-names></name><name><surname>Arakawa</surname><given-names>R</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Tateno</surname><given-names>A</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106</article-title>. <source/>Int J Neuropsychopharmacol (<year>2010</year>) <volume>13</volume>(<issue>7</issue>):<page-range>943–50</page-range>. <pub-id pub-id-type="doi">10.1017/S1461145710000313</pub-id>
</mixed-citation>
</ref>
<ref id="B280">
<label>280</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Berckel</surname><given-names>BN</given-names></name><name><surname>Bossong</surname><given-names>MG</given-names></name><name><surname>Boellaard</surname><given-names>R</given-names></name><name><surname>Kloet</surname><given-names>R</given-names></name><name><surname>Schuitemaker</surname><given-names>A</given-names></name><name><surname>Caspers</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study</article-title>. <source/>Biol Psychiatry (<year>2008</year>) <volume>64</volume>(<issue>9</issue>):<page-range>820–2</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.04.025</pub-id>
</mixed-citation>
</ref>
<ref id="B281">
<label>281</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arango</surname><given-names>C</given-names></name><name><surname>Rapado-Castro</surname><given-names>M</given-names></name><name><surname>Reig</surname><given-names>S</given-names></name><name><surname>Castro-Fornieles</surname><given-names>J</given-names></name><name><surname>Gonzalez-Pinto</surname><given-names>A</given-names></name><name><surname>Otero</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Progressive brain changes in children and adolescents with first-episode psychosis</article-title>. <source/>Arch Gen Psychiatry (<year>2012</year>) <volume>69</volume>(<issue>1</issue>):<fpage>16</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2011.150</pub-id>
<pub-id pub-id-type="pmid">22213785</pub-id></mixed-citation>
</ref>
<ref id="B282">
<label>282</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DeLisi</surname><given-names>LE</given-names></name><name><surname>Szulc</surname><given-names>KU</given-names></name><name><surname>Bertisch</surname><given-names>HC</given-names></name><name><surname>Majcher</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name></person-group>
<article-title>Understanding structural brain changes in schizophrenia</article-title>. <source/>Dialogues Clin Neurosci (<year>2006</year>) <volume>8</volume>(<issue>1</issue>):<page-range>71–8</page-range>.</mixed-citation>
</ref>
<ref id="B283">
<label>283</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steen</surname><given-names>RG</given-names></name><name><surname>Mull</surname><given-names>C</given-names></name><name><surname>McClure</surname><given-names>R</given-names></name><name><surname>Hamer</surname><given-names>RM</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name></person-group>
<article-title>Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies</article-title>. <source/>Br J Psychiatry (<year>2006</year>) <volume>188</volume>:<page-range>510–8</page-range>. <pub-id pub-id-type="doi">10.1192/bjp.188.6.510</pub-id>
</mixed-citation>
</ref>
<ref id="B284">
<label>284</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kahn</surname><given-names>RS</given-names></name><name><surname>Sommer</surname><given-names>IE</given-names></name></person-group>
<article-title>The neurobiology and treatment of first-episode schizophrenia</article-title>. <source/>Mol Psychiatry (<year>2015</year>) <volume>20</volume>(<issue>1</issue>):<fpage>84</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2014.66</pub-id>
<pub-id pub-id-type="pmid">25048005</pub-id></mixed-citation>
</ref>
<ref id="B285">
<label>285</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fillman</surname><given-names>SG</given-names></name><name><surname>Cloonan</surname><given-names>N</given-names></name><name><surname>Miller</surname><given-names>LC</given-names></name><name><surname>Weickert</surname><given-names>CS</given-names></name></person-group>
<article-title>Markers of inflammation in the prefrontal cortex of individuals with schizophrenia</article-title>. <source/>Mol Psychiatry (<year>2013</year>) <volume>18</volume>(<issue>2</issue>):<fpage>133</fpage>. <pub-id pub-id-type="doi">10.1038/mp.2012.199</pub-id>
<pub-id pub-id-type="pmid">23344565</pub-id></mixed-citation>
</ref>
<ref id="B286">
<label>286</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garver</surname><given-names>DL</given-names></name><name><surname>Tamas</surname><given-names>RL</given-names></name><name><surname>Holcomb</surname><given-names>JA</given-names></name></person-group>
<article-title>Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype</article-title>. <source/>Neuropsychopharmacology (<year>2003</year>) <volume>28</volume>(<issue>8</issue>):<page-range>1515–20</page-range>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300217</pub-id>
</mixed-citation>
</ref>
<ref id="B287">
<label>287</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meisenzahl</surname><given-names>EM</given-names></name><name><surname>Rujescu</surname><given-names>D</given-names></name><name><surname>Kirner</surname><given-names>A</given-names></name><name><surname>Giegling</surname><given-names>I</given-names></name><name><surname>Kathmann</surname><given-names>N</given-names></name><name><surname>Leinsinger</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia</article-title>. <source/>Am J Psychiatry (<year>2001</year>) <volume>158</volume>(<issue>8</issue>):<page-range>1316–9</page-range>. <pub-id pub-id-type="doi">10.1176/appi.ajp.158.8.1316</pub-id>
</mixed-citation>
</ref>
<ref id="B288">
<label>288</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cannon</surname><given-names>TD</given-names></name><name><surname>Chung</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Jacobson</surname><given-names>A</given-names></name><name><surname>van Erp</surname><given-names>TG</given-names></name><etal></etal></person-group>
<article-title>Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk</article-title>. <source/>Biol Psychiatry (<year>2015</year>) <volume>77</volume>(<issue>2</issue>):<page-range>147–57</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2014.05.023</pub-id>
</mixed-citation>
</ref>
<ref id="B289">
<label>289</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sekar</surname><given-names>A</given-names></name><name><surname>Bialas</surname><given-names>AR</given-names></name><name><surname>de Rivera</surname><given-names>H</given-names></name><name><surname>Davis</surname><given-names>A</given-names></name><name><surname>Hammond</surname><given-names>TR</given-names></name><name><surname>Kamitaki</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>Schizophrenia risk from complex variation of complement component 4</article-title>. <source/>Nature (<year>2016</year>) <volume>530</volume>(<issue>7589</issue>):<page-range>177–83</page-range>. <pub-id pub-id-type="doi">10.1038/nature16549</pub-id>
</mixed-citation>
</ref>
<ref id="B290">
<label>290</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Drexhage</surname><given-names>RC</given-names></name><name><surname>Knijff</surname><given-names>EM</given-names></name><name><surname>Padmos</surname><given-names>RC</given-names></name><name><surname>Heul-Nieuwenhuijzen</surname><given-names>L</given-names></name><name><surname>Beumer</surname><given-names>W</given-names></name><name><surname>Versnel</surname><given-names>MA</given-names></name><etal></etal></person-group>
<article-title>The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder</article-title>. <source/>Expert Rev Neurother (<year>2010</year>a) <volume>10</volume>(<issue>1</issue>):<fpage>59</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1586/ern.09.144</pub-id>
<pub-id pub-id-type="pmid">20021321</pub-id></mixed-citation>
</ref>
<ref id="B291">
<label>291</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Goff</surname><given-names>DC</given-names></name><name><surname>Henderson</surname><given-names>DC</given-names></name></person-group>
<article-title>Inflammation and schizophrenia</article-title>. <source/>Expert Rev Neurother (<year>2007</year>) <volume>7</volume>(<issue>7</issue>):<page-range>789–96</page-range>. <pub-id pub-id-type="doi">10.1586/14737175.7.7.789</pub-id>
</mixed-citation>
</ref>
<ref id="B292">
<label>292</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Potvin</surname><given-names>S</given-names></name><name><surname>Stip</surname><given-names>E</given-names></name><name><surname>Sepehry</surname><given-names>AA</given-names></name><name><surname>Gendron</surname><given-names>A</given-names></name><name><surname>Bah</surname><given-names>R</given-names></name><name><surname>Kouassi</surname><given-names>E</given-names></name></person-group>
<article-title>Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review</article-title>. <source/>Biol Psychiatry (<year>2008</year>) <volume>63</volume>(<issue>8</issue>):<page-range>801–8</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2007.09.024</pub-id>
</mixed-citation>
</ref>
<ref id="B293">
<label>293</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holden</surname><given-names>JM</given-names></name><name><surname>Meyers-Manor</surname><given-names>JE</given-names></name><name><surname>Overmier</surname><given-names>JB</given-names></name><name><surname>Gahtan</surname><given-names>E</given-names></name><name><surname>Sweeney</surname><given-names>W</given-names></name><name><surname>Miller</surname><given-names>H</given-names></name></person-group>
<article-title>Lipopolysaccharide-induced immune activation impairs attention but has little effect on short-term working memory</article-title>. <source/>Behav Brain Res (<year>2008</year>) <volume>194</volume>(<issue>2</issue>):<page-range>138–45</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbr.2008.06.032</pub-id>
</mixed-citation>
</ref>
<ref id="B294">
<label>294</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moller</surname><given-names>HJ</given-names></name></person-group>
<article-title>Clinical evaluation of negative symptoms in schizophrenia</article-title>. <source/>Eur Psychiatry (<year>2007</year>) <volume>22</volume>(<issue>6</issue>):<page-range>380–6</page-range>. <pub-id pub-id-type="doi">10.1016/j.eurpsy.2007.03.010</pub-id>
</mixed-citation>
</ref>
<ref id="B295">
<label>295</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tandon</surname><given-names>R</given-names></name><name><surname>Nasrallah</surname><given-names>HA</given-names></name><name><surname>Keshavan</surname><given-names>MS</given-names></name></person-group>
<article-title>Schizophrenia, “just the facts” 4. Clinical features and conceptualization</article-title>. <source/>Schizophr Res (<year>2009</year>) <volume>110</volume>(<issue>1–3</issue>):<fpage>1</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2009.03.005</pub-id>
<pub-id pub-id-type="pmid">19328655</pub-id></mixed-citation>
</ref>
<ref id="B296">
<label>296</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dickerson</surname><given-names>F</given-names></name><name><surname>Stallings</surname><given-names>C</given-names></name><name><surname>Origoni</surname><given-names>A</given-names></name><name><surname>Boronow</surname><given-names>J</given-names></name><name><surname>Yolken</surname><given-names>R</given-names></name></person-group>
<article-title>C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia</article-title>. <source/>Schizophr Res (<year>2007</year>) <volume>93</volume>(<issue>1–3</issue>):<page-range>261–5</page-range>. <pub-id pub-id-type="doi">10.1016/j.schres.2007.03.022</pub-id>
</mixed-citation>
</ref>
<ref id="B297">
<label>297</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>F</given-names></name><name><surname>Yuan</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis</article-title>. <source/>Psychiatry Res (<year>2010</year>) <volume>176</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.psychres.2008.10.024</pub-id>
<pub-id pub-id-type="pmid">20067853</pub-id></mixed-citation>
</ref>
<ref id="B298">
<label>298</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>A</given-names></name><name><surname>Diedrich</surname><given-names>M</given-names></name><name><surname>Kaestner</surname><given-names>F</given-names></name><name><surname>Koelkebeck</surname><given-names>K</given-names></name><name><surname>Ohrmann</surname><given-names>P</given-names></name><name><surname>Ponath</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry (<year>2008</year>) <volume>32</volume>(<issue>8</issue>):<page-range>1789–92</page-range>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2008.07.017</pub-id>
</mixed-citation>
</ref>
<ref id="B299">
<label>299</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>B</given-names></name><name><surname>Buckley</surname><given-names>PF</given-names></name><name><surname>Mellor</surname><given-names>A</given-names></name><name><surname>Kirkpatrick</surname><given-names>BW</given-names></name></person-group>
<article-title>Meta-analysis of cytokine alterations in schizophrenia: clinical status, symptoms, and antipsychotic effects</article-title>. <source/>Schizophr Bull (<year>2011</year>a) <volume>37</volume>:<fpage>57</fpage>.</mixed-citation>
</ref>
<ref id="B300">
<label>300</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baumeister</surname><given-names>D</given-names></name><name><surname>Ciufolini</surname><given-names>S</given-names></name><name><surname>Mondelli</surname><given-names>V</given-names></name></person-group>
<article-title>Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment</article-title>? <source/>Psychopharmacology (Berl) (<year>2016</year>) <volume>233</volume>(<issue>9</issue>):<page-range>1575–89</page-range>. <pub-id pub-id-type="doi">10.1007/s00213-015-4044-5</pub-id>
</mixed-citation>
</ref>
<ref id="B301">
<label>301</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>BS</given-names></name><name><surname>Steiner</surname><given-names>J</given-names></name><name><surname>Bernstein</surname><given-names>HG</given-names></name><name><surname>Dodd</surname><given-names>S</given-names></name><name><surname>Pasco</surname><given-names>JA</given-names></name><name><surname>Dean</surname><given-names>OM</given-names></name><etal></etal></person-group>
<article-title>C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications</article-title>. <source/>Mol Psychiatry (<year>2016</year>) <volume>21</volume>(<issue>4</issue>):<page-range>554–64</page-range>. <pub-id pub-id-type="doi">10.1038/mp.2015.87</pub-id>
</mixed-citation>
</ref>
<ref id="B302">
<label>302</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>YK</given-names></name><name><surname>Myint</surname><given-names>AM</given-names></name><name><surname>Verkerk</surname><given-names>R</given-names></name><name><surname>Scharpe</surname><given-names>S</given-names></name><name><surname>Steinbusch</surname><given-names>H</given-names></name><name><surname>Leonard</surname><given-names>B</given-names></name></person-group>
<article-title>Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients</article-title>. <source/>Neuropsychobiology (<year>2009</year>) <volume>59</volume>(<issue>2</issue>):<page-range>123–9</page-range>. <pub-id pub-id-type="doi">10.1159/000213565</pub-id>
</mixed-citation>
</ref>
<ref id="B303">
<label>303</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pollmacher</surname><given-names>T</given-names></name><name><surname>Haack</surname><given-names>M</given-names></name><name><surname>Schuld</surname><given-names>A</given-names></name><name><surname>Kraus</surname><given-names>T</given-names></name><name><surname>Hinze-Selch</surname><given-names>D</given-names></name></person-group>
<article-title>Effects of antipsychotic drugs on cytokine networks</article-title>. <source/>J Psychiatr Res (<year>2000</year>) <volume>34</volume>(<issue>6</issue>):<page-range>369–82</page-range>. <pub-id pub-id-type="doi">10.1016/S0022-3956(00)00032-7</pub-id>
</mixed-citation>
</ref>
<ref id="B304">
<label>304</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>XQ</given-names></name><name><surname>Lv</surname><given-names>LX</given-names></name><name><surname>Li</surname><given-names>WQ</given-names></name><name><surname>Hao</surname><given-names>YH</given-names></name><name><surname>Zhao</surname><given-names>JP</given-names></name></person-group>
<article-title>The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia</article-title>. <source/>Biol Psychiatry (<year>2009</year>b) <volume>65</volume>(<issue>6</issue>):<page-range>481–8</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.10.018</pub-id>
</mixed-citation>
</ref>
<ref id="B305">
<label>305</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cazzullo</surname><given-names>CL</given-names></name><name><surname>Sacchetti</surname><given-names>E</given-names></name><name><surname>Galluzzo</surname><given-names>A</given-names></name><name><surname>Panariello</surname><given-names>A</given-names></name><name><surname>Adorni</surname><given-names>A</given-names></name><name><surname>Pegoraro</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatry (<year>2002</year>) <volume>26</volume>(<issue>1</issue>):<page-range>33–9</page-range>. <pub-id pub-id-type="doi">10.1016/S0278-5846(01)00221-4</pub-id>
</mixed-citation>
</ref>
<ref id="B306">
<label>306</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maes</surname><given-names>M</given-names></name><name><surname>Bosmans</surname><given-names>E</given-names></name><name><surname>Kenis</surname><given-names>G</given-names></name><name><surname>De Jong</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>RS</given-names></name><name><surname>Meltzer</surname><given-names>HY</given-names></name></person-group>
<article-title>In vivo immunomodulatory effects of clozapine in schizophrenia</article-title>. <source/>Schizophr Res (<year>1997</year>) <volume>26</volume>(<issue>2–3</issue>):<page-range>221–5</page-range>. <pub-id pub-id-type="doi">10.1016/S0920-9964(97)00057-1</pub-id>
</mixed-citation>
</ref>
<ref id="B307">
<label>307</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Kenis</surname><given-names>G</given-names></name><name><surname>Bosmans</surname><given-names>E</given-names></name><name><surname>Maes</surname><given-names>M</given-names></name></person-group>
<article-title>Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist</article-title>. <source/>Schizophr Res (<year>2000</year>) <volume>42</volume>(<issue>2</issue>):<page-range>157–64</page-range>. <pub-id pub-id-type="doi">10.1016/S0920-9964(99)00116-4</pub-id>
</mixed-citation>
</ref>
<ref id="B308">
<label>308</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Drzyzga</surname><given-names>L</given-names></name><name><surname>Obuchowicz</surname><given-names>E</given-names></name><name><surname>Marcinowska</surname><given-names>A</given-names></name><name><surname>Herman</surname><given-names>ZS</given-names></name></person-group>
<article-title>Cytokines in schizophrenia and the effects of antipsychotic drugs</article-title>. <source/>Brain Behav Immun (<year>2006</year>) <volume>20</volume>(<issue>6</issue>):<page-range>532–45</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2006.02.002</pub-id>
</mixed-citation>
</ref>
<ref id="B309">
<label>309</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Plitman</surname><given-names>E</given-names></name><name><surname>Iwata</surname><given-names>Y</given-names></name><name><surname>Caravaggio</surname><given-names>F</given-names></name><name><surname>Nakajima</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>JK</given-names></name><name><surname>Gerretsen</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Kynurenic acid in schizophrenia: a systematic review and meta-analysis</article-title>. <source/>Schizophr Bull (<year>2017</year>) <volume>43</volume>(<issue>4</issue>):<page-range>764–77</page-range>. <pub-id pub-id-type="doi">10.1093/schbul/sbw221</pub-id>
</mixed-citation>
</ref>
<ref id="B310">
<label>310</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ceresoli-Borroni</surname><given-names>G</given-names></name><name><surname>Rassoulpour</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>HQ</given-names></name><name><surname>Guidetti</surname><given-names>P</given-names></name><name><surname>Schwarcz</surname><given-names>R</given-names></name></person-group>
<article-title>Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain</article-title>. <source/>J Neural Transm (Vienna) (<year>2006</year>) <volume>113</volume>(<issue>10</issue>):<page-range>1355–65</page-range>. <pub-id pub-id-type="doi">10.1007/s00702-005-0432-z</pub-id>
</mixed-citation>
</ref>
<ref id="B311">
<label>311</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mirjany</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>L</given-names></name><name><surname>Pasinetti</surname><given-names>GM</given-names></name></person-group>
<article-title>Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity</article-title>. <source/>J Pharmacol Exp Ther (<year>2002</year>) <volume>301</volume>(<issue>2</issue>):<fpage>494</fpage>–<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.301.2.494</pub-id>
<pub-id pub-id-type="pmid">11961048</pub-id></mixed-citation>
</ref>
<ref id="B312">
<label>312</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muller</surname><given-names>N</given-names></name><name><surname>Riedel</surname><given-names>M</given-names></name><name><surname>Schwarz</surname><given-names>MJ</given-names></name><name><surname>Engel</surname><given-names>RR</given-names></name></person-group>
<article-title>Clinical effects of COX-2 inhibitors on cognition in schizophrenia</article-title>. <source/>Eur Arch Psychiatry Clin Neurosci (<year>2005</year>) <volume>255</volume>(<issue>2</issue>):<page-range>149–51</page-range>. <pub-id pub-id-type="doi">10.1007/s00406-004-0548-4</pub-id>
</mixed-citation>
</ref>
<ref id="B313">
<label>313</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Cai</surname><given-names>DB</given-names></name><name><surname>Yang</surname><given-names>XH</given-names></name><name><surname>Ungvari</surname><given-names>GS</given-names></name><name><surname>Ng</surname><given-names>CH</given-names></name><name><surname>Muller</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>Adjunctive celecoxib for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials</article-title>. <source/>J Psychiatr Res (<year>2017</year>) <volume>92</volume>:<page-range>139–46</page-range>. <pub-id pub-id-type="doi">10.1016/j.jpsychires.2017.04.004</pub-id>
</mixed-citation>
</ref>
<ref id="B314">
<label>314</label>
<mixed-citation publication-type="book"><article-title>Diagnostic and statistical manual of mental disorders: DSM-5</article-title>. <year>2013</year>, <publisher-name>American Psychiatric Association</publisher-name>, <publisher-loc>Arlington, VA</publisher-loc>.</mixed-citation>
</ref>
<ref id="B315">
<label>315</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muhle</surname><given-names>R</given-names></name><name><surname>Trentacoste</surname><given-names>SV</given-names></name><name><surname>Rapin</surname><given-names>I</given-names></name></person-group>
<article-title>The genetics of autism</article-title>. <source/>Pediatrics (<year>2004</year>) <volume>113</volume>(<issue>5</issue>):<page-range>e472–86</page-range>. <pub-id pub-id-type="doi">10.1542/peds.113.5.e472</pub-id>
</mixed-citation>
</ref>
<ref id="B316">
<label>316</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goines</surname><given-names>P</given-names></name><name><surname>de Water</surname><given-names>J</given-names></name></person-group>
<article-title>The immune system’s role in the biology of autism</article-title>. <source/>Curr Opin Neurol (<year>2010</year>) <volume>23</volume>(<issue>2</issue>):<page-range>111–7</page-range>. <pub-id pub-id-type="doi">10.1097/WCO.0b013e3283373514</pub-id>
</mixed-citation>
</ref>
<ref id="B317">
<label>317</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>Y</given-names></name><name><surname>Chiba</surname><given-names>K</given-names></name></person-group>
<article-title>Involvement of neuroinflammation during brain development in social cognitive deficits in autism spectrum disorder and schizophrenia</article-title>. <source/>J Pharmacol Exp Ther (<year>2016</year>) <volume>358</volume>(<issue>3</issue>):<fpage>504</fpage>. <pub-id pub-id-type="doi">10.1124/jpet.116.234476</pub-id>
<pub-id pub-id-type="pmid">27384073</pub-id></mixed-citation>
</ref>
<ref id="B318">
<label>318</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Onore</surname><given-names>C</given-names></name><name><surname>Careaga</surname><given-names>M</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name></person-group>
<article-title>The role of immune dysfunction in the pathophysiology of autism</article-title>. <source/>Brain Behav Immun (<year>2012</year>) <volume>26</volume>(<issue>3</issue>):<page-range>383–92</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2011.08.007</pub-id>
</mixed-citation>
</ref>
<ref id="B319">
<label>319</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petrelli</surname><given-names>F</given-names></name><name><surname>Pucci</surname><given-names>L</given-names></name><name><surname>Bezzi</surname><given-names>P</given-names></name></person-group>
<article-title>Astrocytes and microglia and their potential link with autism spectrum disorders</article-title>. <source/>Front Cell Neurosci (<year>2016</year>) <volume>10</volume>:<fpage>21</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2016.00021</pub-id>
<pub-id pub-id-type="pmid">26903806</pub-id></mixed-citation>
</ref>
<ref id="B320">
<label>320</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wakefield</surname><given-names>AJ</given-names></name><name><surname>Murch</surname><given-names>SH</given-names></name><name><surname>Anthony</surname><given-names>A</given-names></name><name><surname>Linnell</surname><given-names>J</given-names></name><name><surname>Casson</surname><given-names>DM</given-names></name><name><surname>Malik</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children</article-title>. <source/>Lancet (<year>1998</year>) <volume>351</volume>(<issue>9103</issue>):<page-range>637–41</page-range>. <pub-id pub-id-type="doi">10.1016/S0140-6736(97)11096-0</pub-id>
</mixed-citation>
</ref>
<ref id="B321">
<label>321</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fombonne</surname><given-names>E</given-names></name><name><surname>Chakrabarti</surname><given-names>S</given-names></name></person-group>
<article-title>No evidence for a new variant of measles-mumps-rubella-induced autism</article-title>. <source/>Pediatrics (<year>2001</year>) <volume>108</volume>(<issue>4</issue>):<elocation-id>E58</elocation-id>. <pub-id pub-id-type="doi">10.1542/peds.108.4.e58</pub-id>
<pub-id pub-id-type="pmid">11581466</pub-id></mixed-citation>
</ref>
<ref id="B322">
<label>322</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gerber</surname><given-names>JS</given-names></name><name><surname>Offit</surname><given-names>PA</given-names></name></person-group>
<article-title>Vaccines and autism: a tale of shifting hypotheses</article-title>. <source/>Clin Infect Dis (<year>2009</year>) <volume>48</volume>(<issue>4</issue>):<page-range>456–61</page-range>. <pub-id pub-id-type="doi">10.1086/596476</pub-id>
</mixed-citation>
</ref>
<ref id="B323">
<label>323</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Offit</surname><given-names>PA</given-names></name><name><surname>Coffin</surname><given-names>SE</given-names></name></person-group>
<article-title>Communicating science to the public: MMR vaccine and autism</article-title>. <source/>Vaccine (<year>2003</year>) <volume>22</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S0264-410X(03)00532-2</pub-id>
<pub-id pub-id-type="pmid">14604564</pub-id></mixed-citation>
</ref>
<ref id="B324">
<label>324</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>B</given-names></name><name><surname>Miller</surname><given-names>E</given-names></name><name><surname>Lingam</surname><given-names>R</given-names></name><name><surname>Andrews</surname><given-names>N</given-names></name><name><surname>Simmons</surname><given-names>A</given-names></name><name><surname>Stowe</surname><given-names>J</given-names></name></person-group>
<article-title>Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study</article-title>. <source/>BMJ (<year>2002</year>) <volume>324</volume>(<issue>7334</issue>):<page-range>393–6</page-range>. <pub-id pub-id-type="doi">10.1136/bmj.324.7334.393</pub-id>
</mixed-citation>
</ref>
<ref id="B325">
<label>325</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brown</surname><given-names>AS</given-names></name></person-group>
<article-title>Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism</article-title>. <source/>Dev Neurobiol (<year>2012</year>) <volume>72</volume>(<issue>10</issue>):<page-range>1272–6</page-range>. <pub-id pub-id-type="doi">10.1002/dneu.22024</pub-id>
</mixed-citation>
</ref>
<ref id="B326">
<label>326</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fang</surname><given-names>SY</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Yeh</surname><given-names>HH</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name></person-group>
<article-title>Prenatal Infection and autism spectrum disorders in childhood: a population-based case-control study in Taiwan</article-title>. <source/>Paediatr Perinat Epidemiol (<year>2015</year>) <volume>29</volume>(<issue>4</issue>):<page-range>307–16</page-range>. <pub-id pub-id-type="doi">10.1111/ppe.12194</pub-id>
</mixed-citation>
</ref>
<ref id="B327">
<label>327</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>HY</given-names></name><name><surname>Xu</surname><given-names>LL</given-names></name><name><surname>Shao</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>RM</given-names></name><name><surname>Yu</surname><given-names>ZH</given-names></name><name><surname>Ling</surname><given-names>ZX</given-names></name><etal></etal></person-group>
<article-title>Maternal infection during pregnancy and risk of autism spectrum disorders: A systematic review and meta-analysis</article-title>. <source/>Brain Behav Immun (<year>2016</year>) <volume>58</volume>:<page-range>165–72</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2016.06.005</pub-id>
</mixed-citation>
</ref>
<ref id="B328">
<label>328</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ziats</surname><given-names>MN</given-names></name><name><surname>Rennert</surname><given-names>OM</given-names></name></person-group>
<article-title>Expression profiling of autism candidate genes during human brain development implicates central immune signaling pathways</article-title>. <source/>PLoS One (<year>2011</year>) <volume>6</volume>(<issue>9</issue>):<elocation-id>e24691</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0024691</pub-id>
<pub-id pub-id-type="pmid">21935439</pub-id></mixed-citation>
</ref>
<ref id="B329">
<label>329</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lim</surname><given-names>CK</given-names></name><name><surname>Essa</surname><given-names>MM</given-names></name><name><surname>de Paula Martins</surname><given-names>R</given-names></name><name><surname>Lovejoy</surname><given-names>DB</given-names></name><name><surname>Bilgin</surname><given-names>AA</given-names></name><name><surname>Waly</surname><given-names>MI</given-names></name><etal></etal></person-group>
<article-title>Altered kynurenine pathway metabolism in autism: Implication for immune-induced glutamatergic activity</article-title>. <source/>Autism Res (<year>2016</year>) <volume>9</volume>(<issue>6</issue>):<page-range>621–31</page-range>. <pub-id pub-id-type="doi">10.1002/aur.1565</pub-id>
</mixed-citation>
</ref>
<ref id="B330">
<label>330</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Krakowiak</surname><given-names>P</given-names></name><name><surname>Hertz-Picciotto</surname><given-names>I</given-names></name><name><surname>Hansen</surname><given-names>R</given-names></name><name><surname>Pessah</surname><given-names>I</given-names></name><name><surname>de Water</surname><given-names>J</given-names></name></person-group>
<article-title>Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome</article-title>. <source/>Brain Behav Immun (<year>2011</year>) <volume>25</volume>(<issue>1</issue>):<page-range>40–5</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2010.08.003</pub-id>
</mixed-citation>
</ref>
<ref id="B331">
<label>331</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heuer</surname><given-names>L</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Schauer</surname><given-names>J</given-names></name><name><surname>Goines</surname><given-names>P</given-names></name><name><surname>Krakowiak</surname><given-names>P</given-names></name><name><surname>Hertz-Picciotto</surname><given-names>I</given-names></name><etal></etal></person-group>
<article-title>Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms</article-title>. <source/>Autism Res (<year>2008</year>) <volume>1</volume>(<issue>5</issue>):<page-range>275–83</page-range>. <pub-id pub-id-type="doi">10.1002/aur.42</pub-id>
</mixed-citation>
</ref>
<ref id="B332">
<label>332</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wills</surname><given-names>S</given-names></name><name><surname>Cabanlit</surname><given-names>M</given-names></name><name><surname>Bennett</surname><given-names>J</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name><name><surname>Amaral</surname><given-names>D</given-names></name><name><surname>de Water</surname><given-names>J</given-names></name></person-group>
<article-title>Autoantibodies in autism spectrum disorders (ASD)</article-title>. <source/>Ann N Y Acad Sci (<year>2007</year>) <volume>1107</volume>:<fpage>79</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1381.009</pub-id>
<pub-id pub-id-type="pmid">17804535</pub-id></mixed-citation>
</ref>
<ref id="B333">
<label>333</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grigorenko</surname><given-names>EL</given-names></name><name><surname>Han</surname><given-names>SS</given-names></name><name><surname>Yrigollen</surname><given-names>CM</given-names></name><name><surname>Leng</surname><given-names>L</given-names></name><name><surname>Mizue</surname><given-names>Y</given-names></name><name><surname>Anderson</surname><given-names>GM</given-names></name><etal></etal></person-group>
<article-title>Macrophage migration inhibitory factor and autism spectrum disorders</article-title>. <source/>Pediatrics (<year>2008</year>) <volume>122</volume>(<issue>2</issue>):e<page-range>438–45</page-range>. <pub-id pub-id-type="doi">10.1542/peds.2007-3604</pub-id>
</mixed-citation>
</ref>
<ref id="B334">
<label>334</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name></person-group>
<article-title>Macrophage migration inhibitory factor activates cyclooxygenase 2-prostaglandin E2 in cultured spinal microglia</article-title>. <source/>Neurosci Res (<year>2011</year>) <volume>71</volume>(<issue>3</issue>):<page-range>210–8</page-range>. <pub-id pub-id-type="doi">10.1016/j.neures.2011.07.1821</pub-id>
</mixed-citation>
</ref>
<ref id="B335">
<label>335</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blaylock</surname><given-names>RL</given-names></name><name><surname>Strunecka</surname><given-names>A</given-names></name></person-group>
<article-title>Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders</article-title>. <source/>Curr Med Chem (<year>2009</year>) <volume>16</volume>(<issue>2</issue>):<page-range>157–70</page-range>. <pub-id pub-id-type="doi">10.2174/092986709787002745</pub-id>
</mixed-citation>
</ref>
<ref id="B336">
<label>336</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morgan</surname><given-names>JT</given-names></name><name><surname>Chana</surname><given-names>G</given-names></name><name><surname>Pardo</surname><given-names>CA</given-names></name><name><surname>Achim</surname><given-names>C</given-names></name><name><surname>Semendeferi</surname><given-names>K</given-names></name><name><surname>Buckwalter</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism</article-title>. <source/>Biol Psychiatry (<year>2010</year>) <volume>68</volume>(<issue>4</issue>):<page-range>368–76</page-range>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2010.05.024</pub-id>
</mixed-citation>
</ref>
<ref id="B337">
<label>337</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tetreault</surname><given-names>NA</given-names></name><name><surname>Hakeem</surname><given-names>AY</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><name><surname>Allman</surname><given-names>E</given-names></name><name><surname>Wold</surname><given-names>BJ</given-names></name><etal></etal></person-group>
<article-title>Microglia in the cerebral cortex in autism</article-title>. <source/>J Autism Dev Disord (<year>2012</year>) <volume>42</volume>(<issue>12</issue>):<page-range>2569–84</page-range>. <pub-id pub-id-type="doi">10.1007/s10803-012-1513-0</pub-id>
</mixed-citation>
</ref>
<ref id="B338">
<label>338</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vargas</surname><given-names>DL</given-names></name><name><surname>Nascimbene</surname><given-names>C</given-names></name><name><surname>Krishnan</surname><given-names>C</given-names></name><name><surname>Zimmerman</surname><given-names>AW</given-names></name><name><surname>Pardo</surname><given-names>CA</given-names></name></person-group>
<article-title>Neuroglial activation and neuroinflammation in the brain of patients with autism</article-title>. <source/>Ann Neurol (<year>2005</year>) <volume>57</volume>(<issue>1</issue>):<fpage>67</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1002/ana.20315</pub-id>
<pub-id pub-id-type="pmid">15546155</pub-id></mixed-citation>
</ref>
<ref id="B339">
<label>339</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Careaga</surname><given-names>M</given-names></name><name><surname>Schwartzer</surname><given-names>J</given-names></name><name><surname>Ashwood</surname><given-names>P</given-names></name></person-group>
<article-title>Inflammatory profiles in the BTBR mouse: how relevant are they to autism spectrum disorders</article-title>? <source/>Brain Behav Immun (<year>2015</year>) <volume>43</volume>:<page-range>11–6</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2014.06.006</pub-id>
</mixed-citation>
</ref>
<ref id="B340">
<label>340</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>El-Ansary</surname><given-names>A</given-names></name><name><surname>Al-Ayadhi</surname><given-names>L</given-names></name></person-group>
<article-title>Neuroinflammation in autism spectrum disorders</article-title>. <source/>J Neuroinflammation (<year>2012</year>) <volume>9</volume>:<fpage>265</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-9-265</pub-id>
<pub-id pub-id-type="pmid">23231720</pub-id></mixed-citation>
</ref>
<ref id="B341">
<label>341</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boris</surname><given-names>M</given-names></name><name><surname>Kaiser</surname><given-names>CC</given-names></name><name><surname>Goldblatt</surname><given-names>A</given-names></name><name><surname>Elice</surname><given-names>MW</given-names></name><name><surname>Edelson</surname><given-names>SM</given-names></name><name><surname>Adams</surname><given-names>JB</given-names></name><etal></etal></person-group>
<article-title>Effect of pioglitazone treatment on behavioral symptoms in autistic children</article-title>. <source/>J Neuroinflammation (<year>2007</year>) <volume>4</volume>:<fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-4-3</pub-id>
<pub-id pub-id-type="pmid">17207275</pub-id></mixed-citation>
</ref>
<ref id="B342">
<label>342</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>EJ</given-names></name><name><surname>Kwon</surname><given-names>KJ</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Moon</surname><given-names>CH</given-names></name><name><surname>Baik</surname><given-names>EJ</given-names></name></person-group>
<article-title>Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2</article-title>. <source/>Brain Res (<year>2002</year>) <volume>941</volume>(<issue>1–2</issue>):<fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-8993(02)02480-0</pub-id>
<pub-id pub-id-type="pmid">12031542</pub-id></mixed-citation>
</ref>
<ref id="B343">
<label>343</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sepanjnia</surname><given-names>K</given-names></name><name><surname>Modabbernia</surname><given-names>A</given-names></name><name><surname>Ashrafi</surname><given-names>M</given-names></name><name><surname>Modabbernia</surname><given-names>MJ</given-names></name><name><surname>Akhondzadeh</surname><given-names>S</given-names></name></person-group>
<article-title>Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial</article-title>. <source/>Neuropsychopharmacology (<year>2012</year>) <volume>37</volume>(<issue>9</issue>):<page-range>2093–100</page-range>. <pub-id pub-id-type="doi">10.1038/npp.2012.58</pub-id>
</mixed-citation>
</ref>
<ref id="B344">
<label>344</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaizaki</surname><given-names>A</given-names></name><name><surname>Tien</surname><given-names>L-T</given-names></name><name><surname>Pang</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Numazawa</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Celecoxib reduces brain dopaminergic neuronal dysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide</article-title>. <source/>J Neuroinflammation (<year>2013</year>) <volume>10</volume>(<issue>1</issue>):<fpage>818</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-10-45</pub-id>
</mixed-citation>
</ref>
<ref id="B345">
<label>345</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Mathis</surname><given-names>MA</given-names></name><name><surname>Diniz</surname><given-names>JB</given-names></name><name><surname>Hounie</surname><given-names>AG</given-names></name><name><surname>Shavitt</surname><given-names>RG</given-names></name><name><surname>Fossaluza</surname><given-names>V</given-names></name><name><surname>Ferrao</surname><given-names>Y</given-names></name><etal></etal></person-group>
<article-title>Trajectory in obsessive-compulsive disorder comorbidities</article-title>. <source/>Eur Neuropsychopharmacol (<year>2013</year>) <volume>23</volume>(<issue>7</issue>):<fpage>594</fpage>–<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1016/j.euroneuro.2012.08.006</pub-id>
<pub-id pub-id-type="pmid">22921470</pub-id></mixed-citation>
</ref>
<ref id="B346">
<label>346</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heidari</surname><given-names>M</given-names></name><name><surname>Zarei</surname><given-names>M</given-names></name><name><surname>Hosseini</surname><given-names>SM</given-names></name><name><surname>Taghvaei</surname><given-names>R</given-names></name><name><surname>Maleki</surname><given-names>H</given-names></name><name><surname>Tabrizi</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder</article-title>. <source/>Int Clin Psychopharmacol (<year>2014</year>) <volume>29</volume>(<issue>6</issue>):<page-range>344–50</page-range>. <pub-id pub-id-type="doi">10.1097/YIC.0000000000000043</pub-id>
</mixed-citation>
</ref>
<ref id="B347">
<label>347</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Askari</surname><given-names>N</given-names></name><name><surname>Moin</surname><given-names>M</given-names></name><name><surname>Sanati</surname><given-names>M</given-names></name><name><surname>Tajdini</surname><given-names>M</given-names></name><name><surname>Hosseini</surname><given-names>SM</given-names></name><name><surname>Modabbernia</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial</article-title>. <source/>CNS Drugs (<year>2012</year>) <volume>26</volume>(<issue>10</issue>):<page-range>883–92</page-range>. <pub-id pub-id-type="doi">10.2165/11635850-000000000-00000</pub-id>
</mixed-citation>
</ref>
<ref id="B348">
<label>348</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Erzegovesi</surname><given-names>S</given-names></name><name><surname>Cavallini</surname><given-names>MC</given-names></name><name><surname>Cavedini</surname><given-names>P</given-names></name><name><surname>Diaferia</surname><given-names>G</given-names></name><name><surname>Locatelli</surname><given-names>M</given-names></name><name><surname>Bellodi</surname><given-names>L</given-names></name></person-group>
<article-title>Clinical predictors of drug response in obsessive-compulsive disorder</article-title>. <source/>J Clin Psychopharmacol (<year>2001</year>) <volume>21</volume>(<issue>5</issue>):<page-range>488–92</page-range>. <pub-id pub-id-type="doi">10.1097/00004714-200110000-00006</pub-id>
</mixed-citation>
</ref>
<ref id="B349">
<label>349</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Milad</surname><given-names>MR</given-names></name><name><surname>Rauch</surname><given-names>SL</given-names></name></person-group>
<article-title>Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways</article-title>. <source/>Trends Cogn Sci (<year>2012</year>) <volume>16</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.tics.2011.11.003</pub-id>
<pub-id pub-id-type="pmid">22138231</pub-id></mixed-citation>
</ref>
<ref id="B350">
<label>350</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perlmutter</surname><given-names>SJ</given-names></name><name><surname>Leitman</surname><given-names>SF</given-names></name><name><surname>Garvey</surname><given-names>MA</given-names></name><name><surname>Hamburger</surname><given-names>S</given-names></name><name><surname>Feldman</surname><given-names>E</given-names></name><name><surname>Leonard</surname><given-names>HL</given-names></name><etal></etal></person-group>
<article-title>Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood</article-title>. <source/>Lancet (<year>1999</year>) <volume>354</volume>(<issue>9185</issue>):<page-range>1153–8</page-range>. <pub-id pub-id-type="doi">10.1016/S0140-6736(98)12297-3</pub-id>
</mixed-citation>
</ref>
<ref id="B351">
<label>351</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boedhoe</surname><given-names>PS</given-names></name><name><surname>Schmaal</surname><given-names>L</given-names></name><name><surname>Abe</surname><given-names>Y</given-names></name><name><surname>Ameis</surname><given-names>SH</given-names></name><name><surname>Arnold</surname><given-names>PD</given-names></name><name><surname>Batistuzzo</surname><given-names>MC</given-names></name><etal></etal></person-group>
<article-title>Distinct subcortical volume alterations in pediatric and adult OCD: a worldwide meta- and mega-analysis</article-title>. <source/>Am J Psychiatry (<year>2017</year>) <volume>174</volume>(<issue>1</issue>):<page-range>60–9</page-range>.</mixed-citation>
</ref>
<ref id="B352">
<label>352</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salazar</surname><given-names>A</given-names></name><name><surname>Gonzalez-Rivera</surname><given-names>BL</given-names></name><name><surname>Redus</surname><given-names>L</given-names></name><name><surname>Parrott</surname><given-names>JM</given-names></name><name><surname>O’Connor</surname><given-names>JC</given-names></name></person-group>
<article-title>Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge</article-title>. <source/>Horm Behav (<year>2012</year>) <volume>62</volume>(<issue>3</issue>):<page-range>202–9</page-range>. <pub-id pub-id-type="doi">10.1016/j.yhbeh.2012.03.010</pub-id>
</mixed-citation>
</ref>
<ref id="B353">
<label>353</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>YY</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><etal></etal></person-group>
<article-title>Systemic inflammation induces anxiety disorder through CXCL12/CXCR4 pathway</article-title>. <source/>Brain Behav Immun (<year>2016</year>) <volume>56</volume>:<page-range>352–62</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2016.03.001</pub-id>
</mixed-citation>
</ref>
<ref id="B354">
<label>354</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Antony</surname><given-names>JM</given-names></name></person-group>
<article-title>Grooming and Growing with Microglia</article-title>. <source/>Sci Signal (<year>2010</year>) <volume>3</volume>(<issue>147</issue>):<fpage>jc8</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.3147jc8</pub-id>
<pub-id pub-id-type="pmid">21062990</pub-id></mixed-citation>
</ref>
<ref id="B355">
<label>355</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Banati</surname><given-names>RB</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><name><surname>Kreutzberg</surname><given-names>GW</given-names></name></person-group>
<article-title>PK (‘peripheral benzodiazepine’)—binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia</article-title>. <source/>J Neurocytol (<year>1997</year>) <volume>26</volume>(<issue>2</issue>):<fpage>77</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1023/A:1018567510105</pub-id>
<pub-id pub-id-type="pmid">9181482</pub-id></mixed-citation>
</ref>
<ref id="B356">
<label>356</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hannestad</surname><given-names>J</given-names></name><name><surname>DellaGioia</surname><given-names>N</given-names></name><name><surname>Gallezot</surname><given-names>JD</given-names></name><name><surname>Lim</surname><given-names>K</given-names></name><name><surname>Nabulsi</surname><given-names>N</given-names></name><name><surname>Esterlis</surname><given-names>I</given-names></name><etal></etal></person-group>
<article-title>The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [(1)(1)C]PBR28 PET study</article-title>. <source/>Brain Behav Immun (<year>2013</year>) <volume>33</volume>:<page-range>131–8</page-range>. <pub-id pub-id-type="doi">10.1016/j.bbi.2013.06.010</pub-id>
</mixed-citation>
</ref>
<ref id="B357">
<label>357</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kreutzberg</surname><given-names>GW</given-names></name></person-group>
<article-title>Microglia: a sensor for pathological events in the CNS</article-title>. <source/>Trends Neurosci (<year>1996</year>) <volume>19</volume>(<issue>8</issue>):<page-range>312–8</page-range>. <pub-id pub-id-type="doi">10.1016/0166-2236(96)10049-7</pub-id>
</mixed-citation>
</ref>
<ref id="B358">
<label>358</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martin</surname><given-names>A</given-names></name><name><surname>Boisgard</surname><given-names>R</given-names></name><name><surname>Theze</surname><given-names>B</given-names></name><name><surname>Van Camp</surname><given-names>N</given-names></name><name><surname>Kuhnast</surname><given-names>B</given-names></name><name><surname>Damont</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Evaluation of the PBR/TSPO radioligand [(18)F]DPA-714 in a rat model of focal cerebral ischemia</article-title>. <source/>J Cereb Blood Flow Metab (<year>2010</year>) <volume>30</volume>(<issue>1</issue>):<page-range>230–41</page-range>. <pub-id pub-id-type="doi">10.1038/jcbfm.2009.205</pub-id>
</mixed-citation>
</ref>
<ref id="B359">
<label>359</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>MT</given-names></name><name><surname>Chugani</surname><given-names>HT</given-names></name></person-group>
<article-title>Evaluation of basal ganglia and thalamic inflammation in children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection and Tourette syndrome: a positron emission tomographic (PET) study using 11C-[R]-PK11195</article-title>. <source/>J Child Neurol (<year>2015</year>) <volume>30</volume>(<issue>6</issue>):<page-range>749–56</page-range>. <pub-id pub-id-type="doi">10.1177/0883073814543303</pub-id>
</mixed-citation>
</ref>
<ref id="B360">
<label>360</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fettes</surname><given-names>P</given-names></name><name><surname>Schulze</surname><given-names>L</given-names></name><name><surname>Downar</surname><given-names>J</given-names></name></person-group>
<article-title>Cortico-striatal-thalamic loop circuits of the orbitofrontal cortex: promising therapeutic targets in psychiatric illness</article-title>. <source/>Front Syst Neurosci (<year>2017</year>) <volume>11</volume>:<fpage>25</fpage>. <pub-id pub-id-type="doi">10.3389/fnsys.2017.00025</pub-id>
<pub-id pub-id-type="pmid">28496402</pub-id></mixed-citation>
</ref>
<ref id="B361">
<label>361</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peters</surname><given-names>SK</given-names></name><name><surname>Dunlop</surname><given-names>K</given-names></name><name><surname>Downar</surname><given-names>J</given-names></name></person-group>
<article-title>Cortico-striatal-thalamic loop circuits of the salience network: a central pathway in psychiatric disease and treatment</article-title>. <source/>Front Syst Neurosci (<year>2016</year>) <volume>10</volume>:<fpage>104</fpage>. <pub-id pub-id-type="doi">10.3389/fnsys.2016.00104</pub-id>
<pub-id pub-id-type="pmid">28082874</pub-id></mixed-citation>
</ref>
<ref id="B362">
<label>362</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Esalatmanesh</surname><given-names>S</given-names></name><name><surname>Abrishami</surname><given-names>Z</given-names></name><name><surname>Zeinoddini</surname><given-names>A</given-names></name><name><surname>Rahiminejad</surname><given-names>F</given-names></name><name><surname>Sadeghi</surname><given-names>M</given-names></name><name><surname>Najarzadegan</surname><given-names>MR</given-names></name><etal></etal></person-group>
<article-title>Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: a placebo-controlled, double-blind, randomized trial</article-title>. <source/>Psychiatry Clin Neurosci (<year>2016</year>) <volume>70</volume>(<issue>11</issue>):<page-range>517–26</page-range>. <pub-id pub-id-type="doi">10.1111/pcn.12430</pub-id>
</mixed-citation>
</ref>
<ref id="B363">
<label>363</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>AH</given-names></name><name><surname>Raison</surname><given-names>CL</given-names></name></person-group>
<article-title>Are anti-inflammatory therapies viable treatments for psychiatric disorders? where the rubber meets the road</article-title>. <source/>JAMA Psychiatry (<year>2015</year>) <volume>6</volume>:<page-range>527–8</page-range>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2015.22</pub-id>
</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>